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In numerous countries globally, the morbid obesity pandemic is increasingly posing a 
major lifelong disorder. With one-in-four adults classed as obese, while two-thirds 
are overweight, obesity’s prevalence in England is among the highest in Europe. The 
effect of obesity and obesity-related comorbidity on the UK’s NHS public health 
budgets is second only to smoking, estimated to cost £44.7 billion annually. The 
official UK obesity management is attained via a commissioned service that adopts a 
four-tiered pathway. The first two tiers are outside of this study’s remit, pertaining 
to environmental and population-wide schemes for obesity prevention and 
promotion of a healthy weight and nutritional balanced diet. Tier 3 is a 
Multidisciplinary Weight Management Service, aimed at those whose obesity is 
complex and/or is accompanied by medical needs; patients in this tier may be 
considered for Tier 4, namely bariatric surgery. Exposure to these two clinical tiers is 
the focused in this thesis, which evaluates the clinical effect and health outcomes of 
the commissioned clinical interventions. 
To comprehend the comorbidities and metabolic status of individuals with severe 
obesity living in the UK, the Tier 3 and similar programmes were systematically 
reviewed. Furthermore, Tier 3 was supplemented by research conducted at a local 
clinic. This research extends to patients with a major comorbidity (i.e. insulin-treated 
T2D) and were at high risk of CV, nephropathy or hepatic disease (i.e. respectively 
microalbuminuria and NAFLD at baseline), who had been referred for bariatric 
intervention. Analysis of CV, metabolic and renal outcomes was undertaken. 
 
 v 
Additionally, this thesis presents a chapter appraising the economic effect of surgical 
treatment provision for the morbidly obese. It assesses the costs involved in providing 
clinical care, laboratory tests and pharmacotherapy (typically, antihypertensives, 
aspirin, insulin, GLP-1 analogues, lipids lowering and oral antidiabetic drugs). 
Moreover, it evaluates the likelihood of T2D remission and insulin independency in 
post-bariatric intervention, alongside an in-depth analysis of composite obesity-
related comorbidity events—including asthma, atherosclerosis, cancers (breast, 
bowel or uterine), chronic kidney disease, coronary heart disease, dementia, 
depression, gallstones or gallbladder disease, GORD, gout, hyperlipidaemia, 
hypertension, liver diseases, osteoarthritis, sleep apnoea and stroke.  
Drawing on the systematic review results and local clinic study, a strong correlation 
was identified between those patients requiring Tier 3 services and their risk of 
developing serious comorbidities, profoundly with advanced T2D. Although subtle, 
the short- to mid-term effects of Tier 3 are statistically positive for patients with 
severe obesity. Bariatric patients with serious comorbidities (i.e. insulin-treated T2D), 
gained a longer-term protective effect against certain major elements of CV diseases 
and CKD events, while significant metabolic improvements were experienced by 
patients with NAFLD at baseline. Concerning the analyses of composite obesity-
related comorbidities, the protective effect conferred by the Tier 4 bariatric 
intervention is significant, therefore justifying its cost effectiveness. Therefore, 
clinical interventions for preventing morbid obesity are effective in mitigating or 
resolving numerous comorbidities that affect patients with severe obesity living in 
the UK.  
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1.1 Obesity 
Resulting from excessive increase in body fat, obesity is not only closely correlated 
with a string of chronic illnesses, but it also diminishes life expectancy and is an 
independent risk factor for mortality, which is why it is considered a major health 
problem [1,2]. Extensive research has been conducted on the implications that 
obesity has for health, including physical, psychological, and social implications [3-
5]. The formation and abnormal increase in adipose tissue mass, which is the 
greatest energy storage in the human body, occur when the intake and 
consumption of energy are unequal [6]. In the UK, obesity is diagnosed based on 
the clinical guidelines issued by the National Health Service (NHS) Commissioning 
Board [7] and the National Institute for Health and Care Excellence (NICE) [8]. Thus, 
fitting to the Body Mass Index1 (BMI), five categories of body weight have been 
identified, namely, healthy body weight (18.5-24.9 kg/m2), overweight (25-29.9 
kg/m2), obesity class I (30-34.9 kg/m2), obesity class II (35-39.9 kg/m2), and obesity 
class III (≥40 kg/m2). Nonetheless, the use of BMI can be a misleading measure 
between ethnicities especially within highly diverse populations.  
At global level, the prevalence of obesity has increased nearly three-fold since 
1975, with the proportion of adult individuals classified as overweight and obese 
being 39% and 13%, respectively [1]. This has prompted the World Health 
Organisation (WHO) to declare that obesity was among the non-infectious 
 
1 The body mass index is calculated by using an individual’s body weight in kilograms divided by their height in 
meters squared. 
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pandemics that needed to be urgently addressed in every country [9]. In 
September 2011, the United Nations (UN) General Assembly held a high-level 
meeting regarding non-communicable diseases (NCDs), where the staggering 
increase in obesity levels worldwide was discussed and obesity was acknowledged 
as a difficult health problem confronting all countries [10]. However, that meeting 
did not translate into the formulation of public health policies for tackling obesity 
and type 2 diabetes (T2D) in any country [10]. Consequently, the battle to identify 
solutions for combating the increase in obesity among both adults and children 
continues [9,10]. Figure 1.1 provides an overview of the prevalence of obesity at 
global level [2]. 
Among countries in Europe, obesity has a high prevalence, which has increased 
more than two-fold in the last ten years, especially in England, France, Germany, 
Italy, the Netherlands, Poland, Republic of Moldova, Slovenia, and Sweden [11]. 
The efforts made by countries have been ineffective at halting the increase in adult 
obesity in the period 2010-2016 [11]. Likewise, obesity levels among children are 
high. This determined a large number of countries with membership to the EU to 
publish an Action Plan document (2014-2020) [11]. However, of all the countries 
in Europe, obesity, defined as a BMI higher than 30 kg/m2, is most prevalent in the 
UK, according to official statistics from the WHO (Figure 1.2) [12]. 
A 2016 Health Survey for England revealed that, since 1993, the rate of obesity 
among adult individuals nearly doubled, from 15% to 26% [11]. Furthermore, 
between the periods 2015-2016 and 2016-2017, there was an 18% increase in the 
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number of individuals admitted to hospital with obesity-related conditions, and of 
the 617,000 admissions, 72% were female individuals [13]. Similarly, the 2016-
2017 UK National Childhood Measurement Programme reported that obesity 
occurred in almost 10% of children in the age range 5-6 years old and 20% of 
children in the age range 10-11 years old [11,13]. The 2007 Government’s 
Foresight report anticipated that, by 2050, obesity could affect over 50% of adults 
in the UK, which would increase healthcare costs two-fold and extract £50 billion 
in broader societal and productivity costs every year [14]. This prediction 
suggested a stable rise of 12% compared to the forecast made by the McKinsey 
Global Institute, which conjectured that obesity was the second costliest public 
health problem, second to smoking, costing the NHS £44.7 billion every year [15]. 
Government initiatives, policies, and investment in awareness campaigns, 
surveillance, and research are critical in tackling obesity. However, instead of 
dealing with it themselves, most governments have relegated this challenge to 
individuals, the private sector, and non-governmental organisations [10]. The 
purpose of a multidisciplinary strategy for dealing with obesity is not merely 
limited to promoting weight loss through a negative energy balance [6], since there 
is more than one factor contributing to the onset of obesity, such as primary 
appetite control regulated by the brain, the force of dietary habits, physical 
exercise, and psychological factors [14]. All of these factors must be given due 
consideration if obesity is to be managed effectively. Additional factors must be 
taken into account in relation to severe obesity, including comorbidities, problems 
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of mobility or impairment, socioeconomic status, and access to healthcare 
services.  
 
Figure 1.1 Global prevalence of overweight and obesity. 
Age-adjusted worldwide prevalence of overweight (BMI 25–29.9 kg/m2) (A) and obesity 
(BMI ≥ 30 kg/m2) (A) among male and female individuals of adult age in the period between 








Figure 1.2 Prevalence of obesity in Europe. 
The prevalence of obesity (BMI ≥ 30 kg/m2) among adult individuals in European countries 
in the period 2010-2016 [11,12]. 
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1.2 Type 2 diabetes 
The series of metabolic diseases characterised by hyperglycaemia caused by 
impaired insulin secretion, or action, or both is known as diabetes [16,17]. Among 
the serious complications of diabetes-related chronic hyperglycaemia are long-
term damage, improper function, and failure of a number of organs, particularly, 
the eye, kidney, neural system, and cardiovascular system [16]. 
The diabetes form of highest prevalence is T2D, formerly known as non-insulin 
dependent or adult-onset diabetes. T2D occurs as a result of suboptimal 
production of insulin and resistance to the pancreas-secreted hormone called 
insulin, which is responsible for controlling the levels of glucose in the blood. If 
untreated, diabetes gives rise to hyperglycaemia, which is significantly damaging 
to numerous body structures in the long term, particularly the neural and the 
vascular systems [17]. A progressive step-ladder increase in treatment is 
recommended by clinical guidelines for managing T2D, beginning with changes to 
lifestyle, such as healthier dietary habits, losing weight, and engaging in physical 
activity on a regular basis. If such changes are unsuccessful, the first-line 
monotherapy that is administered is Metformin, which may be supplemented with 
Sulphonylurea, if it cannot regulate glucose levels effectively on its own [18]. The 
complexity of the guidelines increases at this stage, as additional oral antidiabetic 
(OAD) drugs are administered, such as insulin [18].  This approach is justified by 
the lack of definitive evidence about the best medication to administer after 
Metformin to accelerate therapy [19]. Since insulin resistance occurs in both 
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obesity and T2D, insulin administration becomes necessary in numerous T2D cases 
over the long term to keep the levels of glucose normal [20]. However, it has been 
noted that insulin administration leads to an increase in body weight [21]. 
Unlike individuals with normal body weight, individuals with obesity are seven 
times more likely to develop T2D [21]. The heightened predisposition towards 
diabetes is significantly influenced by the manner in which fat is distributed around 
the body, but there are still uncertainties about how these two aspects are 
correlated exactly [22]. Furthermore, there is a lack of clarity as to why obesity 
does not always lead to T2D and why diabetes can be developed by individuals of 
normal weight [23]. There is variation among individuals in terms of independent 
factors such as age, lifestyle, socioeconomic status, ethnic background, and dietary 
habits. However, the mechanism of insulin resistance development is believed to 
be general, being activated by the production of pro-inflammatory chemicals by 
fat cells as a result of abdominal obesity, which interferes with the function of cells 
responsive to insulin [21]. The occurrence of insulin resistance may be further 
compounded by obesity by inducing alterations in metabolic activities, stimulating 
over-expression of fatty acids, glycerol, hormones, pro-inflammatory cytokines, 
and other factors by the adipose tissue [21]. The levels of glucose in the blood can 
no longer be regulated when insulin resistance occurs alongside improper function 
of the islet beta-cells of the pancreas [20]. 
In the UK, diabetes is becoming increasingly prevalent, affecting 4.7 million 
individuals in the period 2018-2019. Of those individuals, adults account for 3.9 
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million. This constitutes a two-fold increase from 1998 [24]. Furthermore, the 
actual number of people with T2D may be higher because around 25% of 
individuals have T2D without knowing it. Given the close correlation between 
obesity and T2D, diabetes will become more and more prevalent as obesity grows 
in prevalence [21]. More specifically, obesity is considered to be responsible for 
around a third of the increase in T2D prevalence, with additional contributing 
factors including ageing and changes in the ethnic structure of the British 
population [21]. 
1.3 Comorbidities 
In addition to T2D, increased BMI is a key risk factor for numerous non-infectious 
comorbidities, such as micro- and macro-cardiovascular diseases (CVDs) [25], 
musculoskeletal disorders (e.g. osteoarthritis) [26], as well as several well-known 
types of cancers [27] (e.g. breast, ovarian, prostate, liver, gallbladder and colon 
cancers) [1]. Moreover, a close correlation exists between obesity and several 
serious health problems, including hypertension [28], gallbladder disease or 
gallstones [29], gout [30], sleep apnoea and/or asthma [31,32], high blood 
cholesterol and/or atherosclerosis, liver diseases (e.g. non-alcoholic fatty liver 
disease) [33], chronic nephropathy [34], gastro-oesophageal reflux disease (GORD) 
[35], as well as depression and/or dementia [36]. 
The clinical impact of obesity-related comorbidities and the need to meet health 
provisions and expectations are the causes of the economic strain placed by high 
obesity prevalence on health systems. Obesity is a complex health problem 
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stemming from multiple factors and often occurs alongside other health disorders, 
particularly T2D. Therefore, the comorbidities must be considered in any obesity 
prevention strategies, else these strategies will not be effective. In 2007, the NHS 
spent £4.2 billion on treating health problems associated to obesity and related 
comorbidities, and that figure is estimated to increase to £9.7 billion by 2050, with 
broader societal costs (e.g. productivity loss) expected to rise to £49.9 billion by 
2050 [21]. Cancer Research UK and NHS, with funding from the Medical Research 
Council and the Health and Safety Executive, conducted the Million Women 
Study2, which revealed that obesity was the reason that one in eight women of 50 
years of age or older were admitted to hospital in England [37].   
1.4 Obesity prevention 
In the context of ‘cradle-to-grave’ welfare state social reforms fostered by the 
suggestions of the Beveridge Report in the aftermath of World War II, which 
peaked in the National Health Service Act of 1946 [38], the NHS was founded on 
July 5th, 1948, at the initiative of the Minister for Health Aneuryn Bevan under the 
Labour government of Clement Atlee. The NHS was intended to be open to all 
people living in the UK lawfully at no cost, with provision of services being 
contingent upon clinical needs rather than capability to pay. Public taxation 
remains the main basis of NHS funding, but some care services (e.g. eye tests, 
dental care, prescriptions) have become subject to extra charges [38]. Although 
 
2 The Million Women Study is a national study of women’s health, involving more than one million UK women 
aged 50 years and over. It is a collaborative project between Cancer Research UK and the National Health 
Service, with additional funding from the Medical Research Council and the Health and Safety Exective. 
  Chapter 1 - Introduction 
 11 
the NHS was designed to eliminate regional inequalities in healthcare, this has not 
been entirely achieved, especially in terms of services for weight management 
[38]. 
Primary care is provided in the UK by general practitioners (GPs), who are 
therefore the initial point of contact for the majority of individuals requiring 
medical help. GPs and other community healthcare practitioners then refer 
patients to secondary care, which includes emergency care, elective planned 
specialist medical care or surgery [38]. Prior to April 2013, obesity management, 
commissioning of weight management services, and prevention initiatives were 
the remit of GP primary care trusts (PCTs), which could commission primary, care, 
secondary care or private sector professionals to tackle obesity cases of high 
severity or complexity [38]. By contrast, specialised commissioning groups (SCGs) 
were responsible for commissioning bariatric surgery at regional level [38]. 
SCGs were empowered to allocate particular specialised services to providers. In 
England, there were ten SCGs, which were involved in the formulation of national 
standards regarding service allocation, with emphasis on the implementation of a 
general strategy at local or regional level. The SCG commissioned bariatric surgery 
and the eligibility criteria were subsequently established at local level [38]. 
According to the NICE Clinical Guidance (CG No. 43), cases were eligible for 
bariatric surgery if they had a BMI ≥ 40 or ≥35 kg/m2 alongside a comorbidity, such 
as hypertension, or if they had a BMI of 50 kg/m2 or above [39]. Similar guidelines 
were issued in 2010 by the Scottish Intercollegiate Guidelines Network (SIGN), with 
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cases with a BMI of 35 kg/m2 or above alongside comorbidity being eligible for 
bariatric surgery [40].  Nevertheless, there were some differences between 
regions, which enabled certain PCTs to refuse bariatric surgery in cases of severe 
and complex obesity or in cases with referral criteria that restricted access to this 
type of surgery, despite fulfilment of clinical needs [41]. Differences exist at 
national level as well, with Northern Ireland having no service of bariatric surgery 
[38]. 
Since its founding, the NHS has been most extensively restructured through the 
Health and Social Care Act of 2012. Although this restructuring maintained the core 
principle of patient-oriented care, it afforded greater authority to healthcare 
practitioners, especially GPs, to commission services based on clinical outcomes in 
the context of clinical commissioning groups [38]. Another consequence of the 
restructuring was the creation of local authority (LA) health and wellbeing boards. 
Whereas healthcare is governed at national level by Public Health England (PHE), 
it is governed by LAs at local level, where the majority of lifestyle weight 
management services are commissioned [38]. Hence, the allocation and influence 
of funds for weight management services has come to be dictated by elected (at 
local levels) individuals without appropriate medical expertise [38]. 
An independent NHS commissioning body (NHS CB) was established to supervise 
the daily operations of the restructured NHS, while PCTs and SCGs were dissolved 
in April 2013. However, the variation in bariatric surgery availability, the so-called 
‘postcode lottery’, and other issues persisted [41]. The new NHS England 
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guidelines formulated by the NHS CB clinical reference group for obesity of high 
severity and complexity were introduced in the immediate aftermath of the NHS 
reorganisation [7]. Since April 2013, the NHS CB has been in charge of provision of 
guidelines on an England-wide contract for bariatric surgery delivery to be 
undertaken by a provider fulfilling the stringent requirements related to the 
intervention [38]. These guidelines specify sources of funding as well as eligibility 
criteria for bariatric surgery in England. 
In keeping with the NICE CG43 BMI thresholds, the commissioning board has 
issued guidance about bariatric surgery eligibility, the procedures that can be 
offered through the NHS, and the clinical criteria that have to be satisfied to justify 
referral [38]. One contentious recommendation is that referral to surgery should 
be provided only after a year or two of ‘medical management’ administered in a 
Tier 3 non-surgical multidisciplinary team (MDT) clinic [38]. However, the available 
Tier 3 non-surgical MDT weight management services vary significantly owing to 
detailed suggestions regarding the anticipated provision of services [42]. 
Weight management services at every level are incorporated in obesity care in the 
UK, including public health campaigns, weight management programmes at 
community level, specialist MDT interventions, and bariatric surgery [38]. 
Interventions have been organised along three tiers according to the obesity 
model proposed by NICE (2006), namely, community weight management (Tier 1), 
specialist weight management (Tier 2), and bariatric surgery (Tier 3) [39]. 
Currently, however, NHS England implements a four-tier weight management 
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framework, which was proposed by NHS Rotherham, which won the 2009 Health 
and Social Care award for Excellence in Commissioning for its Healthy Weight 
Framework for individuals of all ages [43]. The four-tiered obesity management 
framework was further refined in an April 2014 report by a Department of Health 
working group concerned with ‘Joined Up Clinical Pathways for Obesity’ in adults. 
This document also offered guidance regarding the bodies that should be 
accountable for the four tiers and have the power to commission them [44]. 
1.4.1 Tier 1 and Tier 2 
Tier 1 consists of behavioural or general interventions, such as public health 
initiatives for raising awareness about the importance of a healthy diet and 
physical exercise as well as dissemination of basic information. Such interventions 
are typically undertaken by various healthcare practitioners (e.g. GPs, nurses, 
health visitors, school nurses) alongside pharmacists, local leisure providers, and 
related agencies in the context of primary care at local and regional levels. 
Furthermore, besides basic public health interventions, Tier 1 is frequently 
concerned with identifying overweight or individuals with obesity and those who 
have the necessary motivation to gain the most from being referred to weight 
management services at local level [38]. 
Lifestyle weight management services offered for a restricted period of time are 
the focus of Tier 2. Such services are usually provided by local teams in a group 
context at community level and encompass guidance for making modifications to 
diet, nutrition, lifestyle, and behaviour [38]. It has been recently advocated that 
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Tier 2 interventions could be successfully commissioned by commercial providers, 
such as WeightWatchers™, Rosemary Conley, and Slimming World [45], and 
moreover, that such interventions can be an affordable approach for offering 
overweight or obese individuals without comorbidities with general guidance for 
managing their weight (Figure 1.3) [38].  
 
Figure 1.3 Four-tiered structure. 
The implemented four-tiered weight management framework [46,47].  
 
1.4.2 Tier 3 (MWMS) 
Tier 3 constitutes a multidisciplinary weight management service (MWMS) 
delivered by a team made up of at least one bariatric physician, a dietitian, a 
specialist nurse, a clinical psychologist, and a liaison psychiatry professional with 
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access to physical therapy. Eligibility criteria for this tier include adult individuals 
with a BMI of 40 kg/m2 or higher, a BMI of 35 kg/m2 or higher alongside 
comorbidities (e.g. hypertension) or BMI of 30 kg/m2 or higher coupled with T2D 
diagnosed in the last decade. Furthermore, Tier 3 is compatible with ‘Weight 
Assessment and Management Clinic’ offered by NHS primary or secondary care 
[47]. However, if a primary care clinic contributes to weight loss intervention, a 
clear differences from Tier 2 interventions should be enforced [47].   
The bariatric physician is in charge of analysing excessive weight causes of a 
hormonal or genetic nature and associated comorbidities and disabilities. The 
dietitian should provide customised lifestyle and healthy eating guidance as well 
as an adequate physical activity plan in the context of the intervention devised for 
every patient. Furthermore, given the close correlation between obesity and 
various psychological disorders (such as anxiety, depression, self-harm, suicidal 
tendencies, eating disorders, borderline personality disorder, alcohol and 
substance abuse, problems stemming from a disadvantaged childhood, and 
obstacles to voluntary weight), every patient should be assessed for psychiatric 
comorbidities as well. Moreover, a treatment duration should be approximated by 
the psychiatrist for every patient, since more long-term support may be required 
by some [47,48]. 
After every obesity-related comorbidity has been effectively tackled and weight 
decrease has been achieved, the patients are referred by the MDT back to their 
GP. Advancement to Tier 4 bariatric surgery is offered to patients who have put in 
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serious effort in attending the clinic appointments, have a suitable MDT-outlined 
timeframe and the correct weight criteria, and are medically optimised for 
undergoing a surgical intervention. When making this decision, the MDT must take 
into account every contraindication of a medical, surgical, nutritional, 
psychological, and social nature. Additionally, patients must be appropriately 
informed regarding what the surgery involves from a nutritional perspective and 
have awareness about the life-long commitment necessary for post-surgery 
follow-up [47,49]. 
The identification of quantifiable outcomes for weight management programmes 
at community level and Tier 3 clinics should be prioritised by the local authorities 
and clinical commissioning groups [38]. This is necessary to determine how 
effective the relative expenditure is from a clinical and cost perspective by 
comparison to the proven effectiveness of bariatric surgery. In the UK, data on the 
performance of every surgeon can be openly accessed and this should be 
supplemented with similar data related to how effective the interventions at every 
tier are [38]. Figure 1.4 provides an overview of the approach of identification and 
weight evaluation and management (Pathway).  
1.4.3 Tier 4 (Bariatric) 
Patients are prepared to be referred to Tier 4 bariatric surgery based on the Tier 3 
recommendations of the MDT and once they have become physically and 
psychologically primed for the surgical intervention [47]. By comparison to obesity 
management through methods other than surgery, bariatric surgery not only 
  Chapter 1 - Introduction 
 18 
increases the amount of weight lost, but also leads to higher T2D remission rate 
and significantly diminishes reliance on medication for diabetes, antihypertensive, 
and lipid lowering, according to the findings of a meta-analysis of randomised 
controlled trials [50]. Furthermore, comorbidities associated with obesity in the 
analysed studies were unobserved. On the whole, a decrease of 25.9 kg (95%CI: -
30.9 to -21.0) was the mean difference in weight loss among the analysed studies 
from all methods, except gastric band, of bariatric surgery utilised [50].  
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Figure 1.4 Obesity prevention pathway. 
Model of care and patients’ pathway promoted by the NHS [46].  
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The metabolic surgical interventions performed on the organs of the gastric system 
to regulate the amount of food that can be consumed are known under the term 
bariatric. These kinds of procedures are intended to reduce calorie consumption 
by inducing neurohormonal and biological changes [51]. In turn, the reduced 
calorie consumption improves or fully eliminates a large number of diagnosed 
comorbidities, whilst also diminishing the risk of dying and hospitalisation, and 
alleviating healthcare expenditure in the long run [4]. 
In the UK, the ability to offer bariatric surgery exceeds the existing demand, as 
there is evidence that over 2 million individuals may have eligibility for this surgical 
procedure [52]. Employing data from the Health Survey for England (HSE), Ahmad 
and colleagues investigated the criteria for bariatric surgery eligibility as well as the 
socio-demographic characteristics and the comorbidities displayed by eligible 
individuals among a research sample of 9,425 participants. The results showed that 
a proportion of 5.4% of adults in England satisfied the eligibility criteria for bariatric 
surgery, which was considerably greater than the available capacity for this 
intervention [52]. The proportion of eligible individuals is likely to increase further 
[53] as the eligibility threshold is set to be reduced by updated NHS guidelines [47] 
and the number of individuals with obesity continues to increase [13]. 
Nevertheless, a decline in the number of bariatric surgeries from 8,794 to 6,384 
was recorded in the UK in the period 2011-2012 and 2014-2015, which are the 
lowest numbers of operations compared with the western European countries 
[52]. Moreover, bariatric surgery represents a much smaller part of data (less than 
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1% for 2017-2018) disclosed by the Statistics on Obesity, Physical Activity and Diet 
report [52,54].  
Bariatric surgery pursues three major principles, depending on its mechanism. 
Thus it can be a restrictive procedure, whereby solid food intake is restricted by 
making the stomach smaller; it can be a malabsorptive procedure, whereby the 
size of the small intestine is reduced to restrict nutrient assimilation and therefore 
diminish surface area exposure to food; or it can be a combination of the previous 
two principles [51]. In the last two decades, the NHS has commissioned four kinds 
of bariatric surgery [47]. 
Gastric banding: The purpose of the Laparoscopic Adjustable Gastric Band (LAGB) 
(Figure 1.5a) is to restrict food intake by circumscribing the superior part of the 
stomach and thus forming a small pouch. This brings about a sensation of satiety 
with minimal food intake [55].  
Sleeve gastrectomy: This bariatric procedure (Figure 1.5b) is designed to decrease 
the stomach size by around three-quarters. It involves a superior-inferior vertical 
division of the stomach, which produces a banana-shaped pouch along the internal 
curve and the pyloric valve at the inferior side of the stomach. In this way, the 
stomach emptying into the small intestine is controlled, without altering the 
function of the stomach [55]. 
Gastric bypass: This type of bariatric intervention (Figure 1.5c) can be conducted 
in several different ways, the Roux-en-Y gastric bypass (RYGB) being preferred in 
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the UK. The RYGB procedure involves formation of a small pouch by stapling off 
the superior part of the stomach and creation of a new exit from the pouch into a 
‘Y’ loop from the small intestine, thus preventing assimilation of food by the 
previous stomach and a small intestine portion of 100-150 cm. Careful thought is 
given to how big the stomach pouch should be and how much of the small intestine 
should be bypassed to allow sufficient food intake to meet the needs of the body 
at regular weight [55]. 
Duodenal switch: Malabsorption is the main mechanism underpinning this type of 
bariatric intervention (Figure 1.5d), which can be undertaken via two routes, 
namely, an open operation route by making a midline incision from the breastbone 
base or a laparoscopic route. From a technical perspective, the procedure has a 
high level of complexity and can last 5-7 hours. After surgery, the patient must 
typically remain hospitalised for 4-6 days. The procedure involves the removal of 
a small portion of the duodenum at the bottom of the stomach, which is linked to 
the second half of the small intestine. The next step is reconnecting the bypassed 
small intestine portion for the transport of bile and juices from the pancreas to the 
other portion of the small intestine close to its junction with the large intestine 
[55]. 




Figure 1.5 Bariatric surgery procedures. 
(a) Laparoscopic adjustable gastric banding, (b) laparoscopic sleeve gastrectomy, (c) Roux-
en-Y gastric bypass, (d) duodenal switch [34]. 
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1.4.4 Bariatric surgery complications 
Similar to numerous other major surgical interventions, bariatric surgery has a few 
limitations. However, unlike the average patient undergoing general surgery, the 
patient undergoing bariatric surgery may not present obvious manifestations of 
complications due to the fact that their body habitus and incompatibility of fit with 
most diagnostic examination tables make assessment challenging. Thus, 
deterioration may occur quickly and the patient may be inadequately equipped to 
cope [51]. 
Another issue related to bariatric surgery is the significant variation in the technical 
competence possessed by bariatric surgeons. One study reported that, when the 
intervention was performed by highly-skilled surgeons, there was a lower 
proportion of complications after surgery and fewer patients were required to 
undergo surgery or hospitalisation again or had to present to the emergency 
department [56]. Birkmeyer and colleagues developed a surgical skill scale, 
whereby the rates of complications (14.5% vs 5.2%, P < 0.001), mortality (0.26% 
vs. 0.05%, P = 0.01), operation duration (137 minutes vs 98 minutes, P < 0.001), 
and reoperation and readmission (6.3% vs. 2.7%, P < 0.001) were all higher in the 
bottom quartile than in the top quartile of surgical skill [56]. 
Among patients with a BMI lower than 50 kg/m2 and below the age of 55, the 
mortality rate is less than 1% [57]. However, this rate increases to 2–4% among 
patients with a BMI exceeding 60 kg/m2 and who have comorbidities as well [51]. 
Besides surgical skill, a positive correlation exists between reduced morbidity and 
  Chapter 1 - Introduction 
 25 
mortality risk and several factors, including surgical volume at the clinic, surgery in 
a tertiary care setting, gender, age, and respiratory status [58]. On average, the 
rate of complications associated with bariatric surgery is below 10% [59]. Outcome 
improvement can be most effectively achieved in the initial 6-12 hours, with fast 
increase in the likelihood of morbidity and mortality after 24 hours [51]. In spite of 
this, bariatric surgery remains a suitable option for managing severe obesity [59]. 
Nevertheless, long-term data about the impact of weight reduction on the 
comorbidities associated with obesity are necessary, as highlighted by evidence 
from a decade-long prospective study, which revealed that continuous weight 
reduction did not have a favourable effect on every risk factor related to obesity 
[59].   
Anastomotic or staple line leakage may be among the first complications after 
bariatric surgery. Post-RYGB anastomotic leakage occurs in 1.2–3% of cases [60]. 
The physician must examine the matter closely as the clinical presentation can be 
subtle. Constant symptoms include sustained tachycardia, particularly a heart rate 
persistently over 120 bpm, tachypnoea, as well as fever. Identification of 
anastomotic leakage via upper gastrointestinal series and computed tomography 
occurs in just 22% of cases and the skill of the operator is highly influential [60]. 
The leakage is managed via immediate surgery and follow-up examination via 
diagnostic laparoscopy or laparotomy [60]. 
An additional complication of bariatric surgery occurring in 3.1% of cases is post-
operative bleeding [61]. Such bleeding stops on its own in 22% of cases, but 
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necessitates blood transfusion and surgery in 55% and 22% of cases, respectively 
[61]. It is usually in the first six hours after surgery that active bleeding occurs, 
taking the form of secretion of bright red blood from the mouth, rectum or 
abdomen, which can be accompanied by low blood pressure and tachycardia. 
Active bleeding is managed through immediate surgery or endoscopy. On the 
other hand, delayed bleeding typically occurs a number of days after surgery and 
manifests as dark blood in the surgical drains or leaking from the mouth or rectum 
[61]. Although no signs or hemodynamic instability are associated with delayed 
bleeding, assessment via radiology, haematology, and endoscopy can facilitate 
detection [51]. 
Another possible complication of bariatric surgery is band erosion or dislocation, 
which may manifest as signs of proximal gastric outlet blockage, such as dysphagia, 
nausea, vomiting, intolerance to solids, and pain or discomfort in the abdomen, as 
well as immoderate weight loss [51]. The suggested course of action is to refer 
such cases to a bariatric surgeon. Furthermore, LAGB can also result in port or band 
tubing leak, which manifests as an initial sensation of post-prandial fullness, 
followed by subsiding of this sensation and greater tolerance for a greater amount 
of solid food after a couple of days. This can lead to renewed increase in weight or 
inadequate weight loss [51]. 
The formation of scar tissue in the context of healing may be accompanied by 
anastomotic stricture, which may be the reason why patients who have recently 
undergone surgery lose their tolerance to oral intake and start to gradually feel 
  Chapter 1 - Introduction 
 27 
nauseous and vomit when they ingest solid food and are capable of minimal fluid 
intake in one go. The suggested course of action is to refer such cases to a qualified 
dietitian and bariatric surgeon [51]. 
In cases of RYGB, unsuccessful or partial separation of the pouch through stapling 
may lead to the formation of gastrogastric fistulae [62]. This can manifest as the 
ability to eat great amounts of solids, absence of restriction or sensation of 
fullness, the ability to eat foods with textures that are not normally tolerated post-
surgery, renewed increase in weight, or suboptimal weight loss. The suggested 
course of action is to refer such cases to a bariatric surgeon [51]. 
When bariatric surgery is performed via a malabsorptive principle (i.e. reduction 
of nutrients absorption) or a combination of restrictive and malabsorptive, 
dumping syndrome can develop. This is defined as food going straight into the 
small intestine, without going first into the stomach [51]. Initial signs may occur in 
the first half hour after food ingestion and are caused by rapid passage of food and 
liquid into the small intestine. They may encompass nausea, vomiting, stomach 
pain or cramps, diarrhoea, sensation of fullness or bloating, and elevated heart 
rate [51]. Meanwhile, delayed signs occur within 1-3 hours of food ingestion and 
are caused by alteration in the blood levels of insulin and sugar, which is known as 
reactive hypoglycaemia. Among the delayed signs are flushing or sweating, 
pressing need to lie down, sensation of weakness or dizziness, sensation of 
nervousness or shakiness, or a decline in blood pressure [51]. 
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Nausea or vomiting, excess or loose skin, blockage of the small intestine, and ulcers 
are potential complications of bariatric surgery as well. In the majority of cases, 
nausea or vomiting can be alleviated by educating patients about which foods to 
eat and how to eat [51]. However, stricture and blockage evaluation should be 
conducted in cases where vomiting persists. Such cases should also be subjected 
to screening for thiamine deficiency and should be administered supplements if 
neurologic symptoms are identified [49]. When patients lose a significant amount 
of weight, they are often left with excess or loose skin, which can interfere with 
their ability to move and care for themselves, as well as promote the development 
of infections and skin ulcerations. The course of action suggested is to refer such 
cases to a bariatric physician or occupational or physical therapist [51]. Abdominal 
bloating or cramps, pain that can reach a high level of severity, nausea, and 
vomiting are possible symptoms of small intestine blockage, which may be caused 
by adhesions, internal hernia or severe constipation [51]. Upper epigastric pain or 
burning with possible radiation to the back, nausea, vomiting, and lack of tolerance 
to food may be symptoms of stomach ulcers or marginal ulcers (anastomosis). 
Chronic ulcers are typically accompanied by anaemia stemming from iron 
insufficiency [63]. It is important to evaluate patients’ longer term health 
conditions, including self-harm, substance abuse, mental health as well as the 
persisting problem of weight regain.  
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1.5 Thesis narrative, objectives and hypothesis  
The purpose of this overview is to emphasise how important it is to investigate the 
long-term advantages of weight loss and its ability to minimise or fully eradicate 
the impact of comorbidities associated with obesity. From a clinical perspective, 
the aim here is to examine the health outcomes of interventions in the pre- and in 
the post-bariatric surgery, taking specific consideration of the evidence from the 
extant literature as well as from a local service provision. In addition, this thesis 
establishes the extent to which the comorbidities have spread across the adult 
population and the impact of bariatric surgery. The analysis will heavily be based 
upon data originating from local clinics and the British primary care database. 
Based on an economic standpoint and identifying T2D as the primary comorbidity 
in the most extreme obesity cases, this thesis will initiate an exploration into the 
effectiveness of bariatric surgery. The objectives have been inspired or developed 
on light of the 2017 Commissioning Guide (Subsection 7.1 Research 
Recommendations) issued by the British Obesity and Metabolic Surgery Society 
[47]. 
By adopting an evidence-based research design, data analysis is performed using 
information from quantitative databases in conjunction with a qualitative 
approach in the form of a systematic review (refer to Chapter 2). The objective of 
this approach is to conduct a detailed exploration into comorbidities associated 
with obesity. In addition, this approach uses the metabolic results gained in 
previous research into severe obesity. However, due to its qualitative nature, the 
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systematic review may not provide an impartial perspective of the observational 
studies under evaluation. This could be attributed to the nature of qualitative 
typical approaches and the relatively increased risk of subjectivity.  
This thesis focuses upon addressing a series of research questions regarding the 
benefits of clinical and service outcomes of the before and after bariatric surgery 
in cases of severe obesity associated with a range of major comorbidities. 
Emphasis will be placed on cardiometabolic effect, and CKD and CV risks in cases 
with or without microalbuminuria, as well as the positive or negative implications 
of the procedures where the risk of liver disease is high. 
A number of key goals form the foundation of this thesis: determining the 
practicality of the clinical aspect of the four-tiered framework implemented in the 
UK for obesity prevention and weight loss promotion in terms of addressing the 
main comorbidities associated with obesity; determining the efficiency of surgery 
to improve patient health for those suffering from T2D and other comorbidities; 
determining the benefits of bariatric surgery in terms of minimising costs and 
enhancing long-term patient health; and determining areas of health most 
positively impacted by bariatric surgery. 
The clinical aspects of Tier 3 interventions and comorbidity data relating to 
extreme cases of obesity will be the focus of Chapter 2 and Chapter 3. Chapter 2 
includes a literature review related to Tier 3 and similar interventions and an 
overview of the comorbidities reported by the examined studies. Chapter 3 
explores Tier 3 local clinics, with a view to gaining insight into the development of 
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actual comorbidities by individuals with severe obesity. Within mind, the thesis will 
proceed asking whether Tier 4 bariatric surgery is effective in alleviating or 
eradicating the primary comorbidities throughout the following three chapters. 
Using the data sources employed in the fourth, fifth, and sixth chapters, the 
seventh chapter will comprehensively explore the effectiveness of Tier 4 bariatric 
surgery from a cost perspective. In addition to health utilisation, this chapter will 
evaluate composite risk of developing several comorbidities related to severe 
obesity – which were not fully covered in the previous chapters.  
The hypothesis is that commissioned clinical interventions for morbid obesity are 
effective long-term measures, protecting patients from the risk of developing 
obesity-related comorbidities, such as risk of CVDs, CKD, and liver diseases. A key 
benefit of these clinical interventions is the potential cost saving, reducing the 
overall pressure on the national budgets. Thus, this thesis has six main objectives:  
i. Systematically review and summarise obesity-related comorbidities within pre-
operative weight loss interventions. 
ii. Characterise non-surgical weight loss intervention and patients’ comorbidities 
within local clinics (i.e. Tier 3 multidisciplinary weight management service). 
iii. Investigate the cardiometabolic effect of bariatric (Tier 4) intervention on patients 
with major comorbidities (i.e. insulin-treated T2D). 
iv. Investigate the development of CKD in bariatric (Tier 4) intervention for patients 
with increased risk of diabetic nephropathy (i.e. baseline microalbuminuria in 
patients with insulin-treated T2D). 
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v. Explore the metabolic outcomes of diabetic patients with a high risk of liver 
disease (i.e. NAFLD) in the post-bariatric (Tier 4) intervention. 
vi. Establish a health utilisation (i.e. cost effectiveness) comparison of post-bariatric 
(Tier 4) intervention and explore composite obesity-related comorbidity 
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2.1 Summary 
Background and Aim: NHS England has recommended a multidisciplinary weight 
management services (MWMS—Tier 3 services) for patients requiring specialised 
management of obesity, including bariatric surgery, but clinical and measurable health-
related outcomes from these services remains fragmented. This systematic review was 
undertaken to explore the evidence base of effect on body weight loss and comorbidities 
outcomes of Tier 3 or UK pre-bariatric Multicomponent Weight Management 
Programmes (MWMPs). 
Methods: AMED, CINAHL, EMBASE, HMIC, MEDLINE, PsycINFO, PubMed, HDAS search 
and Google Scholar were searched from January 2000 to September 2017 in a free-text 
fashion and crossed-references of included studies to identify potential illegibility. 
Inclusion criteria were as follows: (a) published Tier 3 original study abstracts/articles; (b) 
intervention studies with before and after data; (c) studies that included any sort of 
MWMPs conducted within the UK for patients with obesity (BMI ≥30 kg/m2); and (d) 
studies included T2D measurements in MWMPs. 
Results: In total, 19 studies met the inclusion criteria. The total number of participants 
analysed was N = 11,735. Baseline accumulative average BMI was calculated at 42.54 
kg/m2, weight 117.88 kg and waist circumference 126.9 cm. And at 6 months, 40.73 kg/m2, 
112.17 kg and 120.3 cm, respectively. Secondary outcome variables were as improved 
with reduction in HbA1c, fasting blood sugars, insulin usage and blood pressure. Physical 
activity increased at 3 months then declined after 6 months. Little or no significant 
changes in cholesterol levels throughout. 
Conclusion: Tier 3 and MWMPs have a short to mid-ranged positive effect on patients 
with severe obesity living in the UK regarding accumulated reduction in body weight, 
glycaemic control, blood pressure and with subtle improvements in physical activity. 
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2.2 Background 
Morbid obesity is an increasing lifelong chronic condition that no country has yet 
succeeded to tackle [48]. In England, the prevalence of obesity is among the 
highest in Europe [7]. Two-thirds of adults are overweight and one in four are 
obese BMI of >30 kg/m2) [64]. McKinsey Global Institute reported that, second to 
smoking, obesity has the largest impact on the public health budget with an 
estimated annual cost to the UK’s NHS of £44.7b [15]. The importance of a range 
of obesity prevention initiatives comes from the increasing number of health 
complications and their related high cost. High Blood Pressure (BP), T2D, heart 
attacks, strokes, cancers and other health issues, for instance, are evidently 
associated to the conditions of being overweight or obese [47].  
Even though bariatric surgical intervention is a proven effective approach for 
treating chronic obesity, access and eligibility for bariatric surgery remains low 
[65]. The reasons for this are multifactorial, but may include a lack of developed 
infrastructure for medical assessment and services, unclear referral procedures, as 
well as uncertainties regarding costs and long-term outcomes [66]. In England, the 
rate of bariatric surgical operations dropped by 31% between 2011-2012 and 
2014-2015 (from 8,794 to 6,032 operations, respectively) [47]. It is much worse in 
Scotland and Wales, and there is no NHS bariatric surgery performed in Northern 
Ireland. Provision of bariatric intervention by NHS is, therefore, less than 1% of the 
national need [67]. 
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In the UK, obesity is managed through a 4-levels tiered pathway. Tiers 1 and 2 are 
focused on universally environmental and population-wide prevention services 
[47,68]. Following this, individuals with more complex obesity and/or medical 
needs are considered for Tier 3 MWMS, [69] which may lead to a Tier 4 service for 
consideration of bariatric surgery [70]. Tier 3 MWMS consists of a (bariatric) 
physician, a dietitian, a specialist nurse and a clinical psychologist with access to 
physical therapy. All adults identified with a BMI of ≥40 kg/m2, or ≥35 kg/m2 with 
comorbidities are eligible for bariatric surgery following assessment and input 
from involvement in Tier 3 services3. Tier 3, in this context, could also apply to a 
“Weight Assessment and Management Clinic” provided by primary or secondary 
care [47].  
Within a Tier 3 service, strategies are implemented to make critical changes about 
eating and physical activity habits to improve overall health and identify risk 
factors so that the planned intervention addresses and improves all elements 
comprehensively. Screening for hormonal or genetic causes of excessive weight as 
well as all related comorbidities and disabilities are conducted by the bariatric 
physician and each individual patient should have their own tailored lifestyle and 
healthful eating advice provided by a specialist dietitian [47].  
Although our understanding of the benefits of a Tier 3 service is growing—based 
on our appraisal of current literature [70,71], current evidence remains 
fragmented and needs to be synthesised to produce a more comprehensive 
 
3 This criteria is slightly different between local clinics across England. 
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picture which will help to translate to a safe and cost-effective approach to the 
management of morbid obesity in the UK.  
2.3 Aims 
To explore the evidence base of effect and magnitude on body weight loss in 
addition to other health-related outcomes of adults with severe obesity 
undergoing a Tier 3 or pre-bariatric MWMPs in the UK. We included adults with 
obesity (i.e. with BMI ≥30 kg/m2) living in the UK who have been enrolled in a Tier 
3 service or in any form of MWMP for losing weight. 
2.4 Methods 
2.4.1 Literature search 
A free-text literature search of articles published from January 2000 through 
September 2017 was performed. The search used the Healthcare Databases 
Advances Search (HDAS) via the National Institute for Health and Care Excellence’s 
(NICE) evidence services with access to the following electronic bibliographical 
databases: AMED, CINAHL, EMBASE, HMIC, MEDLINE, PsycINFO and PubMed (an 
example of search strategy is available in Appendix 10.1). An extended search was 
conducted using Google Scholar after reviewing additional studies that were 
included by Brown et al (2017) systematic review [72]. Terms used were related to 
“obesity” and “overweight” in conjunction with geographical restrictions to the UK 
(e.g. England, Wales, Scotland, North Ireland). Terms related to MWMS, Specialist 
Weight Management (SWM) and Tier 3 (e.g. weight management services, weight 
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reduction programmes, weight management interventions, multidisciplinary 
weight loss initiatives and multicomponent weight loss schemes) were utilised on 
the titles and abstracts search. In addition, I screened reference sections of all 
included studies to identify potentially illegible articles that meet the inclusion 
criteria of this review. See Figure 2.1 flow chart. 
2.4.2 Study selection 
This review used a similar pragmatic selection approach to Brown et al (2017) [72]. 
Tier 3 studies for adults (18 years and over with no upper age limit) with a mean 
baseline BMI of ≥40 or ≥35 kg/m2 with a comorbidity or ≥30 kg/m2 with T2D are 
included. In addition, all UK multicomponent pre-bariatric weight loss 
interventions that were planned and delivered for adults with BMI ≥30 kg/m2 
published since January 2000 until September 2017 were screened for potential 
inclusion. Inclusion criteria follow: (a) published Tier 3 original study abstracts 
and/or articles; (b) weight reduction intervention studies with before and after 
data; (c) studies including any sort of MWMP planned for patients with morbid 
obesity living in the UK; and (d) studies that included T2D measurements in a 
MWMP for overweight adults. The review excluded studies on children or 
adolescents and all studies conducted within non-British weight reduction 
intervention programmes. The decision to include or exclude studies was initially 
made based on the article title, then abstract and finally by reviewing the article in 
full-text.  
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2.4.3 Data extraction  
The included studies were projected to extract four major elements of data 
contributions: (a) descriptive to study design and intervention; (b) sample size and 
demographic characteristics; (c) assessed measurements; and (d) health outcome 
records at baseline followed by points of time intervals.  
In the descriptive of study design and intervention, I included the following: 
setting, study design, aim, type of intervention, a brief description of intervention, 
inclusion and exclusion criteria, duration and lost-to-follow-up or drop-out data 
rate. In the demographics: sample size (N), age (years), gender (female, %), 
ethnicity, socioeconomic status (SES), education level, marital status and type of 
financial support. On the assessed measurements (n, %): mental disorder, anxiety, 
depression, sleep apnoea, hypertension, CVD, ischaemic heart disease, 
hyperlipidaemia, diabetes mellitus (DM), impaired fasting glucose, insulin use, oral 
hypoglycaemic and incretin based.   
For the baseline, 3, 6, 12, 18 and 24 months, I extracted (or calculated) the 
following variables of health outcome results: BMI (kg/m2), body weight (kg), waist 
circumference (cm), 5% or more weight loss achieved, 10% weight loss achieved, 
lost ≥5 kg (reported in proportion), lost ≥10 kg (reported in proportion), lost 0 to 
≤5 kg (reported in proportion), lost 5 to ≤10 kg (reported in proportion), lost 10 to 
≤15 kg (reported in proportion), lost 15 to ≤20 kg (reported in proportion), lost ≥20 
kg (reported in proportion), mean weight loss (kg), percentage of body weight lost, 
BP (systolic and diastolic), hypertension, insulin usage, Fasting Blood Sugar (FBS) 
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(mmol/L), glucose (mmol/L), HbA1c4 (% and mmol/mol), cholesterol (mmol/L), HDL 
and LDL (mmol/L), total cholesterol, triacylglycerol and levels of physical activity. 
It was not feasible to extract food intake observations because of heterogeneity of 
stratification methods used by a number of studies in addition to concerns of 
related recall bias. This review supports Brown’s et al (2017) decision regarding the 
difficulty in producing a meta-analysis in reviewing Tier 3 and all MWMPs due to 
heterogeneity [72]. The increased rate of patient drop-out and apparent risk of 
bias are also preventive factors to a meta-analysis. Thus, narrative synthesis was 
carried out.  
 
 




Figure 2.1 PRISMA flowchart. 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart [73].
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2.4.4 Risk of bias assessment 
All included studies were assessed using the Cochrane Handbook for Systematic 
Reviews of Intervention tool [73]. The possibility of the following bias elements 
was carefully evaluated: allocation sequence, allocation concealment, blinding (of 
participants, personnel and outcome assessors), incomplete outcome data, and 
selective outcome for reporting or publication of data. 
2.5 Results  
1,342 article abstracts were identified as potentially relevant, and after reviewing 
418 in full-text, 11 articles and 2 published study abstracts met the inclusion 
criteria and were included in the review. Grey literature search and reference lists 
check including Brown’s et al (2017) systematic review yielded additional 6 study 
articles (see Figure 2.1 Flow chart). In total, 19 studies were eligible for inclusion. 
The reasons for excluding 405 articles were: a) not being a UK based intervention; 
b) not Tier 3 or MWMP; c) did not meet BMI criteria; d) intervention intended for 
children or adolescents; e) no usable data (e.g. qualitative approach for 
satisfactory observations); and f) post-bariatric groups comparison. The 19 
included studies were all published within the last 20 years in 15 different journals, 
all conducted within the UK.  
Table 2.1 summarises details on study design, intervention type and descriptive 
summary, demographic characteristics of participants (N = 11,735), reported 
measurements and baseline characteristics and average reported health outcome 
results in three, six, twelve, eighteen, twenty-four-month intervals. The majority 
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of included studies (90%) did not reach 18 and 24 months, thus reporting MWMS 
true effect at these particular points of time was difficult. However, a decision was 
made to evaluate findings at the last endpoint possible as this may add value. 
The majority of included studies (95%) reported our primary outcome of interest 
in weight and/or BMI from the baseline records up to their study endpoint. Turner 
et al (2015) was the study article that did not report weight in any form at baseline; 
however, this study reported rates of participants who achieved ≥5% and ≥10% 
weight reductions at their intervention endpoint of 12 months (i.e. 36% and 37%, 






Table 2.1 List of included studies with summary characteristics and results. 
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42.9 ± 9.9 
100.0 
 
40.49 ± 8.36† 








HDL: 1.30 ± 0.45 
LDL: 2.87 ± 0.77 
Triacylglycerol: 





1.37 ± 0.32 
2.81 ± 0.78 
 
1.43 ± 0.97 









6 48.2 ± 11.6 
73.7 
49.1 ± 9.2 
135 ± 28.1 
47.6† 
131.4† 
HbA1c: 63.9† 59.6†‡ 




49 SWM (Weight No 
More) 
RCT 4 56.7 ± 9.7 
47.0 
34.1 ± 4.7 
97.2 ± 15.1 
BMI NR 
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Jackson (2007) [79] 
England  
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visitor with 








12 55.8 ± 13.8 
80.9 
37.4 ± 5.85 
103.16 ± 16.9 
33.11 ± 5.7‡ 
91.64 ± 19.0‡ 
BP: 138.4/78.4 
FBS: 5.44 ± 1.08 
Cholesterol: 
5.38 ± 1.19  
124.4/69.6‡ 
5.04 ± 0.60‡ 
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52.7 ± 13.6 
70.0 
 
44.1 ± 7.8 
124.4 ± 27.3 
 
41.0 ± 7.6‡ 
115.8 ± 26.0 
 
BP: 131/76 





3.4 ± 1.0 
 
122/71‡ 
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53.7 ± 14.1‡ 
 
2.8 ± 1.2‡ 




280 Tier 3 SWMS Retrospective 
cohort 
6 Age NR 
67 
49.4 ± 7.4 
138.9 ± 27.2 
48.5 ± 7.5 
136.3 ± 27.5 
NR NR 
Lean (2013) [81] 
Scotland 
 
91 Low-energy Liquid 
diet LELD and Food 
Reintroduction 
Feasibility study 12 45.7 ± 10.7 
81.3 
48.0 ± 7.6 
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45.0 






McLean (2016) [36] 
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12 48.1 ± 12.5† 
72.2† 
43.77 ± 7.23† 
122.5 ± 24.2† 
NR NR NR 
Melville (2011) [84] 
Scotland  




6 48.3 ± 12.0 
59.3 
40.0 ± 8.0 
100.6 ± 26.8 
39.1 ± 8.2‡ 
96.1 ± 26.9‡ 
Waist:  
122.1 ± 15.7 
 
115.8 ± 16.7‡ 
Morrison (2012) [85] 
Scotland  











NR:  Not Reported 
† Observed, calculated or converted by reviewer.  
‡ With statistical significance (i.e., P<0.05). 
* Units: BMI (kg/m2); Weight (kg); Blood Pressure (BP) (mmHg); HbA1c (mmol/mol-1); Fasting Blood Sugars (mmol/L-1); Insulin usage (Units); Cholesterol (mmol/L-1); HDL& LDL (mmol/L-1); Triacylglycerol 
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24 54.6 ± 11.2† 
55.0 
39.5 ± 6.5 
112.0 ± 20.9† 
BMI NR 
99.7 ± 32.4‡ 
HbA1c: 59.6† 
Insulin usage: 




90 ± 124.1‡ 








Before and after 
study (without 
control). 
12 52.2 ± 11.9 
70.0 
46.3 ± 7.2 




Pain: stratified Stratified 








24 Age NR 
72.7† 
NR NR NR NR 
Wright (2012) [90] 
Scotland 
 
199 SWMP Cross-sectional 6 49.7 ± 12.6 
76.4† 
BMI NR 
114.5 ± 23.4 
BMI NR 
109.4 ± 23.1‡ 
NR NR 
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2.5.1 Study design 
The study design ranged: one randomised controlled trial (RCT) [77], a semi-
structured interview (service quality evaluation) study [74], a retrospective case-
control [75], a feasibility study [81], a cross-sectional [90], two single-group 
observational cohort (service evaluation) studies [46,76], three retrospective (data 
analysis) cohort studies [36,80,83], and nine prospective cohort studies 
[78,79,82,84-89].  
Five studies investigated the effect of Tier 3 services [46,74,78,80,90]. Three 
looked into the Glasgow and Clyde Weight Management Service (GCWMS) 
[36,82,85]. Whereas the remaining studies focused on further MWMPs including: 
‘TAKE-5’ GCWMS [84], Dietetic led [75], ‘SLiM’ SWM [76], ‘Weight No More’ SWM 
[77], specialist health visitor programme [79], Low-Energy Liquid Diet (LELD) food 
reintroduction [81], Renal Weight Management Programme (RWMP) [83], 
specialist community weight reduction programme [86], ‘CounterWeight’ SWM 
[87], Orlistat weight reduction [88] and, biopsychological multidisciplinary 
programme [89]. Further details on study design and intervention description are 
in Table 2.1.   
2.5.2 Risk of bias 
All studies showed high risk in selection, performance, detection and attrition bias. 
This is because all included studies, except for the only RCT [77], were designed as 
evaluation (before and after), retrospective analysis or uncontrolled prospective 
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investigation. The risk of publication or reporting bias was low to unclear for all 
studies which may add to the overall reliability (see Figure 2.2). Attrition bias was 
evaluated high in consequence of the increased pattern of patients’ drop-out. 
Drop-out rates were not fully investigated or discussed in all included studies. 
 
 
Figure 2.2 Risk of bias assessment. 
Risk of bias assessment for each risk of bias element for all included studies. 
 
2.5.3 Participants’ characteristics  
Women comprised the largest percentage of participants in all except two studies: 
Cheyette (2007): 47%; and MacLaughlin et al. (2015): 45% [77,83]. One study did 
not include men (Barratt et al., 2008) [75]. Age ranged from 18 to 75 years; mean 
age ranged between 40 and 60 years (mean: 49.2 years). Ethnicity was reported in 
groups by 5 (26%) studies with a clear majority being Caucasian (ranging from 47% 
to 96%); and with Black African or Asian descendants reported second 
[75,76,83,84,86].  
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2.5.4 Socioeconomic status 
SES was reported in 7 (37%) studies in a five-level scoring classification [36,82,85-
87,89,90]. In studies that included SES, the most deprived was reported with the 
highest rate compared to all other deprivation levels (ranging from 27% to 62%). 
Only Jennings et al. (2014) study reported education level, which included three 
layers (≤15 years: 30%, 15-19 years: 52%, and ≥19 years: 18%) [46]. In addition, 
Melville’s et al. (2011) study reported participants’ marital status (Married: 2%; 
Single: 98%) and their type of financial support (Live independently: 7.4%; Family 
carer: 31.5%; Paid carer: 61.1%) [84]. 
2.5.5 Primary outcomes of interest  
Baseline BMI was reported by 90% of included studies except for Turner et al. 
(2015) and Wright et al. (2012) and ranged from 30.1 to 49.1 kg/m2 [36,46,75-89]. 
Two studies reported BMI in stratified groupings which left the accumulative 
average BMI calculated from 16 studies at 42.54 kg/m2. Baseline body weight in 
kilograms was also reported by 90% of included studies except for Morrison et al. 
(2011) and Turner et al. (2015) [36,46,75-84,86-90]. Turner et al. reported 
participants whom lost weight at 12 months, which was their intervention end-
point [74]. Wright et al. (2012) reported weight at baseline and at six months 
(114.5 [±23.4] kg and 109.4 [±23.1] kg, P<0.001; respectively) [90]. The baseline 
accumulative average of weight is calculated at 117.88 kg (see Table 2.2). 
At three months, the calculated average BMI from six studies is 42.40 kg/m2 
[46,76,79,80,86,87]; five of which reported statistical significance at (P<0.001) 
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[46,76,79,86,87]. Morrison et al. (2011), however, reported BMI in a stratification 
[85]. The mean reduction in weight ranged from 3.34 (±3.53) to 4.11 (±4.95) kg 
(P<0.001) in 6 studies [46,76,79,80,86,87]. An average of weight reduction with no 
BMI informed and with a reported statistical significance by Cheyette (2007) (2.2 
[±2.7] kg; P<0.01) [77]. In total, eight studies (42%) reported change in BMI and/or 
body weight at three months from their baseline, and the majority reported 
statistically significance weight reduction with an accumulative average of 114.48 
kg [46,76,77,79,80,85-87]. Six studies (31%) reported a percentage of participants 
who lost 5% or more of their initial weight (calculated mean: 22.95% of 
participants) [36,46,80,82,86,87]. Jennings et al. (2014) was the only study to 
report a 10% or more weight reduction rate among participants (3.6%) [46]. Details 
on rates are summarised in Table 2.3. 
At six months, 11 studies (58%) reported changes in BMI or body weight or both 
[46,75-77,79,80,84,86-88,90]. The calculated average reduction in BMI is 1.89 
kg/m2 ranging from 0.8 to 3.3 kg/m2 in eight studies with a cumulative average of 
40.73 kg/m2 [46,75,76,79,80,84,86,87]. The mean reduction in body weight was 
reported by ten studies (53%), with a calculated accumulative average of 112.17 
kg [46,76,77,79,80,84,86-88,90]. Nine studies (47%) reported a 5% or more weight 
loss rate among participants with a calculated average of 39.2% 
[36,46,76,82,84,86-88,90]. Only two studies (11%) reported an average of 10.0% 
of participants whom lost 10% or more from their initial weight [46,76].  
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At one year, five studies (26%) reported change in BMI or weight or both [46,77-
79,87]. BMI reduction was reported by three studies (16%) with a calculated 
average of 36.67 kg/m2  [46,79,87]. Weight reduction was reported by five studies 
(26%), ranging from 2.8 to 11.6 kg reduction and with a calculated average of 
102.89 kg [46,77-79,87]. An average of 43.4% of participants have achieved 5% or 
more weight loss; as reported by seven studies (37%) [36,46,74,78,82,87,89]. At 
this point, only two studies (11%) have reported 10% or more weight loss with a 
calculated average 29.4% of participants [46,74].  
Table 2.2 Summary of calculated average primary and secondary outcome results covered 
and reported by the included studies. 
 Baseline 3 months 6 months 12 months 18 months 24 months 






±13.6(3)   

















±15.4(1)   






±9.9(2)   






0.6(1)   
Insulin usage, Units 101.0(2) 58.7(1) 76.55(2) 62.0(1)   






±1.3(1)   
BP 
mmHg 
Systolic 134.7(2) 129.5(1) 124.5(2) 123.2(2)   
Diastolic 77.2 72.6 75.9 70.5   
PA 
 
Out of 4† 3.4 2.9 2.7 2.8   
min/week‡ 113.2 123.2 107.4    
Drop-out, %  9.1(1) 33.4(5) 44.1(8)  74.1(4) 
± Calculated standard deviation. 
∆ Superscript in-bracket numbers represent count of studies contributed in calculating the correlated average. 
† Inverse score used by Jennings et al. (2014) to report physical activity where 4 being inactive and 1 is active. 
‡ Physical activity reported by Nield et al. (2016) in minutes per week. 
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At eighteen months, Jennings et al. (2014) was the only study that reported change 
in kilograms [46]. The mean reduction in weight was 12.4 kg (P < 0.001) with 47.9% 
of the remaining participants who lost 5% or more and 26% lost 10% or more of 
their initial weight. At eighteen months, there were no additional outcome 
variables reported by any of the included studies. 
At two years, three studies (16%) briefly reported weight change [46,85,88]. 
Jennings et al. (2014) and Rowe et al. (2005) reported weight change in kilograms 
from the remaining participants with an average reduction of 11.9 kg (P < 0.01) 
with a cumulated average of 105.95 kg  [46,88]. Morrison et al. (2011) reported 
only the rate of participants whom lost 5 kg or more (13.6%) [85]. At this point, 
there were no additional outcome variables reported by any of the included 
studies. In addition, no prospective study went beyond two years of follow up. 
Tables 2.2 and 2.3 and Figure 2.5 represent calculated average results. 
Table 2.3 Calculated average rates of participants who have lost weight covered and 
reported by the included studies (%). 
 3 months 6 months 12 months 18 months 24 months 
≥5% weight loss 23.98(7)∆ 39.20(9) 43.35(7) 47.90(1) 44.40(1) 
≥10% weight loss 3.6(1) 10.0(2) 29.4(2) 26.0(1) 20.0(2) 
≥5kg weight loss 27.20(2) 39.21(2) 40.90(2)  13.60(1) 
≥10kg weight loss   36.0(1)   
∆ Superscript in-brackets numbers represent count of studies contributed in calculating the correlated 
average.  
 
2.5.6 Secondary outcomes of interest 
The included studies reported secondary outcome variables in a heterogeneity 
that made tracking a set of health outcome variables problematic. Eight studies 
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(42%) reported secondary health outcome variables at baseline: waist 
circumference, glycaemic control, lipids, BP and physical activity [46,75-
77,79,84,86,88]. Details on baseline results are in Table 2.2. 
At three months, Jennings et al. (2014) and Nield et al. (2016) reported significant 
reduction in waist circumference by an average of 4.02 cm (P < 0.001). The 
accumulative average of waist circumference was 125.3 cm. They also reported 
significant increase in physical activity levels, but with different measuring 
methodology5 (Jennings: 17.2%; and Nield: 8.8% increase; P < 0.001) [46,86]. 
Cheyette (2007) and Jennings et al. (2014) reported improvements in glycaemic 
control. The reduction in insulin usage reported by Cheyette is 10.1 (±16.4) units 
(P<0.01); and an average of 56.5 mmol/mol in HbA1c6 reported by two studies 
[46,77]. Jackson et al. (2007) reported a significant improvement in FBS by a 
reduction of 0.36 mmol/L from baseline. Jackson also reported improvement in BP 
with a significant mean reduction of 9.0 mmHg systolic and 5.8 mmHg diastolic (P 
< 0.001) and a mean reduction in cholesterol by 0.2 mmol/L (P = 0.02) [79]. Table 
2.2 and Figure 2.3. 
 
5 Jennings et al. (2014) reported physical activity through a 4-level scoring methodology with score 
number 4 being inactive and score number 1 being active. Nield et al. (2016) used minutes per week 
as the unit of measurement.  
6 Calculated average after conversion from percent to mmol/mol measurement units. 
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Figure 2.3 Metabolic outcomes of Tier 3 and MWMPs. 
Average results for BMI (kg/m2), weight (kg) and waist circumference (cm) at baseline and up 
to 24 months follow up from the included studies. 
At six months, three studies (16%) reported further significant reduction in waist 
circumference with an average of 6.6 cm (P < 0.001) [46,84,86]. The waist 
circumference averaged at 120.3 cm. The average reduction in HbA1c from five 
studies (26%) is calculated at 4.86 mmol/mol (P < 0.05) [46,75-77,88]. Rowe et al. 
(2005) reported further significant reductions in insulin usage by a calculated mean 
of 40.0 units (P < 0.001) [88]. In addition, Jackson et al. (2007) indicated a 
significant constant decrease in FBS by 0.3 mmol/L from baseline (P = 0.03) [79]. 
Jackson, nonetheless, reported an insignificant reduction in cholesterol (by 0.15 
mmol/L; P = 0.6). Jennings et al. (2014) reported a very significant increase in 
physical activity (by 26%; P < 0.001) from baseline; whereas Nield et al. (2016), 
reported a decline (from 123.2 min/week at 3 months to 107.4 min/week at 6 
months) [46,86]. The calculated average reduction in BP was reported by two 
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studies (11%); with an average reduction in systolic BP by 10.2 mmHg and diastolic 
by 1.3 mmHg from baseline [46,86]. Five studies reported drop-out rate with an 
average of 33.4%, ranging from 18 to 60% [76,80,84,86,88] (Table 2.2 and Figure 
2.4).  
 
Figure 2.4 Additional outcome results from Tier 3 and MWMPs. 
Calculated average results for systolic and diastolic blood pressure (mmHg), HbA1c 
(mmol/mol), insulin usage (units) as well as participants’ drop-out rate (%) from the included 
studies.  
At one year, HbA1c average results calculated from two studies (11%) was found 
to reclaim to the baseline calculated average (59.4 compared to 58.8 mmol/mol at 
baseline) [46,77]. Turner et al. (2015), however, noted that 36% of participants 
reported a reduction in insulin usage [74]. Cheyette’s (2007) participants 
experienced a similar reduced level of mean insulin usage as they did at three 
months (62.0 [±30.4] units) [77]. Similarly, Jackson et al.’s (2007) participants had 
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Jackson also reported an insignificant change in cholesterol [79]. Both Jackson et 
al. (2007) and Jennings et al. (2014) reported a statistically significant decrease in 
BP with an average systolic reduction of 11.5 mmHg and in diastolic by 6.76 mmHg 
(P=0.001) [46,79]. Only one study reported physical activity with a similar level as 
the three months point of intervention (scored 2.8 at one year compared to 2.9 at 
three months) [46]. Waist circumference remained relatively constant compared 
to six months point; with a mean reported by one study 118.8 cm [46]. Eight 
studies reported increased drop-out rate with an average of 44.1% ranging from 
15.6 to 78.3% [46,78,79,81-83,87,89]. Table 2.2 and Figure 2.3.  
At eighteen and twenty-four months, there were little or no secondary outcome 
variables reported by any of the included studies. Drop-out rate increased to an 
average of 74.13% at two years point; ranging from 62.0 to 80.5%, as reported by 
4 studies [46,85,87,88]. Table 2.2 and Figure 2.4 summarise drop-out rates form 
included studies.  
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Figure 2.5 Rates of weight loss. 
Calculated average rates for weight loss reported by the included studies.  
2.6 Discussion 
Although obesity has an increasing academic and clinical interest globally, the 
evidence on Tier 3 and all other MWMPs in the UK remains scarce [47]. The aim of 
the present review was to examine Tier 3 and MWMPs for adults with severe 
obesity. Our review fulfilled the PRISMA checklist for reporting systematic reviews 
(Appendix 10.2) [73], and it also supports the accumulating obtainable evidence 
that Tier 3 intervention reached positive influence on morbidly and among patients 
with severe obesity in the pre-bariatric stage. Evidence suggests that Tier 3 
interventions are effective obesity treatment, especially during the early months 
of involvement. 
In general, all MWMPs were found to reduce weight considerably and to improve 
other health outcomes measured from baseline on most reported health variables. 
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of intervention. This later observation is crucial with regards to the appropriate 
timing for a bariatric surgical intervention. A small number of included studies 
discuss this phenomenon, perhaps due to the substantial proportion of 
participants who drop out at an accelerating rate beyond the three-month point 
of intervention. In addition, more recent studies have provided novel insights into 
the processes and mechanisms that underpin weight regain after weight loss. In 
addition to environmental and behavioural factors, physiological (or metabolic) 
adaptations to weight loss favour weight regain due to perturbations in the levels 
of circulating appetite-related hormones and energy homoeostasis, in addition to 
alterations in nutrient metabolism and subjective appetite. To maintain weight 
loss, individuals must adhere to behaviours that counteract physiological 
adaptations and other factors favouring weight regain [91,92]. It is difficult to 
overcome physiology with behaviour. Nonetheless, this, and variations in study 
duration, may contribute to preventing this review from comparing the true effect 
size between included studies. Though future research is required to examine 
secondary outcome variables such as glycaemic control and lipids (in 
stratifications) extensively, weight loss goals such as 5% weight loss (NICE 
guidelines) are reachable at early stages of interventions (see Table 2.3).  
This review agrees with Brown’s et al. (2017), which notes most available reviewed 
evidence comes from observational studies in which randomised selection and 
allocation into Tier 3 services would improve inference reliability [72]. The only RCT 
reviewed, for instance, lasted for a short intervention duration (four months) and 
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reported a modest mean reduction in weight (by 2.2 kg) [77]. At three months, the 
mean reduction in body weight from all studies that reported changes (including 
the RCT) reached 4.11 kg, thus almost doubling the reported RCT-measured effect. 
Improvements in secondary health outcome variables were significant until the 
effect of the drop-out rate becomes apparent. This may be because all studies have 
excluded drop-out data from their analyses at each interval. At the three- and six-
month points, however, we can appreciate achieved improvements in glycaemic 
control and BP. Most studies that reported secondary outcome variables related 
magnitude to a statistical significance. Physical activity, for instance, had an 
average increase reached 26% at three months (P < 0.001) then declined 
afterwards [46,86]. Despite the assessed high risk of bias, I have noticed no 
difference in magnitude between small and large sample size studies. Studies that 
reported demographic characteristics such as SES and/or education levels did not 
reveal distinct effects either. Thus, Tier 3 and MWMPs may have been preventive 
tools in the short- and mid-term, treating obesity regardless of sample size, 
demographical characteristics or comorbidities.  
Studies invested in patients’ emotional and motivational status, and which 
reported data for depression and anxiety, were just as likely to have a high rate of 
patient drop-outs as those that did not. This, in count, does not support the notion 
that weight reduction levels in those programmes were superior to other studies 
that did not target emotional health. McLean et al. (2016), for instance, concluded 
that patients with complex obesity who scored high for severe anxiety and/or 
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depression participating in an MWMP with integrated psychological support, 
achieved similar weight reduction outcomes compared to non-severe cases [36]. 
Thus, more research is needed regarding obese people’s mental wellbeing, process 
and pathway for psychological intervention as well as robust outcomes from such 
interventions. 
A majority of included studies were not as precise in discussing participants’ 
reasons for dropping out. Extending efforts to assess and overcome drop-outs, 
appeared to contribute to a successful intervention (especially a multicomponent 
one) and the achievement of desired targets. This is because, as anticipated by 
commissioning parties, Tier 3’s main goal is to help patients, at a minimum, to lose 
weight and improve most of their quality of life aspects, improve and induce 
remission of comorbidities or to optimise patients’ preparation for a Tier 4 bariatric 
surgical intervention. The goal is, optimistically, helping patients to take control of 
their own lives and all other healthful elements; which is the drive for 
commissioning all tiered weight reduction interventions.  
Brown et al. (2017) recently published a systematic review examining a set of 
criteria for interventions similar to the ones this review has covered [72]. This 
review has only excluded two studies from their selection, as one was of non-
British origin and the other was comparing groups in post bariatric [71,93]. They 
reviewed 14 studies, and our conclusions were based on lines of theoretical 
analysis similar to theirs. Our review adds to the evidence base on a stratified basis 
with summaries for weight loss achieved and calculated average outcome results 
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and suggests further research regarding intervention’s high drop-out rates as well 
as outcomes from psychological and physical activity interventions. More RCT-
designed studies would greatly contribute to robust, real-life findings, as all 
possible confounding effects would ideally distribute evenly between study 
groups. 
In summary, the reviewed evidence for the Tier 3 service and MWMPs suggests a 
short- to mid-ranged positive effect on patients with obesity living in the UK 
regarding accumulated reductions in body weight, glycaemic control, BP and 
subtle improvement in physical activity. The high drop-out rate may have 
contributed to limiting longer terms’ progress in all positive results, especially 
those related to physical activity. More randomised trial investigations and drop-
out explorations would improve overall reliability. Tier 3 service and MWMPs can 
assist adults with obesity living in the UK to lose weight and may slightly improve 
their overall health status. 
2.7 Limitations 
Studies published on Tier 3 and UK MWMPs are limited in number. Yet, most if not 
all of included studies are of high risk of bias in terms of allocation sequence, 
allocation concealment, blinding, incomplete outcome data. The only RCT 
reviewed has shown a modest change in weight compared to all included studies 
[77]. The high rate of drop-outs was present in most if not all included studies with 
inadequate reasoning. The majority have excluded non-completers’ data from 
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3.1 Summary 
Objective: There is limited evidence regarding the prevalence of obesity-related 
comorbidities and the effectiveness of specialist multidisciplinary weight management 
(Tier 3) programmes prior to bariatric surgery. This paper aims to evaluate and report on 
the prevalence of comorbidities in patients attending Tier 3 services within a National 
Health Service setting.  
Methods: The current study comprises an observational study of consecutive patients 
who attended the Tier 3 service at the East Midlands Bariatric Metabolic Institute during 
2017. 
Results: 430 patients attended the service over the study observation period. Twelve 
patients (2.8%) were excluded from our analysis due to incompleteness of data. 70.8% of 
patients were women, mean age at baseline was 46.4 years, mean and SD of body weight 
and BMI at baseline were 137.8 (±29.2) kg and 48.0 (±8.6) kg/m2, respectively. The most 
common comorbidities recorded at baseline were T2D (31.1%), hypertension (31.1%), 
depression (26.1%), obstructive sleep apnoea (23.2%), and osteoarthritis (15.6%). 
Significant weight loss was observed at the three-month and six-month follow-up points, 
but not at the nine-month or twelve-month follow-up points. 22.5% of patients achieved 
weight loss of ≥ 5%. 
Conclusion: The prevalence of comorbidities within this Tier 3 service was high. While 
specialised weight management services can achieve moderate weight loss as part of a 
multidisciplinary intervention, any future evaluation of clinical outcomes of specialist 
weight services should also include comorbidity outcomes. 
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3.2 Background and aims 
Obesity is recognised as one of the leading healthcare challenges both in the UK 
and in the global context [94]. National Health Service (NHS) statistics have 
revealed that, in 2015, 27% of UK adults were obese, representing an increase of 
12% from 1993 [95]. The percentage of adults classified as obese (i.e. BMI ≥30 
kg/m2) has since remained steady, but there has been an alarming 18% increase in 
hospital admissions for obesity-related comorbidities. Thus, whilst there were 
525,000 admissions in 2015/16, this figure has risen to 617,000 in 2017/18.2 
Worryingly, 20% of year 6 children (aged 10–11) and 10% of reception year 
children (aged 4–5) are now classed as obese [95]. Studies indicate that obesity 
increases the likelihood of developing serious comorbidities, including, but not 
limited to, diabetes, hypertension [96], gallstones [97], osteoarthritis [98], 
cardiovascular disease [99], sleep apnoea (among males) [100], and fatty liver 
disease [101]. A moderate sustained weight loss of 5–10% has been shown to be 
associated with significant clinical benefits in individuals with obesity and is 
therefore considered an important treatment objective [102]. 
The UK NHS has recommended the implementation of a tiered model for weight 
management [47]. Tier 1 interventions comprise general guidance and advice, as 
provided in widespread community-based environments. Tier 2 interventions 
encompass more complex measures, such as weight loss programmes, which are 
to be provided by either local public health bodies or commercial providers (e.g. 
Weight Watchers™ and Slimming World™). Tier 3 interventions are to be offered 
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by specialist MDT, charged with managing individuals with obesity either in a 
community or hospital setting. These teams consist of specialist dieticians, 
physicians, and clinical psychologist, as a bare minimum. The services are typically 
funded by local health clinical commissioning groups [7,47]. An important remit of 
a Tier 3 service is the preparation of appropriately selected patients for bariatric 
surgical intervention (Tier 4). However, while the prevalence of comorbidities in 
various community-based Tier 3 programmes has been reported (see Chapter 2), 
the prevalence of obesity-related comorbidities within hospital-based Tier 3 
programmes remains unclear. 
The proposed observational study aims both to examine the prevalence of obesity-
related comorbidities and to obtain evidence of the effectiveness of Tier 3 
interventions in patients admitted to the Tier 3 weight management service at East 
Midlands Bariatric Metabolic Institute (EMBMI). The service was evaluated with 
the aid of the Standard Evaluation Framework for Weight Management 
Interventions [103] and measured against the requirements stipulated in the 
Clinical Commissioning Policy: Complex and Specialised Obesity Surgery [7]. 
3.3 Methods 
3.3.1 Setting 
EMBMI is based in the Derby and Burton Teaching Hospitals NHS Foundation Trust. 
It comprises a regional tertiary referral centre for bariatric and metabolic surgery, 
which provides both Tier 3 and Tier 4 services. The Tier 3 service was developed in 
2014 in response to the NHS England requirements formulated in 2013 which 
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required patients to access specialist Tier 3 interventions prior to undergoing 
bariatric surgery. This is a multicomponent specialist weight management service 
available to patients aged 18 years and over with complex obesity, defined by the 
NICE guidelines as BMI ≥ 35 kg/m2 with obesity-related comorbidities or BMI ≥ 40 
kg/m2 without comorbidities. This equates to the obesity class II and class III 
threshold for ‘severely obese’ and ‘very severely obese’. Patients are referred by 
their general practitioner or hospital doctor for consideration for bariatric surgery. 
The service is a time-limited multidisciplinary specialist weight intervention service 
with input from physicians, to aim of which is to screen and manage patient 
comorbidities. Specialist dieticians are provided to educate patients on mindful 
eating and to devise structured frameworks for caloric restriction and regulated 
eating behaviour, including portion control, slowing eating, and appropriate food 
choices. The service also includes a psychologist who can screen and manage 
relevant mental health disorders. The intensity and frequency of follow-up visits 
were determined by the clinical needs of patients and guided by regular MDT 
meetings. Suitability for surgery was assessed at a minimum of three months from 
the first visit. 
3.3.2 Data collection 
Patient data were obtained from electronic patient records. Inclusion criteria for 
this study required that all patients had attended a scheduled appointment at 
some point during 2017. Baseline data were derived from the first Tier 3 
appointments in 2017, from correspondence sent to the patient’s GP, and/or from 
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clinical notes made during the appointment. The following data were collected: 
age, gender, ethnicity, date of first visit, weight, height, BMI, blood pressure, 
previous bariatric surgery (if applicable), Epworth score if symptomatic of sleep 
apnoea, endoscopy results, full blood count, urea and electrolytes, liver function, 
calcium, lipid profile, HbA1c, thyroid, details of comorbidities present, and relevant 
medications received. The follow-up data, however, only included weight and BMI. 
Short-term weight outcomes were also reported as the mean weight change and 
5% weight loss of those completing the programme, in order to generate a 
comparison with other programmes. Follow-up data were collected from a broad 
range of appointments, including dietician appointments and educational sessions. 
Follow-up periods were arranged into groups of three, six, nine and twelve 
months. Drop-outs comprised those patients who failed to attend follow-up 
appointments within Tier 3. 
3.3.3 Statistical analysis 
All referrals in 2017 were followed up until patients either completed or left the 
programme. Data were censured at 1 April 2018 to ensure full data were available. 
A visual inspection of the visual inspection of the histogram and an evaluation of 
the Shapiro–Wilk test revealed that the baseline weight data were found not to be 
normally distributed. Therefore, the Wilcoxon signed-rank test was used to 
statistically test differences in the data. For missing data, the method of last 
observation carried forward was used. The criteria for statistical significance was 
set at a P value of 0.05. SPSS version 24.0.2 (SPSS Inc, Chicago, IL, USA) was used 
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for the statistical analysis of the data. Descriptive patient characteristics were 
described as mean and standard deviations. 
3.4 Results 
3.4.1 Patient flow 
Data were collected from 418 patients as part of the evaluation study. Ninety-eight 
patients provided follow-up data at the three-month stage, 94 supplied follow-up 
data after six months, and 41 were available for follow-up data after nine months. 
Following this, most patients were either discharged or referred for bariatric 
surgery. In total, 191 patients (45.69%) had at least one point of follow-up data. 
Ninety-three patients who did not have follow-up at the three-month stage did 
have a subsequent follow-up later in their treatment plan at the Tier 3 clinic. Figure 
3.1 illustrates the complete flow of patients through the Tier 3 service, from 
admission to the twelve-month point. 
3.4.2 Patients’ baseline characteristics and demographics 
A total of 430 patients was recorded as presenting to the Tier 3 clinic in 2017. Of 
these, 418 met the inclusion criteria for the evaluation study. The remaining twelve 
were excluded because there were no recorded notes pertaining to their visit or 
because vital information, such as baseline body weight data, was unavailable. Of 
those who met the inclusion criteria, 296 (70.8%) were female. The mean and 
standard deviation baseline weight for the sample was 137.8 (±29.2) kg and the 
mean baseline BMI was 48.0 (±8.6) kg/m2. The mean and standard deviation age, 
weight, and BMI for male patients was 47.0 (±12) years, 154.2 (±32.7) kg and 48.1 
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(±8.8) kg/m2, respectively. The respective figures for female patients were 45.8 



















































Figure 3.1 Flowchart diagram of Tier 3 service. 
The progression of patients through the Tier 3 service from their first referral and up to the 
twelve-month of follow-up point. 
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Four patients (1.0%) were classified as overweight, 12 (2.9%) were class I obese, 
48 (11.5%) were class II obese, and the remaining 354 (84.7%) were class III obese. 
In respect of ethnic identity, 267 (63.9%) patients were defined as White British 
whilst the ethnic identity of 115 (27.5%) patients was either not stated or not 
recorded. The remaining 36 (8.6%) patients were divided between a variety of 
ethnicities, including Bangladeshi, Black Caribbean, and Mixed ethnicity. Table 3.1 
summarises the baseline characteristics of the sample. Ninety-eight patients 
delivered follow-up data at the three-month point, 94 supplied follow-up data at 
the six-month point, 41 provided follow-up data at the nine-month point, and 17 
furnished follow-up at the twelve-month point. In total, 191 (45.69%) patients had 
at least one point of follow-up data. A total of ninety-three patients, who did not 
have follow-up at the three-month point, were available to provide follow-up data 
at a further point in their treatment programme at the Tier 3 clinic. 
Commonly occurring comorbidities included T2D (31.1%), hypertension (31.1%), 
depression (26.1%), obstructive sleep apnoea (23.2%), and osteoarthritis (15.6%). 
Table 3.2 details the top thirty comorbidities which were observed. When 
assessing for comorbidity and weight clustering according to the age threshold, no 
significant differences were noted for the prevalence of comorbidities for the age 
thresholds <35 years, 35–49 years, 50–64 years, and over 65 years. 
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Table 3.1 Baseline characteristics. 
Characteristics Number Mean or % SD 
Metabolic   
  Body weight, kg 418 137.2 29.2 
  BMI, kg/m2 418 48.0 8.6 
Demographic   
  Age, years 418 47.1 12.2 
  Male 122 29.2%  
  Female 296 70.8%  
Ethnicity   
  White British 267 63.9%  
  Unknown/not stated 115 27.5%  
  White Other 13 3.1%  
  Indian 3 0.7%  
  Pakistani 3 0.7%  
  Black Caribbean 3 0.7%  
  Black African 2 0.5%  
  White/Black Caribbean 2 0.5%  
  Mixed Other 2 0.5%  
  Other 2 0.5%  
  White and Asian 2 0.5%  
  Asian Other 1 0.2%  
  Bangladeshi 1 0.2%  
  White Irish 1 0.2%  
  White/Black African 1 0.2%  
Obesity classification    
  Overweight 4 1.0%  
  Class I Obese 12 2.9%  
  Class II Obese 48 11.5%  
  Class III Obese 354 84.7%  
 
3.4.3 Baseline body weight by age 
The median and interquartile range (IQR) weight and BMI for patients aged 35 
years or lower were 135.9 (IQR: 121.6–149.1) kg and 42.2 (IQR: 36.2–44.6) kg/m2, 
respectively. The respective data for those aged 35–49 years were 133.4 (IQR: 
116.4–142.8) kg and 40.1 (IQR: 34.0–42.1) kg/m2, for those aged 50–64 years were 
130.2 (IQR: 115.2–139.7) kg and 39.1 (IQR: 33.5–41.8) kg/m2, and for patients aged 
over 65 years the figures were 127.8 (IQR: 112.3–138.8) kg and 38.1 (IQR: 32.1–
40.7) kg/m2 respectively. 
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Table 3.2 Prevalence of disease among Tier 3 patients. 
Disease Number Per cent 
  
Type 2 diabetes 130 31.1 
Hypertension 130 31.1 
Depression 109 26.1 
Obstructive sleep apnoea 97 23.2 
Osteoarthritis 65 15.6 
Asthma 62 14.8 
Limited mobility 60 14.4 
Gastroesophageal reflux disease 43 10.3 
Chronic back pain 41 9.8 
Polycystic ovarian syndrome 38 9.1 
Anxiety 38 9.1 
Fibromyalgia 32 7.7 
Hypothyroidism 32 7.7 
Non-alcoholic fatty liver disease 21 5.0 
Lymphoedema 19 4.5 
Arthritis (not specified) 18 4.3 
Coronary heart disease 15 3.6 
Hiatus hernia 15 3.6 
Irritable bowel syndrome 15 3.6 
High cholesterol 12 2.9 
Chronic knee pain 12 2.9 
Vitamin D deficiency 11 2.6 
Heartburn 10 2.4 
Atrial fibrillation 10 2.4 
Chronic obstructive pulmonary disease  9 2.2 
Migraine 9 2.2 
Diabetic retinopathy 9 2.2 
Previous myocardial infarction 9 2.2 
Peripheral neuropathy  8 1.9 
Previous cerebrovascular accident 7 1.7 
     
 
3.4.4 Weight outcomes 
As a surrogate marker of our patient population and the complex needs recorded 
at presentation, and in order to allow comparison with other evaluation studies, 
we undertook the assessment of short-term weight outcomes for our cohort. A 
significant reduction in median body weight was observed at three months when 
a comparison was made to the baseline (135.9 vs. 134.4 kg; P < 0.001), followed 
by a further reduction at six months (135.8 vs. 130.8 kg; P < 0.001). However, at 
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nine months the weight loss was non-significant, possibly due to the smaller 
number of patients remaining in the programme at this follow-up point since the 
majority of patients would have been transferred to a Tier 4 service at this stage 
(136.4 vs. 128 kg; P = 0.116). Overall, 43 patients out of the total 191 (22.5%) for 
whom follow-up data was provided were shown to have achieved weight loss 
equating to ≥5% of their baseline weight. This represents a success rate of 22.5%. 
Similar patterns of weight loss were observed in males and females. That is, these 
patients demonstrated significant weight loss at the three-month and six-months 
points, followed by non-significant weight loss at the nine-month point (Table 3.3). 
 
Table 3.3 Change in median baseline and follow-up weights at all of the follow-up stages 
with P-values from performing Wilcoxon signed rank test. 
 
 3 months 6 months 9 months 
   
Patients with weight recoded 98 94 41 
Median baseline weight, kg 135.9 135.8 136.4 
Median follow-up weight, kg 134.2 130.8 128.0 
P-value < 0.001 < 0.001 0.116 
    
   
 
3.5 Discussion 
As this evaluation shows, addressing complex obesity and the comorbidities 
related to it is not straightforward. Significant comorbidities were evident in many 
patients at the time of their presentation to the hospital-based Tier 3 service. 
Before undergoing bariatric surgery, these patients required dietary, medical and 
psychological interventions. With a couple of exceptions, the baseline 
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characteristics of the patients in our study showed consistency with those reported 
in other studies. For example, the proportion of female patients in our study was 
70.8%, which is comparable to the 70% recorded by Jennings et al. (2014) [46], and 
other studies [74,80,89]. It is widely recognised in the literature that the 
proportion of female patients who join specialist weight management 
programmes exceeds that of male patients. Also, there were strong similarities in 
the prevalence of major comorbidities between patients in our sample and those 
in Jennings et al.’s (2014) study, specifically depression (26.1% vs 31.3%), 
hypertension (31.1% vs 38.3%) and T2D (31.1% vs 31.7%). The noted exceptions 
were coronary heart disease (3.6% vs 11.7%) and sleep apnoea (23.2% vs 11.7%) 
[46]. We attribute these discrepancies to fundamental differences in the studies; 
our clinical service included detailed tests and questionnaire assessments at 
baseline, designed specifically to screen for comorbidities. 
Notwithstanding the inherent difficulties associated with treating complex obesity, 
or that it was not the intention for this study to primarily be a comparative analysis, 
the format of this study that evaluated short-term weight outcomes permitted the 
differences in our patients’ population and complex needs be compared with those 
in other studies. At the 3-month and 6-month points, significant weight losses had 
been recorded. Furthermore, from their baseline body weight, 22.5% of patients 
managed to lose ≥5% weight. This is significant as with 5% reduction in baseline 
weight, various metabolic improvements in beta cell function, and cardiometabolic 
parameters and systemic insulin sensitivity are reported [102,104]. Moreover, at 
  Chapter 3 - Tier 3 prevalence 
 75 
any length of follow-up, 22.5% of patients who lost ≥5% of their baseline weight is 
similar to the 23.7% of patients who lost ≥5% of their baseline weight during the 
six-to-twelve-month interval, excluding patients with either a three-month follow-
up or no follow-up at all.  
This study’s weight outcomes were compared against those reported for a 
specialist weight management programme in Glasgow, which found that at the 12-
month intervention point, 24% of patients had experienced ≥5% weight loss 
[82,85]. Despite this achievement, these results are less than the values reported 
in other similar studies, such as the 60% for all participants in Jennings et al. [46], 
and 47% at the 12-month period reported in a Canadian study [105]. However, at 
48 kg/m2, the mean baseline BMI for our cohort was greater than that of other 
reported cohorts (44.1 kg/m2 [46], 43.3 kg/m2 [82], and 44.7 kg/m2 [105]). The 
implication is that level of obesity and obesity-related comorbidities of the patients 
in our study was severe than those of the other studies; therefore, our cohort 
would probably have a greater need for complex medical, dietetic and 
psychological interventions. There were also significant differences between our 
patient cohort and those individuals who take part in commercial weight loss 
programmes, such as WeightWatchers™. They report that the baseline mean BMI 
is 38 kg/m2 and that 51% of participants lose 5% of body weight [106]. However, 
the outcome measure for the Lighten Up study was based upon final weights as 
reported by the patient [107]; yet the reliability of self-reporting measures is not 
robust due to possibility of weight being underreported [108]. 
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The ethnicity of the sample group was broadly consistent with ethnicity 
demographic data for the East Midlands obtained from the 2011 census [109]. 
Whilst the ethnicity of 27.5% of the sample was either Unknown or Not stated, 
63.9% were reported as White British. The census value for White British is 85.4%, 
so we assumed that some of the Unknown or Not stated were also White British. 
Similarly, the percentage of White Other in our sample was 3.1%, which is 
consistent with the census’s 3.2%. Although the census figure for South-East Asian 
ethnicities is 5.6%, in our sample, it was only 1.8%. However, with more than a 
quarter of patients returning Unknown or Not stated responses, the actual 
percentage of South-East Asian participants may have been higher than 1.8%. 
Compared to other studies with dropout rates of 14.3%, 62.5%, and 51%, our 
dropout rate at 12 months for 2017 was favourable, losing just 12.2% [46,78,85]. 
Given that our centre serves a geographic area of 4500 square miles with a 
population that exceeds 3 million inhabitants, this low rate of attrition is 
reassuring. Covering such a wide area, the ability to attend follow-up visits can be 
affected by travel or other practical issues rather than lacking motivation to attend 
the appointments. Other patients might have decided against surgery; therefore, 
they were discharged. 
In summary, the Tier 3 service provided by EMBMI conforms with relevant 
commissioning guidelines. Rather than focusing on the effectiveness of specialist 
weight management service as determined by weight-centric assessments, the 
primary outcome measure for this study is the improvement of baseline 
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comorbidities. Indeed, ensuring comorbidities are optimally managed before 
surgery, as one of the key functions within EMBMI service; this can be delivered 
through referrals to relevant specialists or through the Tier 3 multidisciplinary 
management process. Unlike other studies, our study assesses the baseline weight 
and weight outcomes of patients presenting to our hospital-based Tier 3 
programme as surrogate measures of their complex needs. Our study highlights 
the importance of developing a standardised Tier 3 assessment process that 
incorporate standardised outcome measures for comorbidities commonly 
associated with obesity. Explanatory research could be directed from the high 
prevalence of comorbidities revealed in this study. 
3.6 Limitations  
There are several limitations to our study. First, the baseline information collected 
was considerable but not comprehensive; including data of educational and 
socioeconomic status may have revealed additional insights. Also, where feasible, 
measuring each patient’s waist circumference to gauge the proportion of central 
body fat, which has a recognised association of risk for coronary heart disease and 
T2D, would add a further dimension to the outcome measures; the importance of 
such measurements is recognised by NICE and Public Health England [8,21]. 
However, this is not practical with patients with severe obesity. Currently, no 
objective evaluations are made of cardiovascular, musculoskeletal, nephropathy 
or respiratory function as well as comorbid biochemical parameters, such as 
HbA1c, lipid and liver function profiles are not consistently retested at follow-up 
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sessions. Our patients’ psychological state and progress could have been evaluated 
by administering quality of life and anxiety questionnaires (e.g. PHQ-9 and GAD-7) 
at follow-up. Other questionnaires that may have yielded useful information 
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4.1 Summary 
Aim: To compare non-fatal CV events and metabolic outcomes between cohorts of 
insulin-treated T2D patients with obesity, who underwent bariatric surgery, and of 
propensity-matched non-bariatric ones. 
Methods: The Health Improvement Network (THIN) database was utilised to harvest data 
and details belonging to T2D patients. These data enabled the implementation of a 
retrospective cohort study that analysed 11,125 active (living) T2D patients. Propensity 
score matching (up to 1:6 ratio) was used to identify patients who underwent bariatric 
surgery (N = 131) and those who did not (non-bariatric cohort; N = 579). Follow-up analysis 
was conducted for 10 years (9,686 person-years), in order to compare differences in 
metabolic outcomes and CV risk events, including: acute myocardial infarction (AMI), 
stroke, coronary heart disease (CHD), heart failure (HF) and peripheral artery disease 
(PAD). Cox proportional regression was used to compute the outcomes between groups. 
Results: The patients mean age was 52 (±13) years (60% female); the baseline weight and 
BMI were 116 (±25) kg and 41 (±9) kg/m2, respectively. Significant reductions in weight 
and BMI were observed in bariatric group during the 10 years follow-up period. 
Furthermore, bariatric surgery had a significant cardio-protective effect, reducing the risk 
of non-fatal CHD (adjusted hazard ratio [aHR] 0.29, 95%CI: 0.16–0.52, P < 0.001) and PAD 
events (aHR 0.31, 95%CI: 0.11–0.89, P = 0.03). However, the surgery had no significant 
effect on AMI (aHR 0.98, P = 0.95), stroke (HR 0.87, P = 0.76) or HF (HR 0.89, P = 0.73) 
risks. Bariatric surgery had favourable effects on insulin independence, HbA1c and BP. 
Conclusion: Bariatric surgery represents a significant contributor for improving health 
outcome of T2D patients. Specifically, among insulin-treated T2D patients with obesity, 
bariatric surgery is associated with significant reductions in non-fatal CHD and PAD events, 
lower body weight, HbA1c, BP and a greater likelihood of insulin independency during the 
10 years follow-up period. 
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4.2 Background and aims 
Obesity and T2D represent major global health problems, intrinsically linked with 
adverse cardiovascular outcomes [110,111]. At present, raised pro-inflammatory 
state, insulin resistance and endothelial impairments are widely recognised 
consequences derived from excess dysfunctional adipose tissue, which is directly 
responsible for the onset of obesity-associated coronary artery disease and of 
myocardial hypertrophy development [112]. Therefore, it has been demonstrated 
that CV outcome improvements are augmented by the implementation of a wide 
variety of weight loss programmes [113]. Although diet and exercise play a crucial 
role in obesity management, lifestyle alone may not achieve durable weight loss in 
the majority of patients [114]. Therefore, bariatric surgery has emerged as the 
most effective and durable strategy for long-term weight loss, in individuals with 
morbid obesity [115]. Previous studies have shown the beneficial effects of 
bariatric surgical procedures on cardiovascular outcomes [116-118]. 
Many patients with T2D will require insulin treatment to manage hyperglycaemia 
and to reduce the risk of long-term vascular complications [119]. However, insulin 
therapy is known to induce weight gain in the first year of treatment. Specifically, 
a significant increase in weight gain is induced following insulin treatment 
initiation, consequently giving rise to the cardiovascular risk [120]. Furthermore, a 
randomised controlled trial and observational studies revealed evidence 
implicating insulin therapy with increased CV risk and mortality in T2D patients 
[121-124], possibly due to weight gain, recurrent hypoglycaemia and iatrogenic 
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hyperinsulinemia [125,126]. Thus, a cohort of insulin-treated T2D patients 
represents a complex, heterogeneous and challenging group of individuals: many 
display significant comorbidities and high CV disease risk. At present, the bariatric 
surgery impact has yet to be elucidated on cardiovascular parameters and risks of 
insulin-treated T2D individuals, during routine clinical care. Therefore, we 
conducted a retrospective cohort study of PS-matched groups to compare 
stratified non-fatal CV events and metabolic outcomes among patients with severe 
obesity and with insulin-treated T2D who underwent bariatric surgery and a non-
bariatric control cohort. 
4.3 Methods 
4.3.1 Study design and data sources 
A retrospective cohort study was designed with the utilisation of anonymised and 
systematically computerised longitudinal primary care health records, extracted 
from The Health Improvement Network (THIN) database (Appendix 10.3). The 
database comprises details about individuals’ demographics, lifestyle 
characteristics (e.g. alcohol use and smoking), major medical and surgical 
conditions, drug utilisation, and various health outcomes for over 17 million 
patients. Among these, 3.1 million individuals are registered as active (alive) 
patients. Patients’ records were extracted from over 600 UK general practices 
[127]. We chose the dataset slice containing information for active insulin-treated 
T2D patients up to September 2017.  
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4.3.2 Ethics 
Ethical approval was provided to THIN by the NHS South East Multi-centre 
Research Ethics Committee (MREC) (Appendix 10.4). The Scientific Review 
Committee (SRC) reviewed the study protocol for scientific merit and feasibility.  
4.3.3 Study population 
The dataset contained 11,125 adult patients (18 years and older, with no upper 
age limit) diagnosed with T2D, receiving any form of prescribed insulin therapy, up 
to September 2017. According to cohort type, the initial study time-point (patient 
index date) corresponded to bariatric surgery day (for the treated cohort) and to 
the first day of insulin therapy initiation (for the untreated, or control, cohort). The 
dataset was scanned to identify patients with no history of insulin use or those 
diagnosed with type 1 diabetes, for possible exclusion. The study, however, does 
not exclude patients based on Acceptable Mortality Reporting (AMR) because the 
exposed (treated) group found within THIN database is low in number. 
4.3.4 Exposure and outcomes 
This study interest was on bariatric surgical intervention (screened bariatric READ 
code list is available in Appendix 4, Table 10.4.6). The surgery represented patient 
exposure to remedial action. Its effectiveness was monitored during a 10-year long 
follow-up period, inclusive of the primary outcome and of the study concluding 
stage. Because of the time scale, this final stage corresponded to the actual end of 
study for most subjects, but also to unpredicted transfers or demise for some 
patients. Therefore, patients were censored throughout 10 years of follow-up, 
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following the development of primary outcome, transferred out, loss to follow-up 
or at the end of the study. The primary outcome represented patients’ survivability 
against non-fatal CV events. Further stratification included CV events into time 
sections, as well as occurrence of Acute Myocardial Infarction (AMI), stroke, 
Coronary Heart Disease (CHD), Heart Failure (HF) and Peripheral Artery Disease 
(PAD). Specific READ codes from THIN database are available in Appendix 10.5.  
Secondary outcomes included the likelihood of being off insulin during follow-up, 
as well as metabolic and health covariates, such as body weight, calculated BMI, 
HbA1c, total cholesterol and systolic/diastolic blood pressure (screened AHD code 
list is available in Appendix 4). 
4.3.5 Covariates and follow-up strategy 
We followed-up the treatment group, whom underwent bariatric surgery, 
comparing it with the PS-matched non-bariatric insulin-initiators group, from their 
first insulin prescription date up to the endpoint of 10-year of follow-up. Patients 
were excluded from the primary survival estimation on each stratified CV element, 
when CV events occurred prior to the designated baseline point.  
Control (untreated, or non-bariatric) and bariatric surgery (treated) cohorts were 
subjected to the same baseline clinical parameters measurements conducted at 
similar time points. Specifically, bariatric surgery patients had their baseline 
parameters calculated7 from 90 days up to one day before the surgery date. 
 
7 i.e. Average calculation will be taken from patients with more than one observation at a certain time window. 
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Similarly, non-bariatric patients had their baseline parameters calculated via the 
same time window, taking into account their first initiation of insulin therapy. 
Then, covariates were recalculated at 6-month and at each year time-point, for the 
duration of the 10 years follow-up period, with 90 days window on every 
concurring point of time8. 
4.3.6 Statistical analysis 
The primary analysis was time to the risk (or survivability) of stratified non-fatal CV 
events (Appendix 10.6) on PS-matched groups. The PS model was estimated by 
using logistic regression model to adjust for baseline characteristics, thus, 
minimising allocation bias between groups. This PS procedure employed the user 
written coding (PSMATCH2) developed by Leuven and Sianesi (2003) and updated 
in February, 2018 [128]. The measurement of standardised differences, occurring 
before and after procedure, represented the basis for a balance assessment 
between bariatric (treated) and non-bariatric cohorts. The mean from continuous 
covariates and proportion of categorical variables were examined and summarised 
between groups. A maximum of 6 reference, control, individuals were paired to 1 
treated patient, by means of implementing the closest match possible for all 
variables, including estimated PS and based on the likely treatment probabilities 
[129]. The reason for matching up to 1:6 ratio was made based on the maximum 
inclusion of control subjects to allow adequate power to compare the outcome of 
 
8 Patients’ with partially missing observations will be included for multiple imputation procedure for feasible 
predictions. 
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interest of stratified cardio events. Furthermore, we employed a caliper of width 
equal to 0.05 of the standard deviation of the PS logit, to minimise distance within 
matched sets. This may improve match quality, but it would limit excessive number 
of matched subjects [130]. A caliper of width of 0.20, or lower, has been shown to 
result in optimal estimation compared to higher choices of caliper use [131]. PS 
was included in all Cox proportional hazards regression modelling, as it was 
considered a prognostic covariate. 
The stratified log-rank test, with Kaplan-Meier survival curves, was used to 
compare the equality between the PS-matched groups. Thus, the absolute 
reduction in the probability of an event occurring within 10-year follow-up was 
calculated. Additionally, marginal hazard ratios were estimated, enabling the 
adjusted hazard quantification for an event occurring in the bariatric cohort, 
compared to the matched non-bariatric group. Proportional hazards assumptions 
were confirmed through the Schoenfeld residuals test. Point estimates with 95% 
Confidence Intervals (CIs), at the conventional statistical significance level of 0.05, 
were used in the regression models. The proportional hazards assumption was 
examined by comparing cumulative hazard plots grouped on exposure: no 
violations were observed. 
Among covariates, missing data was managed through multiple imputations, using 
predictive means matching for continuous covariates [132], taking the division of  
exposure (i.e. bariatric), with accounting for age, gender, diabetes duration, 
Townsend deprivation status, marital status, smoking and alcohol use. Sensitivity 
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analysis was necessary to test and validate the multiple imputation approach 
suitability in resolving the missing data impact. To this end, the primary endpoints 
were compared with the dataset containing the missing values. These were found 
to be similar, thereby affirming the robustness of the imputation method 
employed, before PS-matching procedure was performed [133].  
The student’s t test was used to estimate the mean changes in continuous 
variables (e.g. body weight and HbA1c) in the PS-matched groups, throughout the 
10-year follow-up period, compared to their baseline measurements. The Pearson 
X2 was used to test on the likelihood of being off insulin at 5 and 10 years from the 
baseline. Statistical significance was considered at P ≤ 0.05. To avoid the 
probability of type II error, the study was powered to 0.80. Additionally, the 
matched sample size of 710 was found to detect a true difference of less than 0.1, 
between the two groups at 5% significance level at baseline. The study fulfilled the 
STROBE criteria for reporting observational studies [134,135]. Throughout, SAS 
Software version 9.4 was used in the dataset management (SAS Institute, Cary, 
NC), the Stata Statistical Software version 15.1 was utilised in all carried analysis 
(StataCorp., College Station, TX), and the GraphPad/Prism version 8.0 was 
employed for results visualisation (La Jolla, CA). 
4.4 Results 
4.4.1 Patients characteristics and total follow-up 
The inspection of the THIN databases enabled the identification of 155 patients 
that underwent bariatric surgery, among a total of 11,125 patients. The PS-
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matching procedure allowed each of the 131 chosen bariatric patients9 to be 
paired with up to 6 control subjects. This yielded a total number of 710 PS-matched 
participants. The median treatment duration was 10.07 years (interquartile range 
(IQR): 6.11–14.31 years). The median follow-up time was 8.42 years (IQR: 2.92–
14.58 years), representing a total follow-up period of 9,686 person-years10.  
In the matched cohorts, the overall mean of age was 51.7 (±12.5) years, and 59.6% 
patients were females. The mean body weight, BMI and HbA1c level were 115.7 
(±25.4) kg, 40.7 (±9.2) kg/m2 and 71.2 (±18.1) mmol/mol, respectively. In both 
bariatric and non-bariatric groups, baseline characteristics were compared and 









9 The PS procedure has excluded 24 bariatric patients because there were no control individuals (or at least 
one individual) fit for the pre-established matching conditions.  
10 Person-years in this study was calculated based on CVD events and censoring duration (years). 
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Table 4.1 Baseline characteristics. 
 Cohort  
Full population  
[N = 11,125] 
  Propensity matched  
[N = 710] 
  
Baseline variables Bariatric 
[n = 155] 
Non-bariatric 




[n = 131] 
Non-bariatric 




      
Age (years), mean (SD) 50.01 (11.1) 57.71 (13.3) -0.694 50.74 (11.0) 51.96 (12.8) -0.110 
Gender, no (%) 
Female 89 (57.4) 5068 (46.2) 0.224 73 (55.4) 351 (60.6) -0.107 
 
Townsend deprivation, % 
Least deprived 14.0 21.7 -0.204 15.7 17.3 -0.044 
Less 24.3 20.7 0.086 24.0 18.1 0.145 
Average 17.6 21.4 -0.094 16.5 20.2 -0.094 
More 20.6 20.9 -0.008 21.5 27.7 -0.144 
Most deprived 23.5 15.3 0.209 22.3 16.8 0.14 
 
Type 2 diabetes (yrs) , mean (SD) 
Diabetes duration 14.15 (7.7) 15.12 (8.4) -0.125 13.97 (7.8) 14.89 (7.6) -0.117 
Insulin duration 7.36 (4.9) 8.01 (5.5) -0.130 7.3 (4.8) 8.68 (5.5) -0.287 
 
Clinical parameters, mean (SD) 
Weight (kg) 127.3 (30.3) 90.79 (20.6) 1.204 123.22 (28.3) 114.88 (24.5) 0.294 
Height (m) 1.7 (0.1) 1.68 (0.1) 0.201 1.7 (0.1) 1.69 (0.1) 0.102 
BMI (kg/m2) 43.87 (10.0) 32.37 (7.5) 1.150 42.77 (9.6) 40.6 (9.0) 0.226 
HbA1c (mmol/mol) 72.34 (19.3) 70.03 (17.2) 0.119 72.41 (18.6) 70.91 (17.9) 0.080 
Fasting glucose (mmol/L) 9.83 (4.3) 9.93 (3.9) -0.023 9.84 (4.3) 9.82 (3.9) 0.004 
Blood glucose (mmol/L) 12.22 (8.8) 11.69 (5.3) 0.071 12.04 (9.1) 11.92 (5.3) 0.016 
SBP (mmHg) 134.64 (14.6) 138.89 (16.5) -0.271 135.06 (14.5) 136.4 (16.0) -0.088 
DBP (mmHg) 78.66 (8.4) 78.94 (9.6) -0.031 79.3 (8.5) 78.77 (9.3) 0.058 
Albumin (g/dL) 3.96 (0.4) 4.15 (0.5) -0.368 3.96 (0.4) 3.96 (0.4) -0.005 
Alkaline Phosphatase (IU/L) 98.31 (47.1) 91.62 (43.0) 0.146 98.79 (48.8) 96.88 (51.5) 0.038 
Serum creatinine (µmol/L) 91.74 (78.4) 92.68 (52.6) -0.014 92.29 (84.0) 88.17 (57.7) 0.056 
C-reactive protein (mg/L) 10.02 (11.4) 14.23 (25.9) -0.208 10.15 (11.7) 10.07 (16.3) 0.006 
Globulin serum (g/L) 30.98 (5.4) 29.93 (4.6) 0.206 30.87 (5.3) 30.73 (4.8) 0.027 
Packed Cell Volume (L/L) 0.39 (0.04) 0.4 (0.05) -0.142 0.39 (0.04) 0.39 (0.06) 0.003 







Triglyceride (mmol/L) 2.33 (1.5) 2.03 (1.3) 0.2 2.34 (1.6) 2.26 (1.4) 0.049 
Total cholesterol (mmol/L) 4.47 (1.2) 4.49 (1.1) -0.019 4.52 (1.2) 4.52 (1.2) 0.002 
Low density lipoprotein 
(mmol/L) 
2.39 (0.9) 2.39 (0.9) 0.001 2.39 (0.9) 2.44 (1.0) -0.05 
High density lipoprotein 
(mmol/L) 
1.07 (0.3) 1.22 (0.4) -0.439 1.07 (0.3) 1.1 (0.3) -0.091 
 
Alcohol status, % 
Unknown 3.7 3.1 0.03 3.3 3.0 0.017 
Ex-drinker 11.8 7.0 0.162 11.6 11.5 0.003 
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Never 33.1 31.3 0.039 33.1 33.1 -0.002 
Current 51.5 58.5 -0.143 52.1 52.4 -0.006 
 
Smoking status, % 
Ex-smoker 33.1 37.1 -0.085 31.4 36.9 -0.116 
Never 52.9 49.7 0.064 52.9 52.2 0.015 
Current 14.0 13.1 0.025 15.7 10.9 0.141 
Diabetes duration is time from first diagnosis of diabetes to date of initiation with insulin drug (index date). 
* Standardised differences are the absolute difference in means or percentages divided by the SD of the treated group. 
Resulting standardised difference after 1:6 matching based on average treatment effect on treated propensity score 
technique and robust variance estimation. 
† Mean of standardised difference after matching (0.081), i.e. at 8% difference measured between the matched groups.  
 
4.4.2 Cardiovascular event rates 
For non-fatal CHD, the survival probability was significantly different between 
matched bariatric and non-bariatric groups at 1-year (98.0% vs 89.6%), 5-year 
(92.2% vs 67.6%) and 10-year (88.2% vs 51.6%) follow-up time-points (log-rank test 
P < 0.001) (Figure 4.1c). A total of 277 (18 vs 259) events were observed, with a 
crude event rate of 52.4 (21.4 vs 58.2) per 1000 person-years (95%CI: 46.6–58.9). 
In addition, for non-fatal PAD, the survival probability was significantly different at 
5-year (90.5% vs 78.8%) and 10-year (84.0% vs 53.1%) follow-up time-points (log-
rank test P = 0.007) (Figure 4.1e). A total of 59 (6 vs 53) events were observed, with 
a crude event rate of 62.1 (25.9 vs 73.8) per 1000 person-year (95%CI: 48.1–80.2). 
For non-fatal AMI, stroke and HF, the survival probabilities displayed little or no 
statistical significance of a difference, after comparison between the matched 
groups throughout the 10 years follow-up period (log-rank test P > 0.5) (Figure 
4.1a, 4.1b and 4.1d). Table 4.2 shows a summary of the events for each of the 
stratified CV components, with absolute event rates. 
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Table 4.2 Non-fatal cardiovascular events, crude incidence rates and hazard ratios of events 
in the matched groups. 
 Bariatric  
(N = 131) 
Non-bariatric  
(N = 579) 
AMI   
No of events/person-years 13/153 95/1084 
Absolute ratesa (95% CI) 84.9 (49.0–146.2) 87.6 (71.6–107.1) 
HRb (95% CI) 1.03 (0.57–1.86) 1 (reference) 
aHRc (95% CI) 0.98 (0.54–1.77) 1 (reference) 
   
Stroke   
No of events/person-years 8/137 40/547 
Absolute rates (95% CI) 58.2 (29.1–116.4) 73.0 (53.5–99.6) 
HR (95% CI) 0.77 (0.34–1.72) 1 (reference) 
aHR (95% CI) 0.87 (0.36–2.10) 1 (reference) 
   
CHD   
No of events/person-years 18/840 259/4446 
Absolute rates (95% CI) 21.4 (13.5–34.0) 58.2 (51.6–65.8) 
HR (95% CI) 0.31 (0.19–0.52) 1 (reference) 
aHR (95% CI) 0.29 (0.16–0.52) 1 (reference) 
   
HF   
No of events/person-years 13/205 91/1327 
Absolute rates (95% CI) 63 (36.9–109.5) 68.6 (55.8–84.2) 
HR (95% CI) 0.81 (0.44–1.49) 1 (reference) 
aHR (95% CI) 0.89 (0.47–1.70) 1 (reference) 
   
PAD   
No of events/person-years 6/231 53/718 
Absolute rates (95% CI) 25.9 (11.6–57.6) 73.9 (56.4–96.7) 
HR (95% CI) 0.27 (0.09–0.74) 1 (reference) 
aHR (95% CI) 0.31 (0.11–0.89) 1 (reference) 
a Absolute rate at 1000 person-years. 
b HR (unadjusted hazard ratio)  
c aHR (adjusted hazard ration). Adjusted for age, diabetes duration, oral antidiabetic drug use, 
diuretics use, antihypertensive drug use, Townsend deprivation status, alcohol & smoking 
status and HbA1c level. 
 
4.4.3 Risk of cardiovascular disease 
By comparing the matched cohorts, analysis of CV stratification elements 
illustrated how bariatric surgery may exercise a protective effect. In particular, in 
the bariatric group, the risk of non-fatal CHD and PAD was significantly lower (by 
71% and 69%, respectively), compared to the matched non-bariatric group (CHD 
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aHR: 0.29, 95%CI: 0.16–0.52, P < 0.001; PAD aHR: 0.31, 95%CI: 0.11–0.89, P = 0.03). 
These findings were adjusted for age, HbA1c level, diabetes duration, oral 
antidiabetic drug use, diuretics use, antihypertensive drug use, Townsend 
deprivation status, alcohol use and smoking status. Despite protective tendency of 
bariatric intervention against non-fatal AMI, stroke and HF, none of which was 
found with statistical significance (AMI aHR: 0.98, 95%CI: 0.54–1.77, P = 0.94; 
stroke aHR: 0.87, 95%CI: 0.36–2.10, P = 0.75; HF aHR: 0.89, 95%CI: 0.47–1.70, P = 
0.73) (Table 4.2). 
4.4.4 Changes in metabolic outcomes 
During the 10-year follow-up period, it became apparent that the bariatric group 
experienced significant benefits including the reduction of body weight and BMI, 
when compared to baseline. This advantage was not observed in non-bariatric 
patients (see Table 4.1 for baseline measurements). In particular, for bariatric vs 
non-bariatric patients, body weight and BMI observations were: at 1-year follow-
up time-point 97.5±24.2 vs 109.8±18.6 kg, 34.2±9.0 vs 38.8±7.4 kg/m2, 
respectively; at 5-year follow-up time-point 98.9±23.3 vs 107.1±18.2 kg, 34.8±9.2 
vs 37.8±7.3 kg/m2, respectively; and at 10-year follow-up time-point 94.1±20.1 vs 
107.6±17.3 kg, 32.9±7.7 vs 38.0±7.1 kg/m2, respectively (Figure 4.2a and 4.2b).  
Furthermore, HbA1c reduction was statistically significant (i.e. P < 0.01), up to 6 
years of follow-up. In the bariatric vs non-bariatric groups, HbA1c levels were: at 
1-year time-point 60.3±18.2 vs 72.0±17.9 mmol/mol, at 3-year time-point 
66.1±16.8 vs 71.3±17.8 mmol/mol, and at 6-year time-point 68.1±16.9 vs 
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72.8±18.8 mmol/mol. Interestingly, analysed HbA1c levels were not significantly 
different between control and treated groups after the 7-year follow-up time-
point (Figure 4.2c). Total cholesterol was found to be significantly reduced during 
the first six months of follow-up (4.12±0.99 vs 4.50±1.14 mmol/L, P = 0.008) (Figure 
4.2d).  
 
Figure 4.1 Cardiovascular survival plots. 
Cardiovascular Kaplan-Meier survival plots for the matched cohort throughout 10 years of 
follow-up. 




Figure 4.2 Metabolic outcomes from the matched groups. 
Mean difference in reduction in weight and health outcome variables between the matched 
groups throughout 10 years of follow-up compared to baseline. 
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In addition, bariatric surgery exercised a positive impact on the patients’ blood 
pressure, from the very early stages post-intervention. Specifically, the systolic 
blood pressure was: at 6-month time-point 130±18 vs 137±16 mmHg, P < 0.001; 
and at 1-year time-point 133±17 vs 137±15 mmHg, P = 0.07 (Figure 4.2e). The 
diastolic blood pressure displayed a statistically significant reduction in the 
bariatric vs non-bariatric groups (P < 0.05) up to 2 years of follow-up (6-month: 
76±10 vs 79±9; 1-year: 77±9 vs 79±9; 2-year: 76±10 vs 79±10 mmHg) (Figure 4.2f). 
Figure 4.2 illustrates the analysed outcome variables reduction in the matched 
cohort, during the 10 years follow-up period, when compared to their baseline 
measurements, with respective 95% confidence intervals.  
 
Figure 4.3 Insulin independency. 
Proportions (%) of insulin independency in bariatric vs. non-bariatric in both matched and 
full cohorts. 
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Analysis of insulin dependency revealed that, following bariatric intervention, 6.4% 
patients became insulin independent at 1-year follow-up time-point, compared to 
7.9% non-bariatric individuals. However, this difference was of little or no 
statistical significance (X2=0.35, P = 0.55). Nevertheless, this effect became 
significant at the 3-year time-point: now, 31.2% bariatric patients became 
independent from insulin use, compared to 17.6% non-bariatric (X2=10.59, P = 
0.001). At 6-year time-point, 41.5% bariatric patients became independent from 
insulin use, compared to 22.2% non-bariatric (X2=11.47, P = 0.001). Finally, at 10- 
year time-point, 77.5% bariatric patients were independent from using insulin, 
compared to 33.7% non-bariatric (X2=28.71, P < 0.0001) (Figure 4.3).   
4.5 Discussion 
Analysing patients’ long-term health records can reveal practices that improve 
both the patient’s own health outcomes and the healthcare system. By studying 
the records of patients stored in the THIN database, this study found an association 
between bariatric surgery and the reduction in risk of non-fatal CHD and PAD 
events by 71% and 69% respectively. These same patients with obesity and T2D 
also demonstrated significant improvements in their body weight, blood pressure, 
HbA1c level and insulin dependency. However, risk of AMI, stroke and heart failure 
showed little or no reduction. 
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Figure 4.4 Metabolic outcomes from the full cohort. 
Mean difference in reduction in weight health outcome variables between the unmatched 
groups (full cohort) throughout 10 years of follow-up compared to baseline. 
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Our findings are consistent with published research into the cardiovascular and 
metabolic benefits of bariatric surgery [116-118]. However, our study differed by 
focusing on T2D patients who receive insulin treatment, as the risks of 
cardiovascular events are recognised as being increased in these patients 
[119,121,122,124]. Even though cardiovascular events and mortality is reduced by 
bariatric surgery, the post-bariatric surgery risk of death in T2D patients is still 35% 
greater than the general population [136]. Thus, this study contributes evidence 
to the cardiovascular benefits of bariatric surgery for this cohort of patients who 
are likely to have an ongoing elevated risk of CV. 
One study notes that although T2D patients had reduced myocardial infarction, 
the incidence of stroke was unaffected [117]. Yet an analysis of the interactions 
between factor and treatment indicate that the effect of bariatric surgery upon 
AMI was greater in those patients with elevated total cholesterol and triglyceride 
levels, suggesting that the greatest benefits were likely to be achieved by patients 
with dyslipidaemia. The mean LDL-cholesterol and triglyceride levels of our PS-
matched cohort were respectively optimised at 2.4 and 2.3 mmol/L after statin 
therapy. This highlights the value of statin therapy for this cohort of patients with 
dyslipidaemia, as well as potentially accounting for the inadequate reduction in 
AMI. Regardless, PAD events within this patient cohort were significantly reduced. 
The clinical significance of this novel finding should not be underestimated. After 
controlling for potential confounders like dyslipidaemia, hyperglycaemia and 
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hypertension, the conclusion of one recent study is there is a casual association 
between obesity and PAD [137]. 
It is well recognised that insulin therapy promotes weight gain [120]. Our study 
revealed that following bariatric surgery, patients experienced significant 
reductions in body weight. The study also predicted that patients who had bariatric 
surgery would lose significantly more weight than control patients do. 
Interestingly, these reductions were enduring, and still in effect 10 years later. 
Weight loss was observed in our PS-matched control cohort, which can probably 
be attributed to the concurrent use of a GLP-1 analogue, an adjunct to insulin 
treatment; randomised controlled trials support the use of GLP-1 for weight loss 
[138,139]. Furthermore, our non-PS-matched control cohort did not demonstrate 
weight loss, indicating the PS-matching protocol used in this study was robust 
(Figure 4.4). Compared to patients who underwent bariatric surgery, fewer 
patients who received GLP-1 therapy in combination with other weight-loss 
antidiabetic interventions such as sodium glucose co-tranporter-2 (SGLT-2) 
inhibitor and restricted calorie intake, became insulin independent in the PS-
matched control cohort. 
It is noteworthy that unlike the reduction in weight that endured over the 10-year 
follow-up duration, the statistically significant reduction in HbA1c only persisted 
for 6 years following surgery. HbA1c levels rose in the intervening follow-up 
assessments. Other studies that have compared medical/lifestyle interventions 
and bariatric surgery outcomes found that regardless of the treatment regimen, 
  Chapter 4 - Bariatric & cardiometabolic 
 100 
T2D patients experienced a decrease in HbA1c for up to 5 years after surgery [140-
142]. The conflict between HbA1c and long-term weight outcomes imply that the 
subsequent increases in HbA1c are not associated with body weight [140]. 
However enduring the benefits that bariatric surgery confers upon HbA1c and 
insulin independence and weight might be, they significantly reduce the long-term 
risk of vascular complications associated with diabetes. This almost certainly 
translates as long-term financial savings for the NHS. 
The relatively large sample size of T2D insulin-treated patients from a real-world 
population is a major strength of this study, and the results can be generalised to 
the entire UK or other comparable populations. That is, the results of our study 
have application in other populations that share a similar demographic profile. The 
study’s statistical power is adequate and the data for other time-varying covariates 
is sufficient to adjust for possible confounders. Using a robust PS-matching 
protocol, we adjusted for a large set of factors that may have varied at baseline. 
This adjustment is important, because the complex decision-making process that 
underpins the success of bariatric surgery often exceeds NICE guidelines.  
In conclusion, this study indicates that the risk of non-fatal CHD and PAD events in 
insulin-treated T2D patients and with severe obesity is significantly reduced by 
bariatric surgery. Also, compared to matched controls, bariatric-surgery patients 
experience significant reductions in BP, HbA1c, insulin dependency and body 
weight.  
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4.6 Limitations 
Being retrospective, one significant shortcoming of this study is identified with our 
inability in measuring and adjusting the insulin therapy dosage. This could give rise 
to some lingering perplexities in the significance of this study. In addition, the 
reliability of diabetes duration constitutes a confusing factor, due to the ongoing 
issue of identifying incident versus prevalent diabetes. Furthermore, the 
classification of exposure into broad bariatric surgery types may have masked the 
effects of individual bariatric surgery types, potentially driving our study away or 
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5.1 Summary 
Aim: To compare the effect of bariatric surgery on renal, cardiovascular and chronic 
kidney disease (CKD) outcomes among insulin-treated T2D patients with obesity, with or 
without microalbuminuria. 
Methods: A retrospective cohort study was conducted among 11,125 active T2D patients, 
whose details were extracted from the THIN database. Propensity score matching (up to 
1:6 ratio) was used to identify patients who underwent bariatric surgery (N = 131), paired 
with non-bariatric cohort of individuals (N = 579). In order to measure potentially existing 
differences in cardiovascular events and renal outcomes risks, a 10-year follow-up period 
was analysed (6,487 person-years).  
Results: For PS-matched cohorts, baseline mean values were as follow: age was 52 (±13) 
years (60% female), body weight was 116 (±25) kg, BMI was 41 (±9) kg/m2, estimated 
glomerular filtration rate (eGFR) was 70.4 (±20) mL/min/1.73m2, and median albumin-
creatinine ratio (uACR) was 2.0 mg/mmol (interquartile range (IQR): 0.9–5.2 mg/mmol). 
Bariatric surgery was significantly associated with a 54% reduction in developing crude 
CKD. A protective effect from CKD was induced by bariatric surgery in patients displaying 
microalbuminuria at baseline (aHR: 0.42, 95%CI: 0.18–0.99, P = 0.050). After comparison 
with baseline values, eGFR was significantly increased, favouring the bariatric group 
during 75% of the follow-up time (i.e. P < 0.05). However, no significant improvements 
were observed when analysing composite non-fatal CVD episodes (aHR: 0.36, 95%CI: 
0.11–1.13, P = 0.079). Albumin levels were significantly reduced throughout two years 
following surgery (3.9 vs 4.1 g/dL, P < 0.001). Little or no statistical association to the 
intervention could be found for uACR as well as total protein levels. 
Conclusion: Bariatric surgery may protect patients with insulin-treated T2D, with or 
without microalbuminuria, against CKD risk. Interestingly, composite non-fatal CVD risk 
was reduced after the procedure, which appeared to exercise a mild protective effect on 
these individuals. Additionally, bariatric surgery is associated with improvements in 
overall renal outcomes, including eGFR. 
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5.2 Background and aims 
Glomerular hyperfiltration, followed by microalbuminuria, is an obesity-associated 
renal function that begins with declining eGFR, and with progressive increases in 
urinary albumin excretion [143-145]. In obesity, dysfunctional adipose tissue is 
associated with increased pro-inflammatory state, insulin resistance, 
hyperglycaemia, endothelial dysfunction and hypertension. These represent 
known risk factors for the development and progression of cardiovascular disease 
and chronic kidney disease [112,146]. Furthermore, many T2D patients require 
insulin treatment to control hyperglycaemia. This is relevant within the context of 
diabetic kidney disease, since insulin therapy is known to induce 4–9 kg weight gain 
during the first year of treatment [120]. Obesity per se represents a significant risk 
factor for the appearance of proteinuria and end-stage renal disease (ESRD) [146].  
Moreover, a direct link exists between insulin therapy and an increased 
cardiovascular risk and mortality in T2D patients, as recently reported following 
randomised controlled trials, and epidemiological and observational studies 
[121,122,124,126]. Thus, a cohort of insulin-treated T2D patients represents a 
complex heterogeneous, challenging group of patients, presenting significant 
comorbidities and high CKD risk. CKD is defined by an estimated GFR of less than 
60 mL/min/1.73m2, or by the presence of increased urinary albumin excretion 
(microalbuminuria indicated by urine ACR of 3.0–30.0 mg/mmol), or overt 
proteinuria (uACR > 30.0 mg/mmol). These are independent risk factors for CV and 
kidney disorders in the general population and in patients with diabetes [147]. 
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Therefore, the significant cardiorenal outcomes amelioration justifies the 
implementation of an effective weight loss programme, able to achieve significant 
and lasting results [113]. Although diet and exercise play a crucial role in obesity 
management, lifestyle alone may not achieve durable weight loss in the majority 
of patients [114]. Therefore, bariatric surgery has emerged as the most effective 
and durable strategy for long-term weight loss in individuals with morbid obesity 
[115]. 
Despite its clear benefits on body weight and glycaemic outcomes in T2D 
individuals, bariatric surgery impact is less clear when considering the 
development and progression of CKD or microalbuminuria. Previous studies have 
reported improvements in uACR [148-151], which can be observed not long after 
surgery [149,150]. This is thought to be driven by multi-factorial improvements in 
blood pressure, HbA1c and BMI [149]. A further study concluded that bariatric 
surgery should be offered as early treatment to patients with microalbuminuria, 
or with overt proteinuria, to prevent CKD from progressing to an end-stage kidney 
disease [152]. However, many of these studies were small case series, not specific 
to individuals with insulin-treated diabetes, had variable albuminuric state at 
baseline, or did not adjust for important confounders. Likewise, a systematic 
review illustrated incosistent results, when assessing renal outcomes following 
bariatric surgery [153]. Additionally, a number of studies noted harmful effects on 
kidneys on patients with obesity who received bariatric intervention. For example, 
there may be an increased risk of kidney stone formation after malabsorptive 
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bariatric surgery, which is considered to be linked with surgery-induced fat 
malabsorption [34]. Furthermore, despite weight loss benefits, there are negative 
metabolic outcomes related to bariatric intervention, such as nutritional 
deficiencies, reduction in lean body mass and bone density loss. These are highly 
relevant in patients with CKD risk [154]. 
A retrospective exploration of bariatric surgery outcomes represents the core 
method of this study, which objective is to ascertain the procedure potential 
contribution in preventing CKD, in improving renal-cardiovascular performance, 
and in influencing health and renal outcomes in patients with and without 
microalbuminuria (i.e. uACR > 3.0 mg/mmol). 
5.3 Methods 
5.3.1 Study Design and Data Sources 
This is a retrospective cohort study, conducted on the same data source slice 
selected for the cardio-metabolic study in Chapter 4 (see Subsection 4.3.1).  
5.3.2 Ethics 
Ethical approval was provided to THIN by the NHS South East Multi-centre 
Research Ethics Committee (MREC). The Scientific Review Committee (SRC) 
reviewed this study’s protocol for scientific merit and feasibility. 
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5.3.3 Study population 
This study was conducted analysing the same population selected from the THIN 
database, as described in the Chapter 4 (see Subsection 4.3.3). 
5.3.4 Exposure and outcomes 
Our exposure of interest is bariatric surgical intervention for insulin-treated T2D 
patients and with severe obesity. The surgery represented patient exposure to 
remedial action. Its effectiveness was monitored during a 10-year long follow-up 
period, inclusive of the primary outcome and of the study concluding stage. 
Because of the time scale, this final stage corresponded to the actual end of study 
for most subjects, but also to unpredicted transfers or demise for some patients. 
Primary outcomes represented patients’ survivability against diagnosed CKD 
events, with further stratification to include CKD and composite CVD events, from 
a selected population with microalbuminuria (uACR > 3 mg/mmol) at baseline. The 
risk of CKD was measured according to observed CKD data, reported with specific 
dates in the main THIN database (screened READ code list is available in Table 
10.4.7, Appendix 4). Additionally, the THIN database contained information on 
CKD events, assessed and reported by healthcare professionals following specific 
NHS good medical practice guidelines related to the illness (eGFR < 60 or ACR > 
3.5), implemented across all primary care establishments.  
The composite CVD events included the first occurrence of either acute myocardial 
infarction, stroke, coronary heart disease, heart failure or peripheral artery 
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disease. Observations of CVD events were obtained in a similar manner as with 
events of CKD reporting system, prearranged and precisely coded by THIN.  
Secondary outcomes included likelihood of improvement in eGFR, as well as in 
health covariates, including levels of uACR, total protein, and albumin and serum 
creatinine.  
5.3.5 Covariates and Follow-up Strategy 
The treatment group comprised individuals undergoing bariatric surgery and being 
insulin-treated T2D from the date of surgery. They were followed up and compared 
with their PS-matched insulin initiators, from their first insulin prescription date up 
to the endpoint of the 10-year follow-up period. 
Patients with diagnosed CKD, or with CVD events occurred prior to the designated 
baseline point, were excluded from the primary survival estimation on each 
stratified element. Depending on the treatment category, all clinical parameters 
measurements were harvested at similar time-point analysis for creating the study 
baseline reference. For instance, patients who underwent bariatric surgery will 
have their baseline parameters calculated for 90 days, up to 1 day before the 
surgery date. Similarly, the non-bariatric patients will have their baseline 
parameters calculated during the same time window, prior to their first initiation 
of insulin therapy. Covariates were recalculated at 6 months and at each year time-
point during follow-up, with a 90-day window on every concurring point of time. 
  Chapter 5 - Bariatric & CKD 
 109 
5.3.6 Statistical Analysis 
Similar to the analysis procedure used in Chapter 4, the primary investigation 
considered time-dependent occurrence linked to the risk of crude CKD events and 
of stratified (according to microalbuminuria basis) CKD and CVD events in the PS-
matched groups. The PS model was estimated by using a logistic regression 
approach, in order to adjust for baseline characteristics, thus, minimising 
allocation bias between groups. The balance assessment was made between 
bariatric (treated) and non-bariatric (untreated) groups by measuring standardised 
differences before and after the matching procedures. The mean from continuous 
covariates and proportion of categorical variables between groups were examined 
and summarised. A maximum of 6 reference, control, individuals were paired to 1 
treated patient, by means of implementing the closest match possible for all 
variables, including estimated PS and based on the estimated treatment 
probabilities [129].  
The technicality of PS matching, managing missing data and related analyses, 
utilised in this study, are fully outlined in Chapter 4 (see Subsection 4.3.5). A 
sensitivity analysis was included in this study. Its necessity stemmed from the need 
to fill gaps from missing data, to assess their impact and to validate our multiple 
inputting adequacy. To this end, in the inputted (or predicted) renal outcomes 
within the dataset, the primary endpoints were compared with the dataset with 
missing values. These were found to be similar up to two years of follow-up. Hence, 
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a decision was made to limit the renal outcome covariates to this point of reliable 
predictions.  
Student’s t test was used to estimate the mean changes in continuous variables 
(e.g. uACR and total protein) in the PS-matched group for 2 years of follow-up, 
compared to their baseline measurements. We limited these variables to 2 years 
because of the significant amount of missing data beyond this point. This 
shortcoming restricted multiple imputation from producing reliable predictions. 
Nonetheless, eGFR was at a predictable level up to 5 years, enabling the 
employment of Pearson X2 to test the likelihood of improvement occurrence 
throughout 5 years, when compared to the baseline. Wilcoxon rank-sum test was 
used to check differences in medians for nonparametric variables (i.e. uACR). 
Statistical significance was considered at P ≤ 0.05. To avoid the probability of type 
II error, the study was powered to 0.86. The matched sample size of 710 was found 
to detect a true difference of less than 0.1, between the two groups at 5% 
significance level. The study fulfilled the STROBE criteria for reporting 
observational studies [134,135].  
Throughout, SAS Software version 9.4 was used in the initial dataset management 
(SAS Institute, Cary, NC), Stata/SE Statistical Software version 15.1 was utilised in 
all carried analysis (StataCorp., College Station, TX), and GraphPad/Prism version 
8.1.0 was employed for results visualisation (La Jolla, CA). 
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5.4 Results 
5.4.1 Patients’ Characteristics and Total Follow-up 
From a total population of 11,125 patients with insulin-treated T2D in THIN 
database, we identified 155 patients who have had bariatric surgical operations. 
The PS matching procedure has allowed 131 bariatric patients to be matched with 
up to six control subjects 579. This yielded a total number of (N = 710) PS-matched 
participants. The median treatment duration was 10.07 years (interquartile range 
(IQR): 6.11–14.31 years). The median follow-up was 12.8 years (IQR: 5.1–14.5 
years) for the matched cohort, representing a total follow-up period of 6,487 
person-years11. The mean age for the matched groups at baseline was 51.7 (±12.5) 
years; 59.6% were females. The mean body weight, BMI and HbA1c level were 
115.7 (±25.4) kg, 40.7 (±9.2) kg/m2 and 71.2 (±18.1) mmol/mol, respectively. The 
mean eGFR was 70.4 (±20.5) mL/min/1.73m2, with a median uACR of 2.0 (IQR: 0.9–
5.2) mg/mmol. The baseline characteristics in both bariatric and non-bariatric 
groups were compared between the full and matched cohort with respective 
standardised differences and are shown in Table 4.1. 
5.4.2 Probability of survival and event rates 
The probability of survival for CKD in the full cohort was significantly different 
between bariatric and non-bariatric groups: at 1 year (99.2% vs 97.7%), 5 years 
(96.9% vs 89.9%) and 10 years (94.9% vs 80.2%) of follow-up (log-rank test P value: 
0.028). However, the estimates of CKD event rate in the unadjusted PS matched 
 
11 Person-years in this study was calculated based on CKD events and censoring duration (years). 
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cohort showed little or no statistical significance of a difference throughout 10 
years of follow-up (log-rank test P value: 0.19). A total of 119 CKD events were 
observed (16 vs 103) with a crude event rate of 18.3 (14.5 vs 19.1) per 1000 person-
years (95%CI: 15.3–21.9). 
The difference in probability of survival for CKD in patients with microalbuminuria 
was statistically insignificant in both full and matched cohorts (log-rank test P 
values: 0.14; and 0.24, respectively). In the matched group, a total of 51 CKD events 
were observed (8 vs 43) with a crude event rate of 22.2 (14.3 vs 25.4) per 1000 
person-years (95%CI: 17.2–29.8). 
The difference in probability of survival for composite CVD in patients with 
microalbuminuria was statistically insignificant in both full and matched cohorts 
(log-rank test P values: 0.28; and 0.54, respectively). In the matched group, a total 
of 43 CVD events were observed (10 vs 33) with a crude event rate of 55.0 (49.5 vs 
56.9) per 1000 person-years (95%CI: 40.8–74.2). Figure 5.1 and Table 5.1 
summarise the observed events, event rates and differences in the probability of 
survival. 
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Figure 5.1 CKD survival plots. 
Bariatric vs. non-bariatric Kaplan-Meier survival plots for diagnosed CKD events in (A) Full 
and (B) matched cohorts, diagnosed CKD events in patients with microalbuminuria (i.e. 
uACR > 3 mg/mmol) at baseline in (C) full and (D) matched cohorts, and composite CVD 
events in patients with microalbuminuria at baseline in both (E) full and (F) matched cohorts 
throughout 10 years of follow-up. 
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5.4.3 Risk of CKD 
Bariatric surgery showed remarkable protective effect against crude CKD in the full 
cohort and in the adjusted matched group. In the full cohort, patients whom had 
been treated with bariatric surgery had 47% lower risk to develop CKD compared 
to non-bariatric patients (aHR: 0.53, 95%CI: 0.30–0.91, P = 0.021). Similarly, the 
matched cohort showed a statistical significance of a magnitude favouring the 
bariatric group with a protective effect of 54% against crude CKD risk (aHR: 0.46, 
95%CI: 0.24–0.85, P = 0.013). Table 5.1a shows a summary of adjusted and 
unadjusted hazard ratios in the crude CKD risk for matched and unmatched patient 
groups. 
5.4.4 Risk of CKD in Patients with Microalbuminuria 
Despite a protective tendency against CKD, patients with microalbuminuria at 
baseline have little or no statistical evidence of a similar protective effect in the full 
cohort (aHR: 0.71, 95%CI: 0.33–1.5, P = 0.38). However, the estimates imply a 
protective influence against CKD favouring the bariatric group in the matched 
cohort (aHR: 0.42, 95%CI: 0.18–0.99, P = 0.050). The adjustments made for this 
model have only omitted 13.2% of observed events. Table 5.1b shows a summary 
of adjusted and unadjusted hazard ratios in CKD risk for patients with 
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Table 5.1 Survival results against CKD and CVD events. 
Survivability of patients against (A) crude CKD events, (B) CKD events in patients with 
microalbuminuria at baseline as well as (C) composite CVD events and their respective crude 
incidence rates and hazard ratios of events in the full cohort and in the matched group. 
 
Survival Analysis Bariatric Non-bariatric 
A. Crude CKD events  
    Full cohort, n 139 9,934 
        Events/person-years, n 16/1,283 2,032/96,843 
        Absolute ratesa (95% CI) 12.5 (7.6–20.3) 20.9 (20.1–21.9) 
        HRb (95% CI) 0.56 (0.33–0.95)† 1 (reference) 
        aHRc (95% CI) 0.53 (0.30–0.91)† 1 (reference) 
    Matched cohort, n 119 548 
        Events/person-years, n 16/1,102 103/5,385 
        Absolute rates (95% CI) 14.5 (8.9–23.7) 19.1 (15.8–23.2) 
        HR (95% CI) 0.67 (0.37–1.22) 1 (reference) 
        aHRd (95% CI) 0.46 (0.24–0.85)† 1 (reference) 
 
B. CKD in patients with 
microalbuminuria 
  
    Full cohort, n 64 3,546 
        Events/person-years, n 8/650 775/34,517 
        Absolute rates (95% CI) 12.3 (6.1–24.6) 22.4 (20.9–24.1) 
        HR (95% CI) 0.59 (0.29–1.20) 1 (reference) 
        aHR (95% CI) 0.71 (0.33–1.5) 1 (reference) 
    Matched cohort, n 53 180 
        Events/person-years, n 8/558 43/1,694 
        Absolute rates (95% CI) 14.3 (7.2–28.7) 25.4 (18.8–34.2) 
        HR (95% CI) 0.62 (0.28–1.39) 1 (reference) 
        aHR (95% CI) 0.42 (0.18–0.99)† 1 (reference) 
 
C. CVD in patients with 
microalbuminuria 
  
    Full cohort, n 22 1,510 
        Events/person-years, n 10/258 710/11,304 
        Absolute rates (95% CI) 38.7 (20.8–72.0) 62.8 (58.3–67.6) 
        HR (95% CI) 0.70 (0.37–1.34) 1 (reference) 
        aHR (95% CI) 0.30 (0.09–0.96)† 1 (reference) 
    Matched cohort, n 16 76 
        Events/person-years, n 10/202 33/580 
        Absolute rates (95% CI) 49.6 (26.7–92.2) 56.9 (40.5–80.0) 
        HR (95% CI) 0.77 (0.34–1.75) 1 (reference) 
        aHR (95% CI) 0.36 (0.11–1.13) 1 (reference) 
a Absolute rate at 1000 person-years. 
b HR (unadjusted hazard ratio).  
c aHR (adjusted hazard ration). Adjusted for age, diabetes duration, duration of antihypertensive 
drug use, diuretics use, antidiabetic drug use (i.e. Premix) and deprivation (Townsend) status. 
d Adjusted for age, diabetes duration and insulin drug use.  
† P < 0.05 (probability reference). 
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5.4.5 Risk of CVD in Patients with Microalbuminuria 
In the full cohort, patients with microalbuminuria, who had been treated with 
bariatric surgery, had a 70% lower risk in developing CVD (aHR: 0.30, 95%CI: 0.18–
0.96, P = 0.043). The added adjustments for this model have omitted 37.1% out 
from the unadjusted model. However, the same adjustments helped to reveal 
evidence of little or no statistical effect of such protection against composite CVD 
in the matched cohort (aHR: 0.36, 95%CI: 0.11–1.13, P = 0.079). Table 5.1c shows 
a summary of adjusted and unadjusted hazard ratios in composite CVD risk for 
patients with microalbuminuria. 
5.4.6 Change in Secondary Outcome Variables 
Significant reductions in the matched cohort (i.e. P < 0.001) favouring the bariatric 
group vs non-bariatric were observed in terms of body weight and BMI throughout 
5 years of follow-up time compared to baseline. Body weight and BMI for bariatric 
vs non-bariatric were at 1-year point (97.5 [±24.2] vs 109.8 [±18.6] kg; 34.2 [±9.0] 
vs 38.8 [±7.4] kg/m2, respectively), at 3-year point (95.7 [±19.4] vs 108.8 [±18.4] 
kg; 33.5 [±7.4] vs 38.3 [±7.2] kg/m2, respectively) and at 5-year point (98.9 [±23.3] 
vs 107.1 [±18.2] kg; 34.8 [±9.2] vs 37.8 [±7.3] kg/m2, respectively). 
The nonparametric analysis for the uACR medians revealed little or no statistical 
significance of a difference between bariatric and non-bariatric groups in both 
matched and full cohorts. In the full cohort, the median uACR in bariatric group at 
baseline was 2.0 vs 1.91 mg/mmol in non-bariatric (Z = −1.28, P = 0.19), at 1-year 
point 2.33 vs 1.90 mg/mmol (Z = −1.86, P = 0.06), and at 2-year point 2.42 vs 2.06 
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mg/mmol (Z = −0.87, P = 0.38), respectively. In the matched cohort, the median 
uACR in the bariatric group at baseline was 2.03 vs 1.90 mg/mmol in the non-
bariatric group (Z = −1.75, P = 0.08), at 1-year point 2.31 vs 1.95 mg/mmol (Z = 




Figure 5.2 Renal outcomes. 
Mean change in (A) Total protein (g/L), (B) Albumin (g/dL), and (C) Serum creatinine 
(µmol/L) in the matched groups, bariatric vs non-bariatric, compared to baseline. 
 
There have been significant improvements in eGFR throughout 5 years of follow-
up favouring the bariatric group in both full and matched cohorts. In the matched 
cohort, the eGFR was at similar levels at baseline with a mean of 68.7 in bariatric 
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patients vs 70.8 mL/min/1.73m2 in non-bariatric (t708 = 1.05, P = 0.29). Mean eGFR 
for the bariatric compared with non-bariatric group were 72.4 vs 68.4 
mL/min/1.73m2 (t708 = −2.07, P = 0.038) at 1 year and 71.4 vs 68.4 mL/min/1.73m2 
(t708 = −1.48, P = 0.13) at 3 years. However, during the fourth and fifth years of 
follow-up, the analysis of mean differences reported statistical significance 
favouring the bariatric group versus non-bariatric with 72.9 vs 66.8 
mL/min/1.73m2 at 4 years point (t708 = −3.14, P = 0.001) and with 74.2 vs 67.8 
mL/min/1.73m2 at 5 years point, respectively. Figure 5.3 illustrates proportions of 
both bariatric and non-bariatric patients with eGFR ≥ 60 mL/min/1.73m2 
throughout 5 years of follow-up.  
 
Figure 5.3 eGFR proportions. 
Proportions of patients (%) in the matched cohort with eGFR ≥ 60 (mL/min/1.73 m2) 
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The serum creatinine was also significantly reduced in the bariatric group 
compared to their PS-matched non-bariatric counterparts during the 2 years of 
follow-up—following the baseline point. Both groups were at similar levels of 
serum creatinine at baseline with a mean of 90.1 (±84.1) μmol/L in bariatric vs 88.4 
(±57.7) μmol/L non-bariatric (t708 = −0.27, P = 0.78). Mean creatinine for the 
bariatric group vs non bariatric was 79.7 vs 91.2 μmol/L (t708 = 2.59, P = 0.009) at 6 
months, 78.4 vs 86.1 μmol/L (t708 = 2.11, P = 0.03) at 1-year point, and 77.2 vs 90.5 
μmol/L at 2-year point (t708 = 2.65, P = 0.008) (Figure 5.2c shows differences in 
serum creatinine compared to baseline observations). 
In the matched cohort, the bariatric group had significantly lower albumin levels 
compared to non-bariatric throughout 2 years of follow-up. The total protein level 
showed a slight clinical change with a statistical significance of a difference at 1-
year point, but with no difference detected in the remaining points of follow-up 
time. Figure 5.2 shows mean differences between the matched groups while 
reflecting back to baseline observations for (a) total protein and (b) blood albumin. 
5.5 Discussion 
This study analysed insulin-treated T2D patients with severe obesity. The obtained 
results established a direct contribution exercised by bariatric surgery intervention 
in promoting a CKD protection effect in these patients. In addition, it observed 
improvements occurring in overall patients’ renal outcomes, benefitting 
individuals with or without microalbuminuria at baseline. Despite the matched 
cohort showing little or no statistically significant difference in the protective 
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action against the risk of composite non-fatal CVD, following surgery, estimates 
suggest a positive influence with lower event rates favouring the bariatric group. 
Furthermore, full cohort survival analysis indicated a profound effect protecting 
those microalbuminuria patients, who had received bariatric intervention 
treatment, when investigating composite non-fatal CVD events. Additionally, an 
overall eGFR levels improvement was noted within the bariatric matched group 
throughout 5 years of follow-up (Figure 5.3). 
This study took advantage of a novel procedure, which has not been previously 
employed, as demonstrated by reviewing published research [155,156]. This novel 
approach included an indirect assessment of time-to-event according to the 
baseline patients’ renal status. This timely phase involved the allocation of full and 
the PS-matched cohorts into further stratifications, leading to proper follow-up for 
survival investigation. With this approach, bariatric surgical intervention provided 
additional evidence for a protective effect benefiting T2D patients, with or without 
detected microalbuminuria at baseline.  
Obesity is associated with glomerular hyperfiltration. Therefore, increased risk of 
microalbuminuria and/or proteinuria exists in patients with obesity, with or 
without renal disease [144,157]. A direct connection had been previously shown 
to exist between bariatric surgery and glomerular hyperfiltration decrease. In 
these studies, this effect appeared within the first year post-surgery and was linked 
with the most significant weight loss outcome [158,159]. The link between fat mass 
and glomerular hyperfiltration is multifactorial. However, it is in part due to 
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increase in angiotensin II levels, which enhances tubular sodium reabsorption and 
activates tubulo-glomerular feedback [160]. These occurrences lead to 
vasodilation of the afferent arterioles, with a consequent increase in renal blood 
flow, intraglomerular pressure and eGFR [159]. However, while a decreased 
glomerular hyperfiltration may induce reductions in microalbuminuria and 
proteinuria levels, eGFR is expected to diminish [161]. At present, limited 
knowledge is available, concerning the longer-term effect of bariatric surgery on 
eGFR and CKD outcomes in insulin-treated T2D patients. Therefore, this patient 
cohort became the natural protagonist for the present study analysis, particularly, 
after taking into account their significant adverse cardiorenal outcome risks 
[121,122,126] and the insulin treatment negative impact on weight gain, which is 
an established predictor of renal problems occurrence [120]. In addition, patients 
with diabetes are associated with accelerated loss of lean muscle mass [162]. 
Interestingly, bariatric surgery is associated with further loss of skeletal muscle 
mass and function [163]. Since markers of both muscle mass and strength 
represent important outcomes predictors in CKD patients [164], this study findings 
contribute to reassure on the protective effects of bariatric surgery against CKD 
progression. In a recent study, for instance, less than 10% progressed to CKD within 
seven years of post-bariatric intervention and five (out of 2,144) patients 
developed ESRD during the follow-up period as they were included in a very high-
risk category [165]. 
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The main strength of this study lays in the inclusion of a relatively large cohort of 
T2D patients, receiving insulin therapy, who underwent bariatric surgery in a real-
world population. In addition, our database is largely representative of the UK 
population. Therefore, this chapter findings can be transposed to a variety of 
populations that share similar demographics with the UK. The relatively large 
patients’ cohort provides adequate statistical power and contains information on 
other time-varying covariates, useful to adjust for potential confounders. We 
adjusted for a set of factors that would likely to differ at baseline.  
Lastly, we should mention that this study discovered that bariatric surgery induced 
a limited, but detectable, protection on composite non-fatal CVD risk, 
notwithstanding its main significant advantageous effect against risk of developing 
CKD on patients with severe obesity and with T2D, with or without 
microalbuminuria. Therefore, bariatric surgery helps overall improvement in renal 
outcomes, such as eGFR. 
5.6 Limitations 
Similarly to the explanation given in Chapter 4 (Subsections 4.6), some residual 
shortcomings may persist in our study. For example, our classification of 
albuminuria was based on a single measurement. This is in contrast to current 
recommendations, requiring at least two measurements for its definition. 
Nevertheless, we believe that a significant amount of predictive information can 
be ascertained from using a single urinary albumin measurement within a large 
patient cohort, such as the one analysed in this study. In addition, the effect of 
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competing hazards may bias estimates of risk, as it is the case with all studies 
assessing CV or ESRD risks associated with eGFR and albuminuria. The reason for 
this is identified in the elevated uACR and low eGFR being risk factors for non-renal 
diseases, and in the associated differential mortality in high-risk individuals, which 
may confound hazard ratio estimates for CV events. Finally, this study did not 
include an assessment of potential baseline alterations induced by the effect of 
medications on glycaemic and blood pressure symptoms. Therefore, this study 
cannot account for any differences that may influence the association between 
uACR and outcomes. However, a necessity exists for prospective investigation and 
appropriate investment to verify or examine real-world effects of bariatric surgical 
intervention on renal function and stability of patients with severe obesity, who 
are dependent on insulin treatment. It is also important to note that the rapid 
decline in body weight usually cause a substantial reduction in patients’ muscle 
mass. This reduction influence almost all blood biochemical elements in which 
such alteration may become a sensible source of bias for CKD evaluation made in 
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6.1 Summary 
Aim: To investigate the metabolic and liver-related outcomes of bariatric surgery among 
patients with insulin-treated T2D and non-alcoholic fatty liver disease (NAFLD) who are at 
high risk of liver fibrosis. 
Methods: The study comprises a retrospective cohort comparison of patients with NAFLD 
and Fib score > 1.45, who received bariatric intervention vs comparable patients who 
received no bariatric intervention. Metabolic (HbA1c, body weight, BMI and Fib-4 score) 
and composite liver-related outcomes (cirrhosis, portal hypertension, liver failure and 
hepatoma) were compared between groups over a period of five years. The outcomes 
were adjusted for baseline and time-varying co-variates.  
Results: 4,108 patients were included in the study sample, 45 of whom underwent 
bariatric surgery. The mean age at baseline was 62.4±12.4, 43.8% female, and the mean 
body weight, BMI, and HbA1c were 89.5 (±20.8) kg, 31.7 (±7.6) kg/m2 and 68.4 (±16.7) 
mmol/mol respectively. In addition, the median Fib-4 score was 2.3 (IQR:1.7–4.2). During 
the five years during which follow-up outcomes were recorded, the body weight and BMI 
reductions were significantly lowered compared to baseline in the bariatric group. 
Similarly, the HbA1c levels were lower in the bariatric group, with a statistical significance 
observed in the first and second post intervention years (bariatric vs non-bariatric at 1-
year: 63.1 vs 68.1; P=0.042; and at 2-year: 62.7 vs 68.1, P=0.028). No significant difference 
(bariatric group 8.9% vs non-bariatric 4.7%) was observed in the Fib-4 scores or the 
likelihood of developing composite liver disease during the follow-ups between the 
groups (X2=1.75, P = 0.18). 
Conclusion: Bariatric surgery amongst patients with insulin-treated T2D and who had at 
high risk of liver fibrosis was associated with significant improvements in metabolic 
outcomes. No significant adverse effect was observed with regards to liver related 
outcomes.  
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6.2 Background and aims 
As the obesity epidemic continues to grow, non-alcoholic fatty liver disease 
(NAFLD) has become the most common cause of chronic liver disease, [166,167] 
with a prevalence estimated to equate to between 20% and 30% of the general 
population. NAFLD is a disease spectrum, which starts with fatty liver and steatosis, 
after which it and progress to steatohepatitis, hepatic inflammation, and cirrhosis, 
where cumulative liver injury results in liver fibrogenesis associated with portal 
hypertension, hepatic synthesis dysfunction, liver failure, and the need for liver 
transplantation [33,168,169].  
NAFLD is also considered to be a metabolic disorder that results from complex 
interactions between genetic, hormonal, and nutritional factors [170]. Up to 85% 
of patients with NAFLD are with obesity and have been diagnosed with type 2 
diabetes (T2D) [166]. Although there are well-recognised associations between 
NAFLD, insulin resistance, and hyperinsulinemia [166,170], little is known about 
liver-related outcomes among T2D patients and with obesity who are receiving 
exogenous insulin treatment [121,171,172].    
The implementation of lifestyle and nutritional management, as a means of 
inducing sustained weight loss, forms the cornerstone of NAFLD treatment. 
However, the extent to which patients with morbid obesity comply with lifestyle 
and nutritional guidelines is variable. There is mounting evidence that bariatric 
surgical intervention is associated with significant improvements in liver histology 
and the resolution of NAFLD [173,174]. However, there are ongoing concerns and 
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uncertainties regarding the safety and efficacy of bariatric surgery when 
performed in patients with more advanced liver disease. This ambiguity is 
associated with reported incidences of sepsis, portal vein thrombosis, anastomotic 
leak, bleeding varices, fulminant hepatic failure, and peri- and post-operative 
mortality following bariatric surgery [175-178]. Furthermore, while findings reveal 
that liver histology was stable in the first year after surgery, progressive fibrosis 
has been reported after 5 years and has been independently associated with high 
body mass index (BMI) and hyperinsulinaemia [179].  
This study, therefore, aims to investigate the safety and metabolic results of 
bariatric surgery in patients with insulin-treated T2D who are at an increased risk 
of liver fibrosis (Fib-4 score > 1.45) during five years of retrospective follow-up.  
6.3 Methods 
6.3.1 Study design and data sources  
The current study comprises a brief retrospective cohort comparison of bariatric 
intervention (exposure) on patients experiencing NAFLD (i.e. Fib-4 score > 1.45) at 
baseline and are with insulin-treated T2D. The sample was grouped according to 
exposure and retrieved from THIN. This study was conducted on the same data 
source slice employed in the cardiometabolic study in Chapter 4 (see Subsection 
4.3.1).  
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6.3.2 Ethics 
Ethical approval was provided to THIN by the NHS South East Multi-centre 
Research Ethics Committee (MREC). The Scientific Review Committee (SRC) 
reviewed this study’s protocol for scientific merit and feasibility. 
6.3.2 Study population 
The dataset contains 11,125 adult patients, aged 18 years and over, who have been 
diagnosed with T2D and prescribed with some form of insulin therapy. The index 
date for patients was based on either the day of bariatric surgery or, in the event 
that they had not received bariatric intervention, the first initiation of insulin 
therapy. The dataset was scanned to identify and potentially exclude patients with 
no history of insulin use, with a Fib-4 score less than 1.45, or with a diagnosis of 
type 1 diabetes. 
6.3.3 Exposure and outcomes 
Our exposure of interest is bariatric surgical intervention for NAFLD patients with 
insulin-treated T2D. The metabolic outcomes of interest included in this study 
comprise body weight, BMI, Fib-4 scores, and HbA1c levels during the five-year 
retrospective follow-up period.  In addition, we examined the variables influencing 
the likely development of composite liver disease, including encephalopathy, liver 
failure, bleeding varices, cirrhosis, and hepatoma (screened READ code list is 
available in Table 10.4.8, Appendix 4). 
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6.3.4 Covariates and follow-up strategy 
The baseline clinical parameters were measured at a similar point in time according 
to the treatment categories of patients. For example, patients who underwent 
bariatric surgery will have their baseline parameters calculated12 from 90 days up 
to one day prior to their scheduled surgery. Similarly, non-bariatric patients will 
have their baseline parameters calculated using the same time window in 
accordance with their first initiation of insulin therapy. Thus, covariates were 
recalculated at the six-month stage, and at each year point during follow-up, with 
a ninety-day window on every concurring point of time up to the five-year follow-
up stage. 
6.3.5 Statistical analysis 
Student’s t test was used to estimate the mean changes in continuous variables in 
the treatment group for a five-year follow-up period. The Wilcoxon rank-sum test 
was employed to test the magnitude of difference between the medians of non-
parametric continuous variables (i.e. Fib-4 scores). Pearson’s X2 test was used in 
proportions between groups regarding liver disease events within the complete 
follow-up period. The statistical significance was set at a p level of 0.05. Missing 
data among covariates were managed through multiple imputations using 
predictive means matching for continuous covariates, taking into account variables 
such as exposure (i.e. bariatric), age, gender, diabetes duration, Townsend 
 
12Average value is calculated for multiple entry records that were found during the 90 days window for the 
same variable. 
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deprivation status, marital status, smoking, and alcohol consumption. To test the 
adequacy of our multiple imputation approach in addressing the impact of any 
missing data, we conducted a sensitivity analysis wherein the primary endpoints in 
the imputed dataset were compared with the dataset with missing values. The 
results were comparable at the follow-up stages. Throughout this process, we used 
Stata/SE Statistical Software version 16.1 for all carried analysis (StataCorp., 
College Station, TX) and GraphPad/Prism version 8.4.2 for visualisation (La Jolla, 
CA).  
6.4 Results 
6.4.1 Patient characteristics 
From a total population of 11,125 patients in the THIN database, we identified and 
included 4,108 NAFLD patients (i.e. with Fib-4 score >1.45) and with insulin-treated 
T2D, 45 of whom underwent bariatric surgical intervention. Of the NAFLD patients, 
43.8% were female. The mean age at baseline of these patients was 62.4 (±12.4), 
with their mean body weight, BMI, and HbA1c being 89.5 (±20.8) kg, 31.7 (±7.6) 
kg/m2, and 68.4 (±16.7) mmol/mol respectively. The median Fib-4 score at baseline 
was 2.3 (IQR: 1.7–4.2). Of this NAFLD sample, 14.2% were defined as most 
deprived, 23.5% as least deprived, and 20.5% towards second, third and fourth 
quintiles on the deprivation scale.   
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Figure 6.1 Change in weight and BMI. 
Mean change in (A) body weight and (B) BMI (95%CI) comparing bariatric vs non-bariatric 




Figure 6.2 Mean HbA1c and median Fib-4 scores. 
Bariatric vs non-bariatric in (A) mean HbA1c and in (B) median Fib-4 score (95%CI) during 
five years of follow-up. 
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6.4.2 Changes in metabolic and liver related outcomes 
During the five years of follow-up period, body weight and BMI were significantly 
lower amongst patients in the bariatric group when compared to their baseline 
measurements. No significant weight change was noted amongst patients in the 
non-bariatric group during this period. (Figures 6.1a & 6.1b, Table 6.1). Similarly, 
HbA1c levels were lower within the NAFLD bariatric group throughout the study 
period. However, this finding only had statistical significance during the first and 
second years of the study period (bariatric vs non-bariatric at 1-year: 63.1 vs 68.1, 
P = 0.042; and at 2-year: 62.7 vs 68.1, P = 0.028) (Figure 6.2a). The Fib-4 scores 
were maintained at lower levels due to the benefits associated with bariatric 
intervention, albeit with little or no statistical significance throughout the entire 
follow-up period (Figure 6.2b). The likelihood of developing composite liver 
disease throughout the study period was higher amongst patients in the bariatric 
group (8.9%) compared to those non-bariatric group (4.7%), again with little or no 
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Table 6.1 Metabolic outcomes for patients with NAFLD at baseline 
 (i.e. Fib-4 score > 1.45). 
 
Metabolic outcomes Bariatric (N=45) Non-bariatric (N=4,063) P-value† 
Body weight kg, mean(SD)   
Baseline 119.2 (30.7) 89.2 (20.4) < 0.0001 
6 months 99.9 (21.6) 90.6 (19.9) 0.002 
1st year 93.6 (20.4) 90.8 (19.8) 0.35 
2nd year 94.9 (23.1) 90.4 (19.7) 0.13 
3rd year 96.2 (19.8) 91.2 (20.0) 0.12 
4th year 100.9 (21.9) 91.3 (20.1) 0.003 
5th year 95.4 (21.0) 90.5 (19.9) 0.13 
BMI kg/m2, mean(SD)   
Baseline 42.5 (11.4) 31.6 (7.5) < 0.0001 
6 months 35.7 (7.6) 32.1 (7.4) 0.002 
1st year 33.0 (7.6) 32.2 (7.3) 0.45 
2nd year 33.7 (9.2) 32.0 (7.3) 0.16 
3rd year 34.0 (7.1) 32.3 (7.3) 0.15 
4th year 36.2 (10.3) 32.4 (7.3) 0.001 
5th year 33.7 (9.2) 32.1 (7.3) 0.16 
HbA1c mmol/mol, mean(SD)   
Baseline 68.0 (20.8) 68.4 (16.7) 0.88 
6 months 65.5 (25.5) 67.9 (16.6) 0.37 
1st year 63.1 (18.5) 68.1 (15.7) 0.042 
2nd year 62.7 (20.5) 68.1 (15.6) 0.028 
3rd year 65.0 (16.7) 68.2 (15.5) 0.22 
4th year 65.3 (17.1) 68.3 (15.7) 0.23 
5th year 66.3 (18.0) 68.6 (16.1) 0.38 
Fib-4 scores, median(IQR)   
Baseline 2.18 (1.79) 2.31 (2.53) 0.59 
6 months 1.11 (0.74) 1.32 (1.36) 0.31 
1st year 1.27 (1.10) 1.34 (1.33) 0.52 
2nd year 1.09 (0.89) 1.38 (1.43) 0.15 
3rd year 1.48 (1.80) 1.36 (1.39) 0.81 
4th year 1.00 (0.96) 1.37 (1.43) 0.030 
5th year 1.52 (1.69) 1.39 (1.41) 0.44 
Composite Liver disease events, 
(%) 
  
During 5 years 8.9% 4.7% 0.18  
† P < 0.05 (probability reference). 
6.5 Discussion 
This increasing prevalence of obesity and NAFLD has caused bariatric surgery to be 
increasingly utilised as a proven means of either halting or reversing the 
progression of liver disease in patients with NAFLD [173,174]. In a large meta-
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analysis involving 766 patients, significant improvement in liver histology was 
reported following different bariatric surgical interventions [180]. Amongst 
patients with cirrhosis, no major complications were reported in six patients who 
underwent laparoscopic sleeve gastrectomy. However, two patients developed 
transient ascites and hepatic encephalopathy [178]. Three further studies have 
been conducted which review laparoscopic sleeve gastrectomy or gastric bypass 
operation in a total of 39 patients with cirrhosis. These studies have reported no 
postoperative mortality or liver-related complications [181-183]. Conversely, 
several studies have reported complications following bariatric surgery in patients 
with cirrhosis. In an early survey of non-laparoscopic bariatric surgeries, 125 cases 
of cirrhosis were identified, of which, 11 patients died peri- or post-operatively 
from fulminant hepatic failure [184]. Whilst laparoscopic procedures have been 
shown to significantly improve clinical outcomes, Dallal’s et al. [185] research 
revealed multiple potential postoperative complications in 9 out of 30 patients 
with cirrhosis, including anastomotic leaks, acute tubular necrosis, prolonged 
intubation, ileus, and the need for blood transfusions. A subsequent case study 
involving 23 patients with cirrhosis who had undergone various laparoscopic 
bariatric procedures reported complications in 8 patients. The complications 
included anastomotic leak, infection, and bleeding requiring blood transfusion. 
However, no liver decompensation or perioperative mortality was reported [186]. 
Therefore, there are ongoing concerns about the safety and efficacy of bariatric 
surgery among patients who already have liver fibrosis at the time of surgery. 
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T2D is independently associated with increased risk of complications from bariatric 
surgery [187] and is intrinsically connected to the pathogenesis associated with 
NAFLD via hyperinsulinaemia and insulin resistance [166,170]. Despite this, many 
of the aforementioned studies have not investigated the risk of adverse liver 
outcomes following bariatric surgery with specific reference to patients with T2D. 
Crucially, earlier research has indicated that bariatric surgery is associated with an 
increased risk of liver fibrosis progression after five years. Furthermore, this 
research also highlights an independent association with hyperinsulinaemia [179]. 
Our study, which was undertaken in patients with insulin-treated T2D at high risk 
of liver fibrosis (defined as Fib 4 score of > 1.45), demonstrated significant 
improvements over the five-year study period in weight and HbA1c outcomes, 
with no significant worsening of liver fibrosis score nor any significant increased 
incidence of composite liver disease outcomes, such as encephalopathy, liver 
failure, bleeding varices, cirrhosis, and hepatoma. Specifically, these findings were 
deduced in comparison with patients who did not have bariatric surgery. Whilst 
this data provided some reassurance regarding the safety and efficacy of bariatric 
surgery in this high-risk group, the non-significant trend towards a higher risk of 
liver-related complications amongst patients who had bariatric surgery suggests 
the need for caution. Scrupulous pre- and post-operative screening needs to be 
implemented in order to identify and manage individuals with more advanced liver 
disease prior to bariatric surgery. Unfortunately, this approach may not be 
consistently applied across all bariatric centres with many patients with significant 
liver disease not being identified or medically optimised prior to bariatric surgery 
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[188]. A large scale study of patients who underwent bariatric surgery reported 
that the presence of compensated cirrhosis was associated with an increased 
length of hospital stay and involved a two-fold increased risk of mortality 
[176,189]. Patients with decompensated cirrhosis had even worse outcomes with 
a combined in-hospital mortality rate for both compensated and decompensated 
cirrhosis of 1.2%, with mortality rates lower at high volume centres (> 100 
procedures per year) compared to lower volume centres [176].  
In summary, this study supports the role of bariatric surgery in improving 
metabolic parameters amongst those high-risk patients with T2D who are also at 
increased risk of liver fibrosis. However, comprehensive pre- and post-operative 
screening needs to be implemented to identify and manage individuals with more 
advanced liver disease prior to bariatric surgery. In this way, it becomes possible 
to reduce the risks of immediate, short- and long-term complications associated 
with bariatric surgery. 
6.6 Limitations 
Several limitations to this study must be addressed. For example, this research 
seeks to investigate a specific patient group at high risk of adverse outcomes, i.e. 
insulin-treated T2D, and Fib-4 > 1.45 and to compare outcomes in the presence or 
absence of bariatric surgery. Consequently, the number of patients in the bariatric 
surgery group is too small to permit a robust proper propensity-matched analysis 
to be performed. Nonetheless, the number of patients analysed in this study who 
have liver disease is comparable or in excess of the numbers previously reported 
  Chapter 6 - Bariatric & NAFLD 
 137 
in a general patient cohort of bariatric surgery patients. The sources of our data 
have allowed us, where possible, to adjust for confounders. In addition, the 
number of patients with diagnosed cirrhosis at baseline and during follow-up is too 
small. Nevertheless, we consider it possible that patients with cirrhosis are often 
missed prior to surgery and, therefore, under-reporting may have influenced the 
information in our database. Utilising a Fib-4 threshold of 1.45 would therefore 
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7.1 Summary 
Aim: To assess the bariatric surgical intervention associated healthcare costs and the risk 
of developing obesity-related comorbidities, in insulin-treated T2D patients with obesity. 
Methods: A retrospective cohort study was conducted among 11,125 insulin-treated T2D 
patients, whose details were stored within the THIN electronic primary care database, in 
the UK. Propensity score matching was performed for bariatric surgery with non-bariatric 
cohort (N=160) in a 1:1 ratio. In order to ascertain the existence of potential significant 
variations between the control and the bariatric surgery cohorts, drug prescriptions costs 
were compared with expenses for GP visits, hospitalisation and laboratory tests, during a 
5-year follow-up period. Cox proportional regression was used to compute differences in 
the composite risk of obesity-related comorbidities. Chi-square analysis was employed to 
explore differences in insulin independency and diabetes remission proportions during 
follow-up. 
Results: The baseline mean values were as follow: age was 48.3 years (±12.9) (61% 
female), and BMI was 39.3 kg/m2 (±9.3). During the follow-up period, anti-diabetic drug 
cost was significantly lower in the bariatric group, than in the non-bariatric (median 
cost/person (£): 527.77 (IQR: 1,196.11) vs. 1,564.13 (IQR: 1,576.01); P < 0.001). Overall, 
aggregate cost analysis showed a significant total healthcare cost reduction in the 
bariatric group (median cost/person (£): 1,597.96 (IQR: 2,631.84) vs. 2,440.12 (IQR: 
2,242.95); P = 0.050). A significant 44% degree of protection, from obesity-related 
comorbidities, was afforded by bariatric surgery, following comparison with non-bariatric 
patients (aHR: 0.56; 95%CI: 0.32–0.96; P = 0.036). Additionally, insulin independency rate 
was significantly higher in the bariatric group, than in the non-bariatric, throughout all 
follow-up points, with the ration being 48.1% vs. 28.9% at year five; P = 0.044. 
Conclusion: Cost efficiency evidence could be detected for bariatric surgery. However, 
this study failed to establish significant cost savings for the procedure. This surgical 
intervention has a protective effect against obesity-related comorbidities and it promotes 
increased likelihood of insulin independency during the 5-year follow-up period. 
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7.2 Background and aims 
Obesity and T2D are major global health problems that are intrinsically linked with 
adverse health outcomes [110,111], the risk of which can be reduced by significant 
weight loss [113]. While diet and exercise play a crucial role in obesity 
management, lifestyle or pharmacotherapy may not achieve durable weight loss 
in the majority of patients [114,190,191]. Therefore, bariatric surgery has emerged 
as the most effective and durable strategy for long-term weight loss maintenance 
in individuals with morbid obesity [115]. Previous studies have shown that bariatric 
surgical procedures may offer important health benefits to people with severe and 
morbid obesity. These benefits include reductions in body weight [192], remission 
of established T2D [50] and other long-term conditions [193], as well as reduction 
in mortality [194,195]. 
It is noteworthy that the significant costs, attached to bariatric surgery and to the 
associated follow-up care, represent an element that may explain its variable 
accessibility across the UK. Some studies suggest that bariatric surgery may 
represent a cost-saving initiative for health systems [196]. However, health care 
utilisation studies have not supported this theory, after analysis of the effect of 
bariatric surgery. A clear demonstration of cost-effectiveness appears to have 
been discovered, but cost savings could not be detected, particularly when 
comparing bariatric procedures with routine medical care or intensive lifestyle 
interventions, due to post-surgical costs after 3 years of surgery [197-199]. 
Therefore, short-term focus on cost saving should shift towards an attention on 
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patients beneficial effects of surgery: further analysis is required for ascertaining 
individuals’ long-term health and well-being improvements following bariatric 
procedure. Importantly, a previous study has reported that the long-term health 
care cost of bariatric surgery varies depending on the patient glucose status at 
baseline [200]. However, at present, no cost studies and only few cost-
effectiveness analyses have examined the impact exercised by specific patient 
subgroups on the health care system, following bariatric surgery. This question is 
critical to establish an economic case for bariatric surgery. 
To this end, many T2D patients will require insulin treatment to manage 
hyperglycaemia and to reduce long-term vascular complications risks. It is an 
established fact that a significant 4 to 9 Kg weight gain is triggered by the initiation 
of insulin therapy within the first year. This side effect is exacerbated by insulin 
dosage increases [120], simultaneously raising CV risks [201]. Thus, a cohort of 
insulin-treated T2D patients represent a complex, heterogeneous and challenging 
group of individuals. Many of them present significant comorbidities, high CV 
disease risk and, therefore, high health care costs. The study aim is to assess a 
number of associated healthcare costs elements from bariatric surgical 
intervention, and the risk of developing composite obesity-related comorbidities 
in insulin-treated T2D patients with severe obesity. 
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7.3 Methods 
7.3.1 Study design and data sources 
This retrospective cohort study was conducted analysing patients data selected 
from the THIN database. THIN is a UK primary health care database that 
systematically computerised longitudinal and anonymised patients health records 
from primary care physicians. Further details on the data source is available in 
Chapter 4 (Subsection 4.3.1). 
7.3.2 Ethics 
Ethical approval was provided to THIN by the NHS South East Multi-centre 
Research Ethics Committee (MREC). The Scientific Review Committee (SRC) 
reviewed the study protocol for scientific merit and feasibility. 
7.3.3 Study population 
The collected THIN dataset contains 11,125 adult patients, aged 18 years and over. 
There was no upper age limit for patients diagnosed with T2D and who had been 
prescribed with a form of insulin therapy, up to September 2017. According to 
cohort type, the initial study time-point (patient index date) corresponded with 
the bariatric surgery day (treated cohort) or with the insulin therapy initiation first 
day, for those not undergoing surgery (untreated, or control, cohort). The dataset 
was scanned to identify patients with baseline date prior to 1 January 2000, with 
no history of insulin use or diagnosed with type 1 diabetes, for possible exclusion. 
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7.3.4 Exposure and outcomes 
Our exposure of interest is bariatric surgical intervention for insulin-treated T2D 
patients with severe obesity. The surgery represented patient exposure to 
remedial action. Its effectiveness was monitored during a 5-year long follow-up 
period, inclusive of the primary outcome and of the study concluding stage. 
Because of the time scale, this final stage corresponded to the actual end of study 
for most subjects, but also to unpredicted transfers or demise for some patients. 
Primary outcomes were defined within the survival rate of patients against 
diagnosed obesity-related comorbidity events. The risk of obesity-related 
comorbidities was estimated during the first occurrence of one of the following 
observed (or diagnosed) episodes:  
i. coronary heart disease or stroke,  
ii. cancers, including breast, bowel or womb cancer,  
iii. hypertension,  
iv. gallbladder disease or gallstones,  
v. osteoarthritis,  
vi. gout,  
vii. sleep apnoea or asthma,  
viii. high blood cholesterol or atherosclerosis,  
ix. liver diseases, including alcohol and non-alcohol fatty liver disease,  
x. chronic kidney disease or nephropathy,  
xi. gastro-oesophageal reflux disease (GORD),  
xii. reported episodes of severe depression or dementia.  
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For our analysis, it was possible to mine the data records within the THIN database 
for specific dates associated with recorded reports of the listed events. Events of 
obesity-related comorbidities were assessed and reported by health professionals, 
following good medical practice standards applied across the NHS primary health 
provision and covered by the THIN database collective systems.  
GBP drug cost distribution was retrieved from specific prescription dates, reported 
within the THIN main database. The cost for each prescribed drug was added 
through the use of current BNF filing systems [202]. Drugs were grouped into the 
following seven main categories:  
i. insulin,  
ii. oral anti-diabetic,  
iii. GLP-1 analogues,  
iv. anti-hypertensive,  
v. lipids lowering,  
vi. diuretics, 
vii. Aspirin.  
A screened drug list, with genericnames, is provided in Appendix 10.7.  
Additionally, it was possible to retrieve from the THIN database details regarding 
GP visits, hospitalisation and requests for laboratory tests, even though different 
forms were used for documenting these factors, requiring some investigative 
exercise. Specifically, GP visits frequency was calculated considering the number 
of blood pressure readings reported in the database. Hospitalisation had several 
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codes, to indicate specific admission procedures, such as ‘Hospital inpatient’ and 
‘Emergency hospital admission’. Each was associated to a specific cost. Finally, the 
THIN database medical records included a specific section for lab tests requests. 
All service costs were added by reflecting each specific service procedure made to 
the National Schedule of Reference Costs (NHS Reference Costs: 2015 to 2016) 
[203]. If provided prior to the specified index-points, prescriptions and health 
services were excluded from this analysis. 
A number of secondary outcomes of interest revealed the following:  
i. likelihood of being off insulin during the follow-up time, due to absence of 
insulin prescriptions,  
ii. being within defined diabetes remission parameters: patients were 
categorised as being in diabetes remission if their estimated HbA1c levels 
were at 48mmol/mol or less, in addition to being off any form of anti-
diabetic prescriptions throughout. 
7.3.5 Covariates and follow-up strategy 
Patients, that received bariatric surgery interventions, represented the treatment 
group and were the subject of this study follow-up focus. Their propensity-score 
was matched to insulin-initiators from their first insulin prescription date. Patients 
with diagnosed obesity-related comorbidity events, which occurred prior to the 
designated baseline point, were excluded from the primary survival estimation. In 
line with patient’s treatment category, the baseline clinical parameters were 
measured at a similar point of time. Specifically, a period, comprising 90 days to 
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one day prior to procedure date, constituted the time when baseline parameters 
were calculated within bariatric surgery patients. Likewise, non-bariatric patients 
had their baseline parameters calculated within the same period, according to 
their first initiation of insulin therapy. Covariates were, recalculated at each year 
time-point during follow-up, with a 90-day window on every concurring point of 
time. 
7.3.6 Statistical analysis 
In the form of PS-matched groups, primary analysis allowed the timeframe to 
incorporate the risks of composite obesity-related comorbidity events. The PS 
model was estimated by using a logistic regression model, in order to adjust 
baseline characteristics, minimising allocation bias between groups. The 
measurement of standardised differences, occurring before and after procedure, 
represented the basis for a balance assessment between bariatric (treated) and 
non-bariatric cohorts. The mean from continuous covariates and proportion of 
categorical variables were examined and summarised between groups. Each 
treatment subject was matched to one reference subject (1:1 ratio) at the nearest 
distance, measured by the estimated PS. This was based on the estimated 
treatment probabilities [129]. In order to minimise distance within matched sets, 
we employed caliper of width equal to 0.1 of the standard deviation of the PS logit. 
The aim was to improve match quality and to limit possibility of excessive numbers 
of matched subjects. A caliper of width of 0.2 or lower resulted in optimal 
estimation, compared to higher choices of caliper use [131]. In consideration of a 
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prognostic covariate, PS was included in all Cox proportional hazards regression 
modelling. 
The stratified log-rank test, with Kaplan-Meier failure-function curves, 
respectively, were used to compare the equality between the PS matched groups. 
The absolute probability reduction of an event occurring within 5-year follow-up 
period was calculated. Additionally, the comparison of the adjusted event 
occurrence hazard quantification, between the bariatric and the matched non-
bariatric groups, was enabled by the estimation of marginal hazard ratios. 
Proportional hazard assumptions were confirmed through Schoenfeld residuals 
test. Point estimates with 95% Confidence Intervals (CIs) were accepted at the 
conventional statistical significance level of P ≤ 0.05, in the regression models. The 
proportional hazards assumption was examined by comparing the cumulative 
hazard plots, grouped on exposure. No violations were observed. 
Missing data among covariates were managed through multiple imputations using 
the predictive means matching for continuous covariates with accounting to 
exposure (i.e. bariatric), age, gender, diabetes duration, Townsend deprivation 
status, marital status, smoking and alcohol use [132]. sensitivity analysis was 
conducted to fill gaps from missing data, to assess their impact and to validate our 
multiple inputting adequacy [133].  
The student’s t test was employed to measure differences between means in 
parametric continuous variables, such as service cost distribution. Wilcoxon’s rank-
sum test was used to test the magnitude of differences between medians of non-
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parametric continuous variables, including drug cost distribution. Finally, 
Pearson’s Chi-square test was used to compare proportions of insulin 
independency, as well as diabetes remission rates between groups. Statistical 
significance was considered at P ≤ 0.05, as standard. To avoid the probability of 
type II error, the study was powered to 0.88 and the matched sample size of 160 
subjects with detected true difference of less than 0.13 between the two groups 
at 5% significance level. The study fulfilled the STROBE criteria for reporting 
observational studies [134,135]. The SAS Software version 9.4 was used 
throughout the initial dataset management (SAS Institute, Cary, NC), Stata/SE 
Statistical Software version 15.1 was employed in all carried analyses and visual 
illustrations (StataCorp., College Station, TX). 
7.4 Results 
7.4.1 Patient characteristics and total follow-up 
From a total population of 11,125 patients, we identified 9,875 patients within the 
inclusion criteria and fit for PS-matching procedure, 133 patients of which were 
identified to have undergone bariatric surgical operations. The PS-matching 
procedure has allowed 80 control subjects to be matched with 80 treatment 
(bariatric) patients. This yielded a total number of 160 PS-matched participants. 
The median treatment duration was 6.06 years (interquartile range [IQR]: 4.67–
8.69 years). The median follow-up was 4.26 years (IQR: 1.61–6.13 years), 
representing a total follow-up time of 693.5 person-years.  
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The mean age for the matched cohort at baseline was 48.3 (±12.9) years; 60.6% 
were females. The mean body weight, BMI and HbA1c level were 111.0 (±26.4) kg, 
39.3 (±9.3) kg/m2 and 72.2 (±18.7) mmol/mol, respectively. The baseline 
characteristics in both bariatric and non-bariatric groups were compared in full and 
matched cohorts with respective standardised differences are illustrated in Table 
7.1. 
7.4.2 Probability of survival against comorbidities 
The unadjusted probability of survival in the PS-matched cohort showed tendency 
towards a protective effect against composite obesity-related comorbidity events 
with little or no statistical significance of a difference from proportions between 
bariatric and non-bariatric groups: at 1-year (81.3% vs 78.8%), 3-year (67.2% vs 
61.2%) and 5-year (60.0% vs 51.9%) of follow-up (log-rank test P = 0.34). A total of 
69 events were observed (31 bariatric vs 38 non-bariatric) with a crude event rate 
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Table 7.1 Baseline characteristics. 
 Cohort  
Full population  
[N = 9,875] 
  PS matched cohort  






[n = 9,742] 
Bariatric 





[n = 80] 
Bariatric 
[n = 80] 
 
Std. diff† 
Demographics       
Age (yrs), mean (SD) 58.4 (13.3) 48.2 (10.2) 0.862 48.4 (15.2) 50.2 (10.2) -0.140 
Gender, no (%) 
Female 6,284 (64.5) 61 (45.7) 0.386 44 (54.7) 51 (63.6) -0.183 
 
Townsend deprivation, % 
Least deprived 12.9 21.6 -0.233 14.7 13 0.049 
Less 25 20.5 0.106 26.7 16.9 0.239 
Average 15.3 21.1 -0.151 17.3 19.5 -0.055 
More 22.6 21 0.039 17.3 22.1 -0.119 
Most deprived 24.2 15.7 0.213 24 28.6 -0.104 
 
Type 2 diabetes (yrs), mean (SD) 
Diabetes duration∆ 14.1 (7.61) 13.7 (7.75) 0.052 11.7 (6.39) 13.7 (8.26) -0.273 
Insulin dependency 6.8 (4.4) 6.9(5.0) -0.016 4.6 (3.3) 6.8 (5.1) -0.522 
 
Drug use duration (yrs), mean (SD) 
Oral antidiabetics  10.5 (5.8) 11.6 (5.8) -0.182 10.2 (5.3) 11.1 (5.8) -0.161 
Antihypertensive 11.9 (6.6) 12.4 (6.7) -0.075 12.0 (5.4) 12.2 (6.7) -0.043 
Lipids lowering 9.9 (4.8) 10.2 (5.3) -0.062 9.6 (4.3) 9.8 (5.4) -0.045 
Diuretics 8.9 (6.9) 8.2 (7.3) 0.089 6.9 (6.3) 7.8 (6.8) -0.133 
Aspirin 8.5 (5.4) 8.0 (5.6) 0.084 7.6 (5.8) 7.4 (5.6) 0.031 
 
Clinical parameters, mean (SD) 
Weight (kg) 90.6 (20.8) 123.8 (30.4) -1.274 108.1 (27.3) 113.9 (25.3) -0.220 
Height (m) 1.68 (0.10) 1.69 (0.11) -0.024 1.68 (0.10) 1.69 (0.12) -0.186 
BMI (kg/m2) 32.2 (7.7) 43.9 (10.7) -1.260 38.7 (10.2) 39.8 (8.3) -0.120 
HbA1c (mmol/mol) 69.7 (17.3) 73.3 (19.7) -0.194 72.2 (18.7) 72.2 (18.8) -0.0014 
Fasting glucose (mmol/L) 9.90 (3.9) 9.83 (4.4) 0.019 9.87 (4.1) 10.04 (4.9) -0.037 
Blood glucose (mmol/L) 11.66 (5.3) 12.34 (9.3) -0.089 12.33 (5.5) 11.11 (5.4) 0.223 
SBP (mmHg) 138.5 (16.4) 134.9 (14.1) 0.236 135.8 (16.3) 135.7 (14.2) 0.011 
DBP (mmHg) 78.9 (9.6) 78.5 (8.3) 0.050 77.9 (9.1) 79.3 (8.6) -0.151 
Triglyceride (mmol/L) 2.04 (1.31) 2.29 (1.59) -0.179 2.53 (1.85) 2.31 (1.54) 0.131 
Total cholesterol 
(mmol/L) 
4.49 (1.16) 4.595 (1.25) -0.087 4.47 (1.36) 4.62 (1.36) -0.107 
Low density lipoprotein 
(mmol/L) 
2.40 (0.98) 2.48 (0.89) -0.082 2.56 (1.01) 2.45 (0.98) 0.1095 
High density lipoprotein 
(mmol/L) 
1.22 (0.39) 1.09 (0.29) 0.358 1.08 (0.26) 1.11 (0.29) -0.113 
 
Alcohol status, % 
Unknown 3.2 3.4 -0.011 2.7 7.8 -0.232 
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Ex-drinker 13.7 7 0.221 14.7 3.9 0.378 
Never 31.5 30.9 0.013 30.7 46.8 -0.335 
Current 51.6 58.7 -0.143 52 41.6 0.21 
 
Smoking status, % 
Ex-smoker 31.5 36.7 -0.112 26.7 33.8 -0.155 
Never 54.8 49.6 0.105 54.7 58.4 -0.076 
Current 13.7 13.7 0.001 18.7 7.8 0.325 
∆ Diabetes duration is time from first diagnosis of diabetes to date of initiation with insulin drug. 
* Standardised differences are the absolute difference in means or percentages divided by the SD of the 
treated group. Resulting standardised difference after 1:1 matching ratio based on average treatment effect 
on treated propensity score technique and robust variance of estimation. 
† Mean of standardised difference in post PS matching (0.054), i.e. at less than 6% difference level measured.  
 
Throughout, however, bariatric surgery showed a significant protective effect 
against composite obesity-related comorbidities in the adjusted13 matched cohort. 
Patients underwent bariatric surgery had 44.3% lower risk to be diagnosed with 
obesity-related comorbidities compared to patients who have not had bariatric 
surgery (aHR: 0.56, 95%CI: 0.32–0.96, P = 0.036). Figure 7.1 and Table 7.2 
summarise the observed events, event rates and differences in the probability of 
survival in the adjusted and unadjusted analyses.  
The exact count with READ codes of obesity-related comorbidity events are 





13 Adjusted for treatment duration, fasting glucose, blood lipids, drug use (i.e. antihypertensive, diuretics and 
aspirin), smoking status and deprivation (Townsend) scale. Number of subjects in post adjustment was N=151, 
with 65 events observed. 
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Table 7.2 Survivability against obesity-related comorbidity events. 
Survivability of patients against observed obesity-related comorbidity events, crude incidence rates 
and hazard ratios of events in the matched Bariatric and Non-bariatric groups. 
 
Survival analysis Non-bariatric Bariatric 
Obesity-related comorbidity events  
    Cohort, n 80 80 
        Events/person-years 38/324 31/369 
        Absolute ratesa (95% CI) 117.2 (85.3–161.1) 83.9 (59.0–119.3) 
        HRb (95% CI) 1 (reference) 0.79 (0.49–1.28) 
        aHRc (95% CI) 1 (reference) 0.56 (0.32–0.96)† 
a Absolute rate at 1000 person-years. 
b HR (unadjusted hazard ratio).  
c aHR (adjusted hazard ration). Adjusted for treatment duration, fasting glucose, blood lipids, drug use (i.e. 
antihypertensive, diuretics and aspirin), smoking status and deprivation (Townsend) scale. 





Figure 7.1 Failure function plots of obesity-related comorbidities. 
Bariatric vs matched non-bariatric Failure Function plots of obesity-related comorbidity 
events. († Adjusted for treatment duration, fasting glucose, blood lipids, drug use (i.e. 
antihypertensive, diuretics and aspirin), smoking status and deprivation (Townsend) scale). 
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7.4.3 Drug and services frequency and cost distribution 
The database was thoroughly screened for all included drug and service categories 
that had been provided to each individual subject in the matched cohort. The total 
frequency of drug and services utilised during follow-up were 24,564 and 3,028 
respectively. Drug use frequency in more details is provided in Appendix 10.9. 
During the five years, bariatric patients cost significantly lower than non-bariatric 
in antidiabetic drug prescriptions (median: £627.60 vs £1,564.11; P < 0.001). The 
additional drug category (included: antihypertensive, lipids lowering, diuretics and 
aspirin) was statistically insignificant for the difference between medians despite 
the higher expenses coming from bariatric patients (£108.02 vs £90.72; P = 0.97). 
Similarly, bariatric group was with higher cost in the service utilisation category 
(included: GP visits, hospitalisation and laboratory test requests) with little or no 
statistical significance of this difference between cost means (bariatric £1,505.32 
vs non-bariatric £1,058.54; P = 0.056).  
The reduction in antidiabetic drug costs was found to be overwhelmingly leading 
this comparison towards a reduction in the aggregated cost favouring the bariatric 
group. This included all analysed categories with a statistical significance favoring 
the bariatric group (median: £1597.96 vs £2440.12; P=0.050). Cost and frequency 
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Table 7.3 Drug and service cost (in British Pounds) and frequency comparison between 
matched bariatric and non-bariatric groups throughout five years of follow-up. 
Cost elements Non-bariatric (N = 80) Bariatric (N = 80)  





Probability of a 
difference 
Drug utilisation overall 13,352 1,685.5 (1,860.9) 11,212 727.8 (1,554.1) Z(157)= 4.02; P< 0.001 
Total spent 151,898.20 103,926.60 – 
Antidiabetic drug use 6,428 1,564.1 (1,576.0) 3,536 627.6 (1,205.7) Z(153)= 4.38; P< 0.001 
Total spent 135,219.70 75,095.51 – 
   Insulin 3,022 1,161.9 (1,191.4) 1,271  604.3 (1,159.1) Z(133)= 2.83; P= 0.004 
        1st year 854  289.3 (252.3) 252  171.7 (240.9) Z(123)= 3.42; P< 0.001 
        2nd year 636   287.1 (179.4) 252  205.8 (233.9) Z(100)= 2.23; P= 0.023 
        3rd year 601   286.2 (168.5) 273  228.5 (233.4) Z(91)= 1.16; P= 0.25 
        4th year 524   302.2 (203.2) 232   221.7 (219.0) Z(79)= 2.22; P= 0.026 
        5th year 407   260.4 (280.6) 262  294.6 (275.6) Z(70)= -0.57; P= 0.57  
        Total spent  95,464.50 45,240.32 – 
 Oral antidiabetic drugs 3,226   140.1 (366.1) 2,102 85.0 (119.1) Z(134)= 1.49; P= 0.13 
        1st year 793  34.6 (42.2) 446  23.1 (32.7) Z(123)= 2.51; P= 0.012 
        2nd year 679   32.6 (46.3) 451   28.8 (40.9) Z(109)= 0.89; P= 0.37 
        3rd year 608   28.8 (74.1) 457   22.4 (30.4) Z(99)= 1.01; P= 0.32 
        4th year 697   34.6 (93.3) 394   33.3 (37.8) Z(86)= 0.62; P= 0.54 
        5th year 449   28.5 (118.9) 354   22.1 (64.1) Z(78)= 0.61; P= 0.55 
        Total spent 25,801.76 16,616.09 – 
 GLP-1 analogues 180   863.3 (1,230.1) 166   863.2 (1,955.2) Z(23)= 0.12; P= 0.90 
        1st year 66  549.4 (266.1) 26  163.8 (163.7) Z(15)= 1.25; P= 0.21 
        2nd year 44   561.3 (235.4) 49   667.1 (245.7) Z(12)= -0.96; P= 0.33 
        3rd year 19   359.9 (104.1) 34   559.6 (313.9) Z(9)= -1.11; P= 0.26 
        4th year 26   392.4 (174.0) 32   470.9 (235.4) Z(10)= -0.63; P= 0.53 
        5th year 25   313.9 (156.9) 25   235.4 (255.9) Z(11)= 0.28; P= 0.78 
        Total spent 13,953.45 13,239.10 – 
Additional drug use 2,629 90.7 (282.4) 3,831 108.0 (236.3) Z(139)= 0.042; P= 0.97 
Total spent 16,678.45 28,831.12 – 
 Antihypertensive drug 3,513 72.3 (156.1) 3,876 67.2 (143.0) Z(111)= 0.31; P= 0.76 
        1st year 996  18.8 (38.3) 854  15.2 (45.9) Z(101)= 0.99; P= 0.32 
        2nd year 792   19.2 (30.1) 874   20.1 (40.6) Z(95)= -0.05; P= 0.95 
        3rd year 623   14.4 (29.8) 771   20.6 (41.6) Z(86)= -1.29; P= 0.19 
        4th year 612   17.0 (34.0) 709   18.1 (44.9) Z(77)= -0.35; P= 0.73 
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        5th year 490   21.8 (28.8) 668   16.6 (48.4) Z(68)= -0.18; P= 0.86 
        Total spent 10,113.76 14,152.48 – 
 Lipids lowering drugs 1,755   20.1 (29.8) 2,034  24.0 (39.8) Z(124)= 0.21; P= 0.84 
        1st year 432  6.0 (5.9) 441  6.1 (7.5) Z(108)= 0.24; P= 0.81 
        2nd year 358   6.1 (4.8) 445   6.2 (8.1) Z(104)= -0.04; P= 0.97 
        3rd year 346   5.2 (6.0) 438   8.1 (7.1) Z(94)= -1.35; P= 0.18 
        4th year 349   5.3 (8.3) 377   7.9 (6.5) Z(81)= -1.02; P= 0.31 
        5th year 270   5.9 (7.4) 333   8.4 (7.8) Z(70)= -1.26; P= 0.21 
        Total spent 3,782.35 3,366.74 – 
 Diuretics 873   32.3 (69.8) 933  23.1 (73.8) Z(63)= 0.68; P= 0.50 
        1st year 259   13.7 (15.2) 203   9.1 (12.6) Z(48)= 1.21; P= 0.22 
        2nd year 214   12.6 (19.9) 208   9.8 (18.8) Z(43)= 0.41; P= 0.68 
        3rd year 156   16.8 (22.7) 208   13.2 (22.1) Z(37)= -0.17; P= 0.87 
        4th year 132   12.6 (20.3) 163   7.4 (23.1) Z(31)= 0.09; P= 0.92 
        5th year 112   14.7 (18.3) 151   18.9 (28.9) Z(25)= -0.57; P= 0.56 
        Total spent 1,637.18 9,816.07 – 
 Aspirin 784   21.3 (51.1) 836  27.0 (39.8) Z(68)= 0.71; P= 0.48 
        1st year 262 9.9 (9.9) 198 7.1 (12.8) Z(57)= 1.74; P= 0.080 
        2nd year 170 9.2 (7.4) 164 8.8 (5.7) Z(47)= -0.12; P= 0.90 
        3rd year 121 7.8 (12.8) 190 7.9 (9.9) Z(41)= -0.21; P= 0.83 
        4th year 119 12.8 (9.9) 146 7.5 (5.7) Z(32)= 1.49; P= 0.14 
        5th year 112 12.9 (8.2) 138 8.5 (8.5) Z(29)= 2.26; P= 0.024 
        Total spent 1,145.16 1,495.83 – 
Service cost distribution ∆ Frequency Mean cost (SD) Frequency Mean cost (SD) Probability of a difference 
Clinical utilisation overall 1,571 1,058.5 (1,059.5) 1,457 1,505.3 (1,752.4) t(155)= -1.92; P= 0.056 
Total spent 81,508.13 120,445.00 – 
 GP visits 876 679.1 (452.4) 953 719.3 (531.6) t(154)= -0.51; P= 0.61 
        1st year 252 208.9 (139.2) 257 207.3 (130.4) t(144)= 0.07; P= 0.94 
        2nd year 198 176.4 (163.4) 203 189.3 (149.9) t(129)= -0.47; P= 0.64 
        3rd year 163 159.5 (134.7) 185 184.0 (168.6) t(119)= -0.89; P= 0.38 
        4th year 150 175.6 (112.3) 175 193.4 (137.7) t(103)= -0.73; P= 0.47 
        5th year 113 172.9 (126.1) 133 198.5 (147.7) t(77)= -0.83; P= 0.41 
        Total spent 52,288.44 56,824.88 – 
 Laboratory tests use 636 103.3 (81.4) 390 65.8 (47.3) t(96)= 2.77; P= 0.0067 
        1st year 142 32.9 (27.1) 66 25.5 (13.4) t(54)= 1.16; P= 0.25 
        2nd year 120 25.0 (16.7) 74 22.2 (16.9) t(64)= 0.65; P= 0.52 
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        3rd year 156 35.2 (32.5) 72 24.3 (13.7) t(58)= 1.54; P= 0.13 
        4th year 122 31.0 (27.6) 89 24.1 (17.6) t(60)= 1.16; P= 0.25 
        5th year 96 30.1 (24.4) 89 31.4 (22.3) t(47)= -0.21; P= 0.83 
        Total spent 5,164.32 3,158.68 – 
Total Health Utilisation Frequency Median cost (IQR) Frequency 
Median cost 
(IQR) 
Probability of a 
difference 
Aggregate distribution 14,923 2,440.1 (2,242.2) 12,669 1,597.9 (2,631.8) Z(160)= 1.95; P= 0.050 
† Non-parametric probability test used for reported drug users only. 
∆ parametric probability test used for reported service users only. 
 
7.4.4 Change in BMI 
There have been reductions in BMI favoring the bariatric group vs non-bariatric 
throughout all follow-up time points and with established statistical significance 
except for the fifth year. The mean BMI for bariatric vs non-bariatric was at 1-year 
(34.1 [±8.3] vs 38.2 [±9.7] kg/m2, P = 0.005), at 3-year (33.5 [±7.2] vs 37.3 [±7.8] 
kg/m2, P = 0.001), and with little or no statistical significance of a difference at 5-
year point (34.0 [±8.4] vs 36.1 [±8.5] kg/m2, P = 0.13), respectively.  
7.4.5 Proportions of insulin independency and diabetes remission 
During follow-up, patients underwent bariatric surgery have had a significantly 
higher likelihood of being off insulin compared to their matched controls. 
Throughout, the average proportion of insulin independency from the bariatric 
group was 41.5% compared to 19.7% non-bariatric (Figure 7.2). Diabetes remission 
proportions were at higher levels during follow-up, favoring the bariatric group 
with statistical significance at 5-year point (11.5% vs 2.0%, P=0.050). Throughout, 
the bariatric group was twofold higher in overall remission proportion, compared 
to non-bariatric; 12.9% vs 5.2%, respectively (Figure 7.3).  
 




Figure 7.2 Insulin independency. 





Figure 7.3 T2D remission proportions. 
T2D remission proportions (i.e. off AD and with HbA1c < 48 mmol/mol) comparing bariatric 
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7.5 Discussion 
Bariatric surgery is more effective, than medical or lifestyle intervention, for long-
term weight loss and for achieving remission of diabetes [50,115]. However, it 
remains to be established whether bariatric surgery reduces expenditures 
sufficiently to achieve cost savings beyond three years of procedure [199]. The 
appreciation of significant cost reductions has received limited attention in regards 
of assessing different treatment strategies required by the various diabetic 
patients’ subgroups [200]. In this cost-utilisation study, bariatric surgery was 
shown to be cost effective among insulin-treated T2D patients with obesity, driven 
by the significant reduction in the total cost of anti-diabetic drug therapy. In 
addition, total healthcare cost reduction is evident in the bariatric group, over a 
period of five years post-surgery. However, it should be noted that a subtle 
advantage exists for promoting bariatric surgery, despite its combined costs linked 
to the procedure, medical treatment and follow-up appointments. The reduction 
of a patient lifetime health expenditures is unlikely for a procedure that reduces 
mortality and morbidity in a complex, heterogeneous population, as was the case 
in this study. When taking into account the cost of surgery as well as the cost of 
medical treatment and follow-up of patients, bariatric surgery will not necessarily 
offer cost savings. However, it is noteworthy that our data highlighted how 
bariatric surgery could significantly protect against multifactorial obesity-related 
comorbidities, increased insulin independency rate and augmented the rates of 
diabetes remission post-surgery. The patients’ quality of life improved 
significantly. 
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Previous studies have found that bariatric surgery was cost-effective for morbid 
obesity treatment [197-199]. The incremental cost-effectiveness ratio, ranging 
between £2,000 and £4,000 per QALY, was gained over a 20-year time period 
[204]. However, bariatric surgery costs are high: in the UK, £5,500 is the standard 
rate, based on current tariff, and higher price tags can be observed during the long 
analysis period in the present study. Therefore, predictably, bariatric surgery is less 
likely to achieve significant cost-saving advantages for most eligible patients. 
Further expenses accrued when the costs of medical follow-up, in-patient 
treatment, further surgery and complications management are added to the price 
of the initial surgery. In addition, supplementary costs are incurred when proactive 
individuals seek to ameliorate their health outcome, by pursuing a medical 
consultation and diligently attending follow-up clinics. This last statement should 
not be read as a detriment to the strife of these individuals taking ownership of 
their own health before it becomes absolutely necessary.  
The UK National Bariatric surgery registry, which included data of 18,283 
procedures from 2010 to 2013, revealed that, 61% patients with sleep apnoea 
were able to come off their treatment one year after surgery. Additionally, 65% 
T2D patients were in remission of T2D after two years from surgery, with 
significantly higher rates of insulin independencies [205]. Thus, an important policy 
question is whether bariatric surgery needs to be cost-effective (i.e. more effective 
but more costly than usual care), or does it need to achieve the higher standard of 
cost savings (i.e. more effective and less costly than usual care) to justify its 
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increased commissioning throughout the UK. Although bariatric surgery does not 
appear to produce economical savings, it is associated with substantial health gains 
at expenses that are below the accepted thresholds for cost-effectiveness. 
Furthermore, true cost savings may only accrue over a longer follow up of patients, 
which include the unaccounted expense in the improvement of patients’ mental 
health and general well-being. For example, in the United States, for patients with 
a BMI of 35 or greater, annual health care costs are between $3000 and $10 000 
per year [198,200]. Hence, even if total healthcare (drugs and clinical visits) 
expenses are reduced by 50% after surgery, cost neutrality may be achieved only 
after 20 years.  
It has to be recognised that a variety of factors hinder the ability to execute a 
thorough assessment of the immediate and longer-term post bariatric surgery 
costs. These factors include the reduced patients’ number in the database, beyond 
5 years after surgery, as well as poorly recorded details, relating to costs of surgical 
complications, follow-up and re-operations. Nevertheless, studies have reported 
cost savings for bariatric surgery, when analysing longer-term follow-up and health 
economic models [206,207]. Further analysis is required to ascertain whether 
better cost efficiency could be achieved in different patients’ subgroups or with 
specific types of bariatric surgery. The identification of this potential saving would 
be invaluable for informing clinical commissioners during the decision making 
process. Procedures, such as sleeve gastrectomy, was thought to yield cost savings, 
due to the relatively low complication rates and early evidence of clinical outcomes 
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that are comparable with RYGB [51,57]. However, the long-term outcome of sleeve 
gastrectomy, on diabetes remission and insulin independence, remains unclear.  
This chapter main advantage derives from the inclusion of a specific insulin-treated 
T2D cohort in a real-world population. This enables the generalised application of 
our results to the rest of the UK population, as well as to a similar demographic 
community. The analysed patients’ cohort provides adequate statistical power and 
contains sufficient information on other time-varying covariates for adjusting for 
possible co-founders. Adjustments were made for a large set of factors, which 
could have differed at the baseline, through a robust PS-matching protocol. This is 
very important, because it is routine clinical practice that bariatric surgery 
implementation depends on a multifaceted decision-making process, which 
exceeds the UK NICE guidelines. 
This research was based on empirical data for health care utilisation costs, 
estimated from the electronic health records of a large participants’ sample, 
managed in primary care in the UK. We have used conservative assumptions, 
including health care utilisation costs after surgery not associated with weight loss 
or other unreported forms of morbidity. These include psychological and mental 
health benefits, productivity at work or any positive surgery ‘spill over’ effects, 
which are transmitted to other family members, such as lifestyle changes and 
health behaviours of the entire family. In addition, this study has only covered a 
small clinical part of the whole real picture of formal and informal cost utilisation. 
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Patients’ quality of life, productivity and psychological or mental status are all, 
among other aspects, economically worthy.     
In conclusion, cost efficiency appears to be evident when bariatric surgery is 
performed. Specifically, the saving appears to stem from the reduced need for 
prescribing antidiabetic medications. Additionally, it is an effective measure in 
protecting insulin-treated T2D patients with severe obesity against composite 
obesity-related comorbidities. Patients, who underwent bariatric surgery, 
displayed an increased likelihood of becoming independent from insulin treatment 
and appeared to acquire a greater tendency towards subsequent diabetes 
remission. 
7.6 Limitations 
In this study, some residual shortcomings may persist, because of our inability to 
measure and adjust for insulin therapy dosage or for diabetes duration, due to 
ongoing issues of identifying incidents versus prevalent diabetes. The exposure 
classification, into broad kind of bariatric surgery, may have masked the effects of 
the individual procedure type and could have driven our study away, or closer, to 
the null hypothesis. Nonetheless, previous high-profile studies, on cardiovascular 
benefits of bariatric surgery, have not examined individual procedure types for the 
same objectives. For the purpose of this study, it is worth clarifying that, in the UK, 
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8.1 Discussion 
The preceding chapters have focused on the clinical impact of comorbidities 
associated with obesity together with the clinical service requirement to cater for 
these issues. Given that the obesity epidemic has significant implications for the 
NHS, the aforementioned disease states have been evaluated from both practical 
and economic perspectives.  
Obesity is a complex condition. It seldom presents in isolation and typically co-
exists with one or more comorbidity. Thus, UK citizens with elevated BMI are 2.5 
times more likely to develop CKD, for example, than are individuals with BMIs 
within the normal range [208]. Any guideline designed to tackle obesity must 
consider the presence of concurrent medical conditions. The extent of this issue is 
under-represented within adult admission criteria for entry into Tier 3, with a tight 
criteria of BMI 40 kg/m2, BMI ≥ 35 kg/m2 existing alongside comorbidities or BMI ≥ 
30 kg/m2 and T2D onset within the last decade. Hence, it remains unclear whether 
Tier 3 can reduce the current burdensome demand for Tier 4 surgical intervention. 
The viability of short- to medium-term success has been demonstrated in a 
number of observational studies into British obesity, as outlined in Chapter 2, 
albeit with the possibility of bias and perceptible patient loss during the follow-up 
stages. The full extent of this field of interest was revealed during the literature 
review, which explored studies into obesity-related comorbidities. This 
empowered a better understanding to acquire more in-depth knowledge of the 
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work required in the current thesis. Later chapters in this thesis explore potential 
solutions to the clinical problems. Thus, Chapter 3 postulates that the loss of 
patients beyond the six-month follow-up stage might be a consequence of their 
being discharged into the care of their own GPs, a lack of interest in their condition, 
or their onward referral to Tier 4 bariatric intervention.  
Morbid obesity is a complicated clinical condition. Those patients who, despite 
their best efforts, have failed to achieve BMI reductions are often referred for Tier 
4 intervention. Yet, to ensure success at this stage, patients must be sufficiently 
motivated and equipped with the knowledge necessary to manage post-operative 
requirements. Only patients in whom significant clinical improvement can be 
anticipated should be selected for bariatric procedures. Moreover, bariatric 
surgery is an extremely specialised field and should preferably be performed in 
dedicated centres by surgeons with demonstrable expertise in this area. In 
addition, support from specialist multi-disciplinary teams is highly desirable [55].  
In addition to issues of accessibility and availability, the level of intervention 
provided by Tier 3 services may be inadequate for such patients if recovery from 
comorbidities is also to be achieved. Hence, the referral criteria for Tier 3 services 
should be modified to include subjects with BMI ≥ 35 kg/m2 alone or with BMI ≥ 
30 kg/m2 with T2D or with pre-diabetic syndrome (e.g. HbA1c of 42–47 mmol/mol). 
This proposal is in keeping with the literature in that it has demonstrated that such 
patients already possess an increased probability of presenting with significant 
obesity-related comorbidities. The presence of diabetes, hypertension, and 
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hypercholesterolaemia were found to be related to excess body weight in male 
and female subjects from a wide range of socioeconomic and ethnic backgrounds 
[209].  
The work presented in Chapter 4 illustrates that specialist surgical intervention has 
failed to mitigate the risk of AMI, stroke, and HF. These results accord with the 
acknowledged CV and metabolic effects of bariatric procedures. The current 
research, however, focuses on subjects with insulin-treated T2D who have a 
greater CV risk.  Although a lower incidence of CV-related disease or death is 
associated with the performance of bariatric surgery, the post-operative risk of 
death in patients with T2D remains over a third higher than expected [136].  
In patients with microalbuminuria and who are thus at significant risk of renal 
disease, there was an observed tendency towards a reduction of composite CVD 
risk following bariatric surgery. However, as shown in Chapter 5, this effect did not 
reach statistical significance. A new method to evaluate composite CVD risk was 
devised. This involved evaluating survivability based on the patient’s initial kidney 
function status. 
Furthermore, patients with liver cirrhosis not only have a greater risk from bariatric 
procedures, but also experience poorer clinical outcomes. The presence of T2D in 
these patients is an additional and independent risk factor [187]. Furthermore, 
hyperinsulinaemia and insulin resistance have been implicated in the aetiology of 
NAFLD [166,170]. The risk of hepatic complications in diabetic patients undergoing 
bariatric surgery has yet to be fully described in the literature. However, it has been 
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observed that bariatric surgery can accelerate cirrhotic progression over a five year 
period, which suggests that hyperinsulinaemia is an independent risk factor for 
liver function deterioration [179]. The work discussed in Chapter 6, however, 
demonstrated improvements in respect of clinical measurements of body weight, 
HbA1c, and the stability of hepatic fibrosis scores. Moreover, there was no 
significant rise in incidences of hepatic failure or associated complications, such as 
cirrhosis, hepatoma, encephalopathy, or variceal bleeding, amongst bariatric 
insulin-dependent T2D patients with NAFLD at baseline.  
Tier 4 bariatric procedures significantly reduce the risk of developing PAD, CHD, 
and CKD, irrespective of the presence of microalbuminuria at baseline. Clinical 
improvements are also seen in terms of body weight, glycaemic control, eGFR, 
insulin dependency, and diabetes remission. In addition to the similar 
improvements in respect of metabolic parameters for patients with NAFLD at 
baseline. Surgery appears to reduce the likelihood of obesity-related 
comorbidities, as per the 13 components of composite chronic disease outlined in 
Chapter 7. However, BP, total cholesterol, albumin and serum creatinine either 
remain constant or demonstrate only short-term improvements. 
Whilst statistically significant short- to medium-term metabolic improvements 
were evident in patients in receipt of Tier 3 care, the clinical outcomes were 
somewhat checked. That is, any improvements were fleeting. Moreover, not only 
was the available data pertaining to the six-month follow-up stage limited, but the 
service capabilities were sporadically endangered.   
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Only short- to medium-term improvements in body weight, glycaemic control, and 
BP occurred with a modest benefit in terms of physical activity. This finding 
confirms the need to query the ability of Tier 3 services to help patients transition 
to bariatric intervention. In addition, it indicates the possibility that intervention 
which is both multifaceted and multidisciplinary might impact potential clinical 
outcomes in post-bariatric surgery contexts when referral to Tier 4 services were 
implemented.  
Commissioning guidelines act to standardise the elements of the Tier 3 service 
offered by EMBMI. The outcome considerations employed in Chapter 3 refer to 
baseline comorbidities. This is deemed a more preferable approach to 
conventional weight-focused metrics as a means of evaluating the effectiveness of 
therapeutic intervention. Tier 3 services are expected to play an important role in 
optimising the management of comorbidities prior to bariatric surgery, either 
through the implementation of referrals to appropriate clinicians or through the 
utilisation of multi-disciplinary teams. The volume of patients with comorbidity 
issues lends weight to the earlier proposal to improve patient access to Tier 3 care, 
even in respect of patients with class I obesity (i.e. BMI ≥ 30 kg/m2). 
The current research confirms the contention that the primary fiscal drain is 
associated with conditions which coexist with obesity. Hence, there is a clear need 
to explore the economic impact of therapeutic interventions. As a bare minimum 
this appraisal should incorporate cost per capita considerations [103]. However, it 
seems likely that a more inclusive strategy is required, perhaps akin to that 
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outlined in Chapter 7. Comparing 160 PS-matched cohort revealed only minimal 
cost-saving emerging from bariatric intervention, although there was added cost-
efficiency when the study was extended to encompass composite obesity-related 
comorbidities. 
Wang et al. (2011) anticipate that by 2030, there will be an extra 11 million adults 
with obesity in the UK. It is projected that this will create an additional 6–8.5 
million cases of diabetes, 5.7–7.3 million instances of heart disease, and 0.49–0.7 
million incidences of cancer. Accompanying this is the forecast loss of between 26 
and 55 million quality-adjusted life years [210]. These scenarios could be almost 
entirely eradicated if relevant health care measures were implemented. However, 
this would require an estimated increase in spending of £1.9–2 billion per annum 
until 2030 [210]. According to Wang et al. (2011), it would be possible to reduce 
this expenditure through the introduction of multimodal lifetime treatment 
pathways that includes medical assessment, psychological evaluation, as well as 
bariatric intervention. 
In cases where bariatric intervention is considered, as mentioned previously, the 
choice of patient, their awareness, the effective treatment of comorbidities, and 
psychological evaluation are all paramount to the success of any surgical options. 
Bariatric procedures must be offered more consistently in the UK. Moreover, they 
should be tailored to the physiological needs of individual patients. In addition, any 
non-surgical interventions for patients with severe obesity should not exceed a 
reasonable length of time (e.g. six months in duration based on inferences made 
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in Chapters 2 and 3) in cases where less invasive options have been fully explored 
and considered within a multi-targeted management strategy.  
8.2 Research recommendations 
In light of the guidelines explored in the preceding chapters, it is clear that the 
assessment of obesity-related comorbidities comprises a valuable gauge against 
which to measure the effectiveness of service provision. The monitoring of the 
extent to which patients absorb advice pertaining to diet and exercise can help to 
ensure that they possess enough information to enable them to adopt appropriate 
calorie intake and lifestyle changes. Moreover, management strategies can be 
tailored to take into account the unique risk factors and problems associated with 
each patient.  
Further randomised control studies are required to evaluate the clinical outcomes 
of specific therapeutic interventions. Liaison with ethical approval bodies is 
required to ensure that randomisation in study control groups does not deny 
patients access to any clinically necessary treatments. Another option would be to 
conduct prospective studies designed to assess the impact bespoke therapeutic 
interventions for patients with obesity-associated comorbidities.  
Evaluating the viability of the present tiered system from a policy perspective 
represents another useful approach. The current thesis contends that Tier 3 
services produce moderate, albeit unstainable, metabolic improvements. 
Moreover, this paper recommends the incorporation within existing Tier 4 services 
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of a multidisciplinary weight management programme, comparable to that 
currently used within Tier 3 service provisions. It is proposed that this could 
enhance and accelerate access to surgical interventions.  
In patients selected for bariatric surgery who also present with existing liver 
pathology, it is essential to implement protocols for pre- and post-interventional 
screening. Patients would also benefit from psychological input and clinical care 
after specialist surgery in order to address any new issues arising from their 
procedures, including the presence of loose or excess skin as a consequence of 
weight loss.  
I also suggest the detailed documentation of data related to bariatric interventions 
and potential complications, including the type of surgery performed, 7-day and 
30-day readmission rates, 30-day reoperation rates, in-hospital mortality, and day 
case use. The acquisition of data relating to in-patient readmissions, follow-up 
procedures, length of hospital stay, intensive care admissions, out-patient visits, 
use of additional medical services, and the impact on associated comorbidities 
could assist in the identification of financial burdens on the NHS associated with 
this clinical issue. Thus, this analytical strategy could provide clear insights for both 
budget holders and policy makers. 
8.3 Final conclusions 
The evaluation of obesity-related pathologies should be incorporated within the 
monitoring of clinical progress for all patients. This can be accomplished using 
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standardised clinical outcome metrics and through the consistent documenting of 
evaluations in patient records. Whilst the non-invasive interventions offered as 
part of Tier 3 services tend only to generate time-limited benefits in respect of 
body weight, glycaemic control, BP, and physical activity, they are associated with 
less sustained, almost imperceptible, positive progress in patients.   
Medical literature supports the notion that the prevention of related pathologies, 
such as advanced T2D, represents a rational clinical approach to the management 
of patients with morbid obesity. The risk of serious CVD, such as PAD or CHD, can 
be significantly reduced by performing bariatric procedures. Surgery is also reno-
protective in patients with a risk of CKD, such as those with baseline 
microalbuminuria. Furthermore, bariatric intervention promotes the optimisation 
of metabolic parameters in NAFLD patients. Substantial improvements in body 
weight also have a significant positive correlation with the normalisation of eGFR, 
cholesterol, BP and HbA1c. It is reasonable to assume that the subsequent 
improvements in patient well-being also generate enhancements in life quality and 
work performance. The satisfactory resolution of comorbidities and the generation 
of lower insulin requirements also reduce the need for clinic appointments and the 
demand for numerous related health services. Bariatric intervention, therefore, 
has positive financial implications for both the British economy and the NHS.   
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Appendix 10.1 Search strategy example. 
 
 
(((‘tier 3’) OR (‘weight reduc*’) OR (‘weight manag*’) 
OR (‘weight program*’) OR (‘overweight program*’) OR 
(‘MWMS’) OR (’specialist weight management’) OR (‘SWM’) 
OR (‘weight reduction program*’) OR (‘weight management 
interven*’) OR (‘multidisciplinary weight loss 
initiatives’) OR (‘multicomponent weight loss schemes’) 
AND ((‘UK’) OR (‘england’) OR (‘british’) OR (‘wales’) 
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Appendix 10.2 PRISMA checklist for Tier 3 systematic review. 
Section/topic  # Checklist item  Reported  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  YES 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number.  
YES 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  YES 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study 
design (PICOS).  
YES 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information 
including registration number.  
YES 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) 
used as criteria for eligibility, giving rationale.  
YES 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched.  
YES 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  YES 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis).  
YES 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
YES 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  YES 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis.  
YES 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  YES 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-
analysis.  
YES 
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Section/topic  # Checklist item  Reported   
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
YES 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
YES 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
YES 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  YES 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
YES 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  YES 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
YES 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
YES 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  YES 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
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Appendix 10.3 THIN database. 
 
The longitudinal database, The Health Improvement Network (THIN), comprises 
extensive anonymised primary care records, provided by a significant number of 
participating UK general practices. It was established in 2002, by the Epidemiology 
and Pharmacology Information Core (EPIC) in partnership with In Practice Systems 
(IPS), London. EPIC recruited Primary Care practices and began data collection in 
2003. It regulates the participating practices by setting, upgrading and monitoring 
adherence to stipulated standards on data collection, quality, handling and 
storage, in line with NHS guidelines. Currently, THIN represents a collaboration 
between INPS and Cegedim Healthcare Software (the company that writes the 
data collection software used). 
The initial data management of THIN dataset was done under the guidance of 
Uchenna Anyanwagu, a senior PhD candidate during 2018. This entailed using the 
Drug and BNF codes to extract information from the dataset on all significant drug 
prescriptions and store these in separate data-files. Similarly, Additional Health 
Data (AHD) codes were used to extract important covariates, with their record 
dates. Separate data files were created for each covariate. Time-dependent 
covariates, such as weight, height, HbA1c levels, and laboratory investigations, 
were stratified yearly according to the detection dates. Individual data files were 
established to include READ codes for significant medical diagnoses and their 
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dates. Specifically, these records encompass details for coronary heart disease 
(CHD), acute myocardial infarction (MI), cerebrovascular disease (stroke), 
peripheral arterial disease (PAD), heart failure (HF), CKD and composite obesity-
related comorbidities. 
On 27th February 2018, the version numbered 14THIN031 (termed “THIN1709”) 
was obtained for this thesis. This version contains updated data for 11,125 active 
insulin-treated T2D patients, up to September 15th, 2017. The raw data-files are in 
a simplified flexible structure format, organised by practice and by patients in the 
form of flat ASCII (American Standard Code for Information Interchange). Each 
practice data is split into four standard ASCII fixed width text files and three linked 
files (Tables 10.2.1, 10.2.2 and 10.2.3). These comprise records relating to patient, 
medical, therapy and AHD information. The linked files include postcode variable 
indicators (PVI), consultation and staff files (Figure 10.2.1). Additionally, a series of 
dictionaries and look-up tables are present, allowing the interpretation of the 
coded information. The obtained data slice is in SAS format. We converted it to 
Stata format for all carried management and analyses. 
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Table 10.3.1 THIN Data SAS Files. 
   
File Name Description File Size 
ahd.sas7bdat Additional Health Information 1.5 GB 
medical.sas7bdat Medical File 389.6 MB 
patient.sas7bdat Patient File 896 KB  
staff.sas7bdat Staff File 25.2 MB  
therapy.sas7bdat Therapy Data File 1.4 GB 




Table 10.3.2 THIN Data Ancillary TXT Files. 
 
File name Description 
AHDCodeFrequencyEver1709.txt Frequency of all AHDcodes found in the AHD file ever 
AHDCodes1709.txt Additional Health Data codes, in excel and Access 
AHDLookups1709.txt AHD tables lookups, in excel 
AHDReadcodeFrequencyEver1709.txt 
Frequency count of all Read codes found in the AHD 
file ever 
ATCterms.1709.txt 
Anatomical Therapeutic Chemical Classification 
System code 
BNFcodes1709.txt Lookup of all BNF chapters 
DeathAHDcomments1709.txt List of Death AHD comments available 
Dosage1709.txt 
Complete list of all dosage codes and dosage 
instructions 
DrugcodeFrequencyEver1709.txt 
Frequency of all drug codes found in the Therapy file 
ever 
Drugcodes1709.txt Drug dictionary, in access and text 
FileList1709.txt List of files on external hard drive 
FirstAndLast1709.txt 
First and last records for each file on external hard 
drive, in excel 
MedicalReadcodeFrequencyEver1709.txt 
Frequency count of all Read codes found in the 
medical file ever 
MidYearCounts1709.txt Breakdown of population in 1 year age bands 
NHSspeciality1709.txt Clinical specialty lookup, in excel and text 
Pack1709.txt Lookup for detailed information at pack level 
Packsize1709.txt Look up for pack size information in excel and text 
PatientStats1709.txt Count of patients within each practice 
Readcodes1709.txt Medical dictionary, in access and text 
THINlookups.txt Application readable THIN and AHD Lookup values 
THINDataFormat1709.docx Format for THIN Data 
THINDataGuide1709.pdf Guide to using the database 
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Table 10.3.3 THIN Data Ancillary SAS Files. 
 
File name Description 
AHDCodeFrequencyEver1709.sas7bdat Frequency of all AHDcodes found in the AHD file  
AHDCodes1709.sas7bdat Additional Health Data codes, in excel and Access 
AHDLookups1709.sas7bdat AHD tables lookups, in excel 
AHDReadcodeFrequencyEver1709.sas7bdat 
Frequency count of all Read codes found in the AHD 
file  
ATCterms1709.sas7bdat 
Anatomical Therapeutic Chemical Classification 
System code 
BNFcodes1709.sas7bdat Lookup of all BNF chapters 
DeathAHDcomments1709.sas7bdat List of Death AHD comments available 
Dosage1709.sas7bdat 
Complete list of all dosage codes and dosage 
instructions 
DrugcodeFrequencyEver1709.sas7bdat Frequency of all drug codes found in the Therapy file  
Drugcodes1709.sas7bdat Drug dictionary, in access and text 
THIN_SAS file list 1709.xlsx List of files on external hard drive 
FirstAndLast1709.sas7bdat 
First and last records for each file on external hard 
drive, in excel 
MedicalReadcodeFrequencyEver1709.sas7bdat 
Frequency count of all Read codes found in the 
medical file  
MidYearCounts1709.sas7bdat Breakdown of population in 1 year age bands 
NHSspeciality1709.sas7bdat Clinical specialty lookup, in excel and text 
Pack1709.sas7bdat Lookup for detailed information at pack level 
Packsize1709.sas7bdat Look up for pack size information in excel and text 
PatientStats1709.sas7bdat Count of patients within each practice 
Readcodes1709.sas7bdat Medical dictionary, in access and text 
THINlookups1709.sas7bdat Application readable THIN and AHD Lookup values 
THINPrac1709.sas7bdat Practice file for data 
THINDataFormatSAS1709.docx Format for THIN Data 
THINDataGuide1709.pdf Guide to using the database 
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Appendix 10.4 Ethical approval. 
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Appendix 10.5 READ codes from THIN database. 
 
Table 10.5.1 Screened Acute Myocardial Infarction (AMI). 
Description Code 
Acute ST segment elevation myocardial infarction G30X000 
Acute anterolateral infarction G300.00 
Acute anteroseptal infarction G301100 
Acute coronary syndrome G311500 
Acute inferolateral infarction G302.00 
Acute myocardial infarction G30..00 
Acute myocardial infarction NOS G30z.00 
Acute non-ST segment elevation myocardial infarction G307100 
Attack - heart G30..11 
Coronary thrombosis G30..12 
Heart attack G30..14 
Inferior myocardial infarction NOS G308.00 
MI - acute myocardial infarction G30..15 
Other specified anterior myocardial infarction G301.00 
Posterior myocardial infarction NOS G304.00 
Silent myocardial infarction G30..17 
Subsequent myocardial infarction G35..00 
 
 
Table 10.5.2 Screened Coronary Heart Diseases (CHD). 
Description Code 
Acute coronary insufficiency G31y000 
Acute inferoposterior infarction G303.00 
Angina at rest G311200 
Angina on effort G33z300 
Angina pectoris G33..00 
Angina pectoris NOS G33zz00 
Anterior myocardial infarction NOS G301z00 
Arteriosclerotic heart disease G3...11 
Asymptomatic coronary heart disease G34z000 
Atherosclerotic cardiovascular disease G342.00 
Atherosclerotic heart disease G3...12 
Chronic myocardial ischaemia G34y100 
Coronary artery disease G340.12 
Coronary artery spasm G332.00 
Coronary atherosclerosis G340.00 
Crescendo angina G311.11 
Double coronary vessel disease G340100 
Dressler's syndrome G310.11 
IHD - Ischaemic heart disease G3...13 
Ischaemic cardiomyopathy G343.00 
Ischaemic chest pain G33z400 
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Ischaemic heart disease G3...00 
Ischaemic heart disease NOS G3z..00 
Lateral myocardial infarction NOS G305.00 
Mural thrombosis G30A.00 
New onset angina G33z600 
Old myocardial infarction G32..00 
Other acute and subacute ischaemic heart disease G31..00 
Other chronic ischaemic heart disease G34..00 
Other specified ischaemic heart disease G3y..00 
Prinzmetal's angina G331.00 
Single coronary vessel disease G340000 
Stable angina G33z700 
Triple vessel disease of the heart G340.11 
Unstable angina G311.13 
Worsening angina G311400 
 
 
Table 10.5.3 Screened Cerebrovascular Accident (Stroke). 
Description Code 
Amaurosis fugax F423600 
Brain stem stroke syndrome G663.00 
CVA - Cerebrovascular accident unspecified G66..13 
CVA - cerebral artery occlusion G64..11 
CVA - cerebrovascular accid due to intracerebral haemorrhage G61..11 
CVA unspecified G66..11 
Carotid artery occlusion G631.00 
Carotid artery stenosis G634.00 
Cerebellar haemorrhage G613.00 
Cerebellar infarction G64z.12 
Cerebral aneurysm, nonruptured G673.00 
Cerebral arterial occlusion G64..00 
Cerebral embolism G641.00 
Cerebral infarct due to thrombosis of precerebral arteries G63y000 
Cerebral infarction NOS G64z.00 
Cerebral infarction due to embolism of cerebral arteries G641000 
Cerebral infarction due to embolism of precerebral arteries G63y100 
Cerebral infarction due to thrombosis of cerebral arteries G640000 
Cerebral thrombosis G640.00 
Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs G6X..00 
Cerebrovascular disease G6...00 
Cerebrovascular disease NOS G6z..00 
Chronic cerebral ischaemia G671100 
Drop attack G65..11 
Extradural haemorrhage - nontraumatic G620.00 
Hypertensive encephalopathy G672.00 
Infarction - cerebral G64..12 
Infarction - precerebral G63..11 
Infarction of basal ganglia G64z400 
Intracerebral haemorrhage G61..00 
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Intracerebral haemorrhage NOS G61z.00 
Intracerebral haemorrhage, intraventricular G617.00 
Left sided CVA G667.00 
Left sided cerebral infarction G64z200 
Middle cerebral artery syndrome G660.00 
Other transient cerebral ischaemia G65y.00 
Pontine haemorrhage G614.00 
Posterior cerebral artery syndrome G662.00 
Pure motor lacunar syndrome G665.00 
Right sided CVA G668.00 
Right sided cerebral infarction G64z300 
Stenosis, carotid artery G631.11 
Stroke and cerebrovascular accident unspecified G66..00 
Stroke due to cerebral arterial occlusion G64..13 
Stroke due to intracerebral haemorrhage G61..12 
Stroke unspecified G66..12 
Subclavian steal syndrome G652.00 
Subdural haematoma - nontraumatic G622.00 
Subdural haemorrhage - nontraumatic G621.00 
Subdural haemorrhage NOS G623.00 
Transient cerebral ischaemia G65..00 
Transient cerebral ischaemia NOS G65z.00 
Transient global amnesia G655.00 
Transient ischaemic attack G65..12 
Vertebrobasilar insufficiency G656.00 
 
 
Table 10.5.4 Screened Heart Failure. 
Description Code 
Acute congestive heart failure G580000 
Acute heart failure G582.00 
Acute left ventricular failure G581000 
Biventricular failure G580.14 
Cardiac failure G58..11 
Cardiac failure NOS G58z.12 
Chronic congestive heart failure G580100 
Congestive cardiac failure G580.11 
Congestive heart failure G580.00 
Decompensated cardiac failure G580200 
Heart failure G58..00 
Heart failure NOS G58z.00 
Heart failure confirmed 1O1..00 
Impaired left ventricular function G581.13 
Left ventricular diastolic dysfunction G5yyA00 
Left ventricular failure G581.00 
Left ventricular systolic dysfunction G5yy900 
New York Heart Association classification - class I 662f.00 
New York Heart Association classification - class II 662g.00 
New York Heart Association classification - class III 662h.00 
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New York Heart Association classification - class IV 662i.00 
Pulmonary oedema - acute G581.12 
Right heart failure G580.12 
Right ventricular failure G580.13 
 
 
Table 10.5.5 Screened Peripheral Arterial Disease (PAD). 
Description Code 
AAA - Abdominal aortic aneurysm without mention of rupture G714.11 
Abdominal aortic aneurysm without mention of rupture G714.00 
Aortic aneurysm G71..00 
Aortic aneurysm repair 7A14.11 
Aortic atherosclerosis G700.00 
Arterial embolism and thrombosis G74..00 
Arterial leg ulcer M271300 
Axillo-unifemoral PTFE bypass graft 7A10300 
Bypass femoral artery by fem/pop art anast c vein graft NEC 7A48200 
Cardiac failure therapy 8B29.00 
Chronic peripheral venous hypertension G8y3.00 
Claudication G73z011 
Diabetic peripheral angiopathy G73y000 
Dissecting aortic aneurysm G710.00 
Embolism and thrombosis of the axillary artery G74y700 
Embolism and thrombosis of the femoral artery G742400 
Embolism and thrombosis of the iliac artery unspecified G74y300 
Embolism and thrombosis of the subclavian artery G74y500 
Extremity artery atheroma G702.00 
Femoro-femoral prosthetic cross over graft 7A48E00 
Gangrene of finger G732200 
Gangrene of foot G732100 
Gangrene of toe G732000 
Intermittent claudication G73z000 
Ischaemia of legs G73..12 
Ischaemic leg ulcer M271.12 
Ischaemic ulcer diabetic foot M271000 
Mixed venous and arterial leg ulcer M271400 
Other bypass of common femoral artery 7A48.12 
Other bypass of femoral artery 7A48.14 
Other bypass of femoral artery or popliteal artery 7A48.00 
Other bypass of femoral artery or popliteal artery NOS 7A48z00 
Other bypass of femoral artery or popliteal artery OS 7A48y00 
Other bypass of superficial femoral artery 7A48.16 
Other emergency bypass of femoral artery 7A47.16 
Other emergency bypass of popliteal artery 7A47.14 
Other peripheral vascular disease G73..00 
Other specified peripheral vascular disease NOS G73yz00 
Percutaneous transluminal balloon angioplasty of aorta 7A1A000 
Peripheral gangrene G732.00 
Peripheral ischaemia G73..13 
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Peripheral ischaemic vascular disease G73..11 
Peripheral vascular disease NOS G73z.00 
Peripheral vascular disease monitoring 662U.00 
Raynaud's disease G730000 
Raynaud's phenomenon G730100 
Raynaud's syndrome G730.00 
Ruptured abdominal aortic aneurysm G713.11 
Ruptured aortic aneurysm NOS G715.00 
Saddle embolus G740.14 
Thoracic aortic aneurysm which has ruptured G711.00 
Thoracic aortic aneurysm without mention of rupture G712.00 
Thrombosis - arterial G74..12 
 
 
Table 10.5.6 Screened bariatric READ codes. 
Description Code 
Bariatric operative procedure 14NE.00 
Roux-en-y oesophagogastrectomy 7600111 
Total gastrectomy 7610.12 
Total gastrectomy and anastomosis oesophagus to jejunum NEC 7610400 
Polya partial gastrectomy and anastomosis stomach to jejunum 7611215 
Partial gastrectomy and gastrojejunostomy 7611216 
Sleeve gastrectomy and duodenal switch 7611400 
Sleeve gastrectomy NEC 7611500 
Laparoscopic sleeve gastrectomy 7611600 
Plastic operations on stomach 7613.00 
Gastroplasty NEC 7613000 
Laparoscopic adjustable gastric banding 7613200 
Partitioning of stomach using band 7613300 
Bypass of stomach by anastomosis of stomach to duodenum 7614100 
Bypass of stomach by anastomosis of stomach to jejunum NEC 7616000 
Laparoscopic gastric bypass 7616600 
Gastrostomy operations 7617.00 
Gastrostomy operation NOS 7617z00 
Gastropexy NEC 7618000 
Pyloromyotomy 761B.11 
Ramstedt pyloromyotomy 761B011 
Pyloroplasty NEC 761B200 
Pyloromyotomy and wedge resection 761B500 
Gastroscopy and extirpation of lesion 761D.11 
Fibreoptic endoscopic laser destructn lesion upper GI tract 761D100 
Other therapeutic gastroscopy 761E.11 
Temporary percutaneous endoscopic gastrostomy 761E300 
Other operations on stomach 761H.00 
Insertion of gastric balloon 761H500 
Other operation on stomach NOS 761Hz00 
Other fibre endos extirp lesion upper gastrointestinal tract 761M.00 
Stomach and pylorus operations NOS 761z.00 
Closure of perforation of duodenum NEC 7623100 
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Roux-en-y cholecystojejunostomy 7811212 
Roux-en-y procedure for biliary atresia 7824400 
Roux-en-y pancreaticojejunostomy 7835.12 
 
 
Table 10.5.7 Screened Chronic Kidney Disease (CKD). 
Description Code 
Kidney disease 14D..11 
Chronic kidney disease stage 1 1Z10.00 
Chronic kidney disease stage 3 1Z12.00 
Chronic kidney disease stage 4 1Z13.00 
Chronic kidney disease stage 5 1Z14.00 
Chronic kidney disease stage 3B without proteinuria 1Z1G.00 
Kidney and ureter disease NOS K13z.00 
Injury to kidney S76..00 
Kidney injury without open wound into cavity, unspecified S760000 
Kidney injury without mention of open wound into cavity NOS S760z00 
 
 
Table 10.5.8 Screened liver diseases. 
Description Code 
alcoholic fatty liver J610.00 
acute alcoholic hepatitis J611.00 
alcoholic cirrhosis of liver J612.00 
alcoholic liver damage unspecified J613.00 
alcoholic hepatic failure J613000 
alcoholic hepatitis J617.00 
local ligation of oesophageal varices 7609300 
fibreoptic endoscopic banding of oesophageal varices 760C500 
glycogenosis with hepatic cirrhosis C310400 
oesophageal varices in cirrhosis of the liver G852200 
gastric varices G857.00 
cirrhosis and chronic liver disease J61..00 
chronic hepatitis J614.00 
chronic active hepatitis J614100 
chronic lobular hepatitis J614400 
chronic hepatitis nos J614z00 
cirrhosis - non alcoholic J615.00 
non-alcoholic cirrhosis nos J615z00 
macronodular cirrhosis of liver J615z11 
cryptogenic cirrhosis of liver J615z12 
cirrhosis of liver nos J615z13 
biliary cirrhosis J616.00 
primary biliary cirrhosis J616000 
other non-alcoholic chronic liver disease J61y.00 
non-alcoholic fatty liver J61y100 
hepatosplenomegaly J61y200 
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hepatic fibrosis J61y400 
hepatic sclerosis J61y500 
steatosis of liver J61y700 
nonalcoholic steatohepatitis J61y800 
fatty change of liver J61y900 
chronic liver disease nos J61z.00 
[x]other and unspecified cirrhosis of liver Jyu7100 
hepatitis c status 2J1..00 
hepatitis c immune 2J11.00 
viral hepatitis A70..00 
viral (infectious) hepatitis a A701.00 
viral (serum) hepatitis b A703.00 
viral hepatitis c without mention of hepatic coma A705000 
acute hepatitis e A705200 
hepatitis non a non b A705400 
chronic viral hepatitis c A707200 
chronic viral hepatitis, unspecified A707X00 
hepatitis c genotype 3 A70C.00 
unspecified viral hepatitis A70z.00 
hepatitis c A70z000 
right iliac fossa pain 1977.00 
malignant neoplasm of liver and intrahepatic bile ducts B15..00 
primary carcinoma of liver B150000 
hepatocellular carcinoma B150300 
malignant neoplasm of liver unspecified B152.00 
secondary malignant neoplasm of liver B153.00 
malignant neoplasm of common bile duct B161200 
malignant neoplasm of ampulla of vater B162.00 
secondary malignant neoplasm of liver B577.00 
liver metastases B577.11 
benign neoplasm of gallbladder B715200 
focal nodular hyperplasia of liver B715800 
[m]cholangiocarcinoma BB5D100 
[m]hepatoma nos BB5D511 
[m]hepatoma, malignant BB5D512 
[m]hepatobiliary adenoma or carcinoma nos BB5Dz00 
acute hepatic failure J600000 
[x] hepatic failure J625.00 
[x] liver failure J625.11 
hepatic failure nos J62y.11 
liver failure as a complication of care SP14211 
[so]liver 7N33000 
portal vein thrombosis G81..00 
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Table 10.5.9 Screened Additional Health Data (AHD). 
Description AHD Code 
Alanine Aminotransferase 1001400006 
Albumin 1001400002 
Albumin Creatinine Ratio 1001400319 
Alkaline Phosphatase 1001400004 
Ambulatory blood pressure 1001400253 
Aspartate Aminotransferase 1001400007 
Asthma status 1009581000 
Bilirubin 1001400009 
Blood Group 1012000000 
Blood glucose 1001400067 
Blood pressure 1005010500 
C Reactive protein 1001400144 
Creatinine clearance 1001400020 
Differential white cell count 1001400178 
Ethnicity 1082000000 
Fasting glucose 1001400139 
Full blood count 1001400081 
Glomerular filtration rate 1001400326 
Haematology screening tests 1001400317 
HbA1C - Diabetic control† 1001400140 
Height 1005010100 
High Density Lipoprotein 1001400031 
Lactate Dehydrogenase 1001400033 
Liver enzymes 1001400235 
Low Density Lipoprotein 1001400035 
Packed Cell Volume 1001400213 
Platelets 1001400064 
Serum cholesterol 1001400017 
Serum creatinine 1001400019 
Serum globulin 1001400248 
Smoking 1003040000 
Total protein 1001400043 
Triglycerides 1001400045 
Urea - blood 1001400051 
Urea and Electrolytes 1001400112 
Urine microalbumin 1001400311 
Very low density lipoprotein 1001400054 
Waist circumference 1006100000 
Weight 1005010200 
† HbA1c is reported in per cent and in mmol/mol. A decision was made to convert all units  
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Appendix 10.6 Survival analysis. 
 
The development of a predicted outcome of interest is observed and analysed 
within a set time period during cohort studies: to accomplish this objective, 
anonymised patients records were harvested and investigated utilising the THIN 
database (see Chapters 4, 5, and 7). These studies measure specific outcomes 
incidence, usually, expressed as a rate. For example, the incidence of new CKD 




This is presented as rates per 100, or 1,000, or 10,000 person-time. The person-
time denotes the ‘at risk’ period: the sum total of the period during which each 
participant is at risk of the predicted outcome.  
In longitudinal data, the collected information comprises the length of follow-up 
time during which participants are examined. One great advantage of the Cox 
regression over linear, logistic or Poisson regression models, lays in the ability to 
not make assumptions that incidence rates are constant over the study period, or 
constant within specific calendar-time periods or age bands. This is useful, since 
specific outcomes rates may be subject to rapid change over time. For example, 
following insulin use, CKD events rate varies with the treatment duration.  
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The Cox regression model sits within a framework of examinations for time to 
event data, known as survival analysis. It is noteworthy that an actual survival time 
period (time to event occurrence) could not be ascertained for all patients. 
Therefore, the Cox regression data model is useful for analysing varied information 
of events occurring during the studied set time period. The merit of the Cox model 
is that it allows these specific patients to be included in the analysis. Additionally, 
it is robust, flexible, powerful, and able to cope with complex survival data subject 
to multiple unpredictable factors, and it can handle many covariates and 
interactions.  
The Cox proportional hazards model is used to compute risk rates. It uses a 
conditional likelihood procedure to take account of particular observations. 
Additionally, it derives hazard ratios in which the risk rates are compared in 
different exposure groups. The Cox regression model is based on the hazard rate 
during a specific time, t, within the follow-up period, h(t). Interestingly, during the 
set follow-up time period, any change value can be observed within the hazard 
rate, which is intrinsically not a constant factor.  
The following steps are involved in fitting a Cox regression model: 
i. Survival analysis: this first step analyses the time to the outcome of interest 
occurrence, e.g. the CKD event, and the loss to follow-up or the predicting loss 
date. It is worth mentioning that a follow-up time is known for all analysed 
patients. However, it is not possible to have an actual survival time (time to even 
occurrence) for all patients. This represents a significant shortcoming.   
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ii. Kaplan-Meier plots: in building a Cox regression model, this second step allows for 
simple comparisons between different study-groups, using the log rank test, which 
provides a direct way of comparing survival curves. All survival times, exact or 
predicted, were used to compare treatment groups (i.e. bariatric) during the 
period after the cohort start until the study end point. It is based on calculations 
of survival probabilities and median survival time, throughout the study. The log 
rank test is used to compare the probabilities of survival within the entire follow-
up duration, by computing the observed survival within the different groups and 
comparing it with the expected events, if all groups had similar survival.  
iii. Fitting the Cox model first for unadjusted and for adjusted measures of effect.  
Hazard ratio represents the scale of events risks in individuals exposed (i.e. 
bariatric) vs those not subjected (non-bariatric) to treatment. When comparing 
groups of individuals exposed and non-exposed to treatment, an increased hazard 
rate is suggested when the ratio value is greater than 1. This implies that survival 
is decreased. Conversely, values below 1 indicate a lower hazard rate and 
increased chance of survival (i.e. protective effect from treatment or exposure). 
Likelihood ratio tests (LRT) and Wald’s tests can be calculated for the Cox 
proportional hazards model, to determine statistical significance. Additionally, 
both categorical and continuous covariates can be included in the Cox model 
during adjustment, to obtain a tailored hazard ratio with a 95% confidence interval.  
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Appendix 10.7 Screened drug categories and pharmacological genericnames. 
 
Table 10.7.1 Insulin. 
 
genericname 
Insulin Human insulin 100iu/ml preloaded injection pen 
Human insulin 1mg unit dose blisters 
Human insulin 3mg unit dose blisters 
Human isophane insulin 100iu/ml injection cartridges 
Human isophane insulin 100iu/ml preloaded injection pen 
Insulin aspart 100units/ml solution for injection 1.6ml cartridges 
Insulin aspart 100units/ml solution for injection 10ml vials 
Insulin aspart 100units/ml solution for injection 3ml cartridges 
Insulin aspart 100units/ml solution for injection 3ml pre-filled disposable devices 
Insulin aspart biphasic 30/70 100units/ml suspension for injection 3ml cartridges 
Insulin aspart biphasic 30/70 100units/ml suspension for injection 3ml pre-filled disposable devices 
Insulin aspart human pyr 100 iu/ml injection 1 10ml vial(s) 
Insulin biphasic 100 units/ml injection 
Insulin biphasic aspart human pyr 30:70; 100 units/ml injection 5 3ml disposable pen(s) 
Insulin biphasic isophane human emp 30:70; 100 units/ml injection 
Insulin biphasic isophane human prb 10:90; 100 units/ml injection 
Insulin biphasic isophane human prb 20:80; 100 units/ml injection 
Insulin biphasic isophane human prb 30:70; 100 units/ml injection 
Insulin biphasic isophane human prb 40:60; 100 units/ml injection 
Insulin biphasic isophane human prb 50:50; 100 units/ml injection 
Insulin biphasic isophane human pyr 10:90; 100 units/ml injection 
Insulin biphasic isophane human pyr 20:80; 100 units/ml injection 
Insulin biphasic isophane human pyr 30:70; 100 units/ml injection 
Insulin biphasic isophane human pyr 30:70; 100 units/ml injection 5 3ml cartridge(s) 
Insulin biphasic isophane human pyr 40:60; 100 units/ml injection 
Insulin biphasic lispro human prb 25:75; 100 units/ml injection 5 3ml disposable pen(s) 
Insulin biphasic lispro human prb 50:50; 100 units/ml injection 5 3ml disposable pen(s) 
Insulin degludec 100units/ml solution for injection 3ml cartridges 
Insulin degludec 100units/ml solution for injection 3ml pre-filled disposable devices 
Insulin degludec 200units/ml solution for injection 3ml pre-filled disposable devices 
Insulin detemir 100units/ml solution for injection 3ml cartridges 
Insulin detemir 100units/ml solution for injection 3ml pre-filled disposable devices 
Insulin glargine 100units/ml solution for injection 10ml vials 
Insulin glargine 100units/ml solution for injection 3ml cartridges 
Insulin glargine 100units/ml solution for injection 3ml pre-filled disposable devices 
Insulin glargine 300units/ml solution for injection 1.5ml pre-filled disposable devices 
Insulin glulisine 100units/ml solution for injection 10ml vials 
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Insulin glulisine 100units/ml solution for injection 3ml cartridges 
Insulin glulisine 100units/ml solution for injection 3ml pre-filled disposable devices 
Insulin human 1mg inhalation powder blisters 
Insulin human 3mg inhalation powder blisters 
Insulin isophane biphasic Porcine 30/70 Mix 100units/ml suspension for injection 1.5ml cartridges 
Insulin isophane biphasic Porcine Isophane 100units/ml suspension for injection 1.5ml cartridges 
Insulin isophane biphasic human 10/90 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 10/90 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic human 15/85 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 15/85 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic human 20/80 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 20/80 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic human 25/75 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 25/75 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic human 25/75 100units/ml suspension for injection 5ml vials 
Insulin isophane biphasic human 30/70 100units/ml suspension for injection 10ml vials 
Insulin isophane biphasic human 30/70 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 30/70 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic human 40/60 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 40/60 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic human 50/50 100units/ml suspension for injection 1.5ml cartridges 
Insulin isophane biphasic human 50/50 100units/ml suspension for injection 10ml vials 
Insulin isophane biphasic human 50/50 100units/ml suspension for injection 3ml cartridges 
Insulin isophane biphasic human 50/50 100units/ml suspension for injection 3ml pre-filled disposable 
devices 
Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 1.5ml cartridges 
Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 10ml vials 
Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 3ml cartridges 
Insulin isophane bovine 100units/ml suspension for injection 10ml vials 
Insulin isophane bovine 100units/ml suspension for injection 3ml cartridges 
Insulin isophane human 100units/ml suspension for injection 1.5ml cartridges 
Insulin isophane human 100units/ml suspension for injection 10ml vials 
Insulin isophane human 100units/ml suspension for injection 3ml cartridges 
Insulin isophane human 100units/ml suspension for injection 3ml pre-filled disposable devices 
Insulin isophane human 100units/ml suspension for injection 5ml vials 
Insulin isophane human crb 100iu/ml injection 
Insulin isophane human emp 100unit/ml injection 
Insulin isophane human prb 100iu/ml injection 
Insulin isophane human vial 100unit/ml sterile suspension injection 
Insulin isophane porcine 100units/ml suspension for injection 1.5ml cartridges 
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Insulin isophane porcine 100units/ml suspension for injection 10ml vials 
Insulin isophane porcine 100units/ml suspension for injection 3ml cartridges 
Insulin isophane porcine 100units/ml suspension for injection 3ml cartridges 5 3ml cartridge(s) 
Insulin lispro 100units/ml solution for injection 1.5ml cartridges 
Insulin lispro 100units/ml solution for injection 1.5ml pre-filled disposable devices 
Insulin lispro 100units/ml solution for injection 10ml vials 
Insulin lispro 100units/ml solution for injection 3ml cartridges 
Insulin lispro 100units/ml solution for injection 3ml pre-filled disposable devices 
Insulin lispro 200units/ml solution for injection 3ml pre-filled disposable devices 
Insulin lispro biphasic 25/75 100units/ml suspension for injection 3ml cartridges 
Insulin lispro biphasic 25/75 100units/ml suspension for injection 3ml pre-filled disposable devices 
Insulin lispro biphasic 50/50 100units/ml suspension for injection 3ml cartridges 
Insulin lispro biphasic 50/50 100units/ml suspension for injection 3ml pre-filled disposable devices 
Insulin protamine zinc bovine 100units/ml suspension for injection 10ml vials 
Insulin soluble bovine 100units/ml solution for injection 10ml vials 
Insulin soluble bovine 100units/ml solution for injection 3ml cartridges 
Insulin soluble human 100units/ml solution for injection 10ml vials 
Insulin soluble human 100units/ml solution for injection 3ml cartridges 
Insulin soluble human 100units/ml solution for injection 3ml cartridges 5 cartridge 
Insulin soluble human prb 100unit/ml injection 
Insulin soluble human pyr 100unit/ml injection 5 3ml cartridge(s) 
Insulin soluble porcine 100units/ml solution for injection 1.5ml cartridges 
Insulin soluble porcine 100units/ml solution for injection 1.5ml cartridges 5 3ml vial(s) 
Insulin soluble porcine 100units/ml solution for injection 10ml vials 
Insulin soluble porcine 100units/ml solution for injection 3ml cartridges 
Insulin zinc crystalline human 100units/ml suspension for injection 10ml vials 
Insulin zinc lente 100iu/ml injection 
Insulin zinc mixed bovine 100units/ml suspension for injection 10ml vials 
Insulin zinc suspension amorphous porcine 100unit/ml injection 
Insulin zinc suspension mixed human pyr 100unit/ml injection 
Insuman comb 25 100iu/ml Injection 
Isophane insulin 100iu/ml injection 
Neutral insulin 100iu/ml injection 
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Acarbose 100mg tablets 
Acarbose 50mg tablets 
Alogliptin 12.5mg / Metformin 1g tablets 
Alogliptin 12.5mg tablets 
Alogliptin 25mg tablets 
Alogliptin 6.25mg tablets 
Canagliflozin 100mg tablets 
Canagliflozin 300mg tablets 
Chlorpropamide 100mg tablets 
Chlorpropamide 250mg tablets 
Dapagliflozin 10mg tablets 
Dapagliflozin 5mg / Metformin 1g tablets 
Dapagliflozin 5mg tablets 
Empagliflozin 10mg tablets 
Empagliflozin 12.5mg / Metformin 1g tablets 
Empagliflozin 25mg tablets 
Glibenclamide 2.5mg tablets 
Glibenclamide 5mg tablets 
Glibenclamide 5mg/5ml oral suspension 
Gliclazide 30mg modified-release tablets 
Gliclazide 40mg tablets 
Gliclazide 40mg/5ml oral suspension 
Gliclazide 60mg modified-release tablets 
Gliclazide 80mg tablets 
Glimepiride 1mg tablets 
Glimepiride 2mg tablets 
Glimepiride 3mg tablets 
Glimepiride 4mg tablets 
Glipizide 2.5mg tablets 
Glipizide 5mg tablets 
Gliquidone 30mg tablets 
Guar gum 5g granules sachets sugar free 
Guar gum 5g/sachet granules 
Guar gum 90% granules 
Linagliptin 2.5mg / Metformin 1g tablets 
Linagliptin 2.5mg / Metformin 850mg tablets 
Metformin & rosiglitazone 1g+2mg tablets 
Metformin & rosiglitazone 1g+4mg tablets 
Metformin & rosiglitazone 500mg+1mg tablets 
Metformin & rosiglitazone 500mg+2mg tablets 
Metformin 1g / Sitagliptin 50mg tablets 
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Metformin 1g modified-release tablets 
Metformin 1g oral powder sachets sugar free 
Metformin 500mg modified-release tablets 
Metformin 500mg oral powder sachets sugar free 
Metformin 500mg tablets 
Metformin 500mg/5ml oral solution 
Metformin 500mg/5ml oral solution sugar free 
Metformin 750mg modified-release tablets 
Metformin 850mg tablets 
Metformin hydrochloride 500mg sachets 
Metformin with rosiglitazone 1000mg + 2mg tablet 
Metformin with rosiglitazone 1000mg + 4mg tablet 
Metformin with rosiglitazone 500mg + 1mg tablet 
Metformin with rosiglitazone 500mg + 2mg tablet 
Nateglinide 120mg tablets 
Nateglinide 180mg tablets 
Nateglinide 60mg tablets 
Pioglitazone 15mg / Metformin 850mg tablets 
Pioglitazone 15mg tablets 
Pioglitazone 30mg tablets 
Pioglitazone 45mg tablets 
Repaglinide 1mg tablets 
Repaglinide 2mg tablets 
Repaglinide 500microgram tablets 
Rosiglitazone 1mg / metformin 500mg tablets 
Rosiglitazone 2mg / metformin 1g tablets 
Rosiglitazone 2mg / metformin 500mg tablets 
Rosiglitazone 4mg / metformin 1g tablets 
Rosiglitazone 4mg tablets 
Rosiglitazone 8mg tablets 
Saxagliptin 2.5mg / Metformin 1g tablets 
Saxagliptin 2.5mg / Metformin 850mg tablets 
Saxagliptin 2.5mg tablets 
Saxagliptin 5mg tablets 
Sitagliptin 100mg tablets 
Sitagliptin 25mg tablets 
Sitagliptin 50mg tablets 
Tolazamide 100mg tablet 
Tolazamide 250mg tablets 
Tolbutamide 500mg tablets 
Vildagliptin 50mg / Metformin 1g tablets 
Vildagliptin 50mg / Metformin 850mg tablets 
Vildagliptin 50mg tablets 
  Appendix 10.7 
 220 





Dulaglutide 0.75mg/0.5ml solution for injection pre-filled disposable devices 
Dulaglutide 1.5mg/0.5ml solution for injection pre-filled disposable devices 
Exenatide 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable 
devices 
Exenatide 2mg powder and solvent for prolonged-release suspension for injection 
pre-filled disposable devices 
Exenatide 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable 
devices 
Insulin degludec 100units/ml / Liraglutide 3.6mg/ml solution for injection 3ml 
pre-filled disposable devices 
Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices 
Lixisenatide 10micrograms/0.2ml solution for injection 3ml pre-filled disposable 
devices 
Lixisenatide 10micrograms/0.2ml solution for injection 3ml pre-filled disposable 
devices and Lixisenatide 20micrograms/0 
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Acebutolol 100mg capsules 
Acebutolol 200mg capsules 
Acebutolol 400mg tablets 
Aliskiren 150mg tablets 
Aliskiren 300mg tablets 
Amiodarone 100mg tablets 
Amiodarone 200mg tablets 
Amlodipine 10mg / Valsartan 160mg tablets 
Amlodipine 10mg tablets 
Amlodipine 5mg / Valsartan 160mg tablets 
Amlodipine 5mg / Valsartan 80mg tablets 
Amlodipine 5mg tablets 
Amlodipine 5mg/5ml oral suspension 
Atenolol & co-amilozide 50mg+2.5mg+25mg capsules 
Atenolol 100mg tablets 
Atenolol 25mg tablets 
Atenolol 25mg/5ml oral solution sugar free 
Atenolol 50mg / Nifedipine 20mg modified-release capsules 
Atenolol 50mg tablets 
Atenolol 5mg/10ml solution for injection ampoules 
Atenolol with amiloride and hydrochlorothiazide capsules 
Azilsartan medoxomil 40mg tablets 
Bendroflumethiazide 5mg with propanolol 160mg modified-release 
capsules 
Betaxolol 20mg tablets 
Bisoprolol 1.25mg tablets 
Bisoprolol 10mg tablets 
Bisoprolol 2.5mg tablets 
Bisoprolol 3.75mg tablets 
Bisoprolol 5mg tablets 
Bisoprolol 7.5mg tablets 
Candesartan 16mg tablets 
Candesartan 2mg tablets 
Candesartan 32mg tablets 
Candesartan 4mg tablets 
Candesartan 8mg tablets 
Captopril 12.5mg tablets 
Captopril 25mg tablets 
Captopril 50mg tablets 
Carvedilol 12.5mg tablets 
Carvedilol 25mg tablets 
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Carvedilol 3.125mg tablets 
Carvedilol 6.25mg tablets 
Celiprolol 200mg tablets 
Celiprolol 400mg tablets 
Celiprolol hydrochloride 200mg tablets 
Cilazapril 1mg tablets 
Cilazapril 2.5mg tablets 
Cilazapril 500microgram tablets 
Cilazapril 5mg tablets 
Cilostazol 100mg tablets 
Cilostazol 50mg tablets 
Cinnarizine 75mg capsules 
Clonidine 100microgram tablets 
Clonidine 250microgram modified-release capsules 
Clonidine 300microgram tablets 
Co-prenozide 160mg+0.25mg modified release tablets 
Co-tenidone 100mg/25mg tablets 
Co-tenidone 50mg/12.5mg tablets 
Co-zidocapt 25mg/50mg tablets 
Diltiazem 120mg modified-release capsules 
Diltiazem 120mg modified-release tablets 
Diltiazem 180mg modified-release capsules 
Diltiazem 200mg modified-release capsules 
Diltiazem 240mg modified-release capsules 
Diltiazem 300mg modified-release capsules 
Diltiazem 360mg modified-release capsules 
Diltiazem 60mg modified-release capsules 
Diltiazem 60mg modified-release tablets 
Diltiazem 90mg modified-release capsules 
Diltiazem 90mg modified-release tablets 
Diltiazem hydrochloride 120mg modified release capsules 
Diltiazem hydrochloride 180mg modified release capsules 
Diltiazem hydrochloride 300mg modified release capsules 
Diltiazem hydrochloride 60mg modified release tablets 
Diltiazem hydrochloride 90mg modified release capsules 
Disopyramide 100mg capsules 
Doxazosin 1mg tablets 
Doxazosin 2mg tablets 
Doxazosin 4mg modified-release tablets 
Doxazosin 4mg tablets 
Doxazosin 4mg/5ml oral suspension 
Doxazosin 8mg modified-release tablets 
Dronedarone 400mg tablets 
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Enalapril 10mg tablets 
Enalapril 2.5mg tablets 
Enalapril 20mg / Hydrochlorothiazide 12.5mg tablets 
Enalapril 20mg tablets 
Enalapril 5mg tablets 
Enalapril 5mg/5ml oral suspension 
Enalapril maleate starter pack 
Enalapril titration pack 
Eprosartan 300mg tablets 
Eprosartan 400mg tablets 
Eprosartan 600mg tablets 
Felodipine 10mg modified-release tablets 
Felodipine 2.5mg modified-release tablets 
Felodipine 5mg modified-release tablets 
Flecainide 100mg tablets 
Flecainide 200mg modified-release capsules 
Flecainide 50mg tablets 
Fosinopril 10mg tablets 
Fosinopril 20mg tablets 
Generic Tritace titration pack tablets 
Generic tritace titration pack capsules 
Glyceryl trinitrate 10mg/24hours transdermal patches 
Glyceryl trinitrate 15mg/24hours transdermal patches 
Glyceryl trinitrate 1mg modified release buccal tablets 
Glyceryl trinitrate 1mg modified-release buccal tablets sugar free 
Glyceryl trinitrate 2% ointment 
Glyceryl trinitrate 2.5mg/24hours transdermal patches 
Glyceryl trinitrate 2.6mg modified release tablets 
Glyceryl trinitrate 2mg modified release buccal tablets 
Glyceryl trinitrate 2mg modified-release buccal tablets sugar free 
Glyceryl trinitrate 300microgram sublingual tablets 
Glyceryl trinitrate 3mg modified release buccal tablets 
Glyceryl trinitrate 3mg modified-release buccal tablets sugar free 
Glyceryl trinitrate 400mcg spray 
Glyceryl trinitrate 400micrograms/dose aerosol sublingual spray 
Glyceryl trinitrate 400micrograms/dose pump sublingual spray 
Glyceryl trinitrate 500microgram injection 
Glyceryl trinitrate 500microgram sublingual tablets 
Glyceryl trinitrate 5mg modified release buccal tablets 
Glyceryl trinitrate 5mg modified-release buccal tablets sugar free 
Glyceryl trinitrate 5mg/24hours transdermal patches 
Glyceryl trinitrate 600microgram sublingual tablets 
Glyceryl trinitrate pump 400mcg CFC-free spray 
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Hydralazine 25mg tablets 
Hydralazine 50mg tablets 
Hydralazine hydrochloride 50mg tablets 
Imidapril 10mg tablets 
Imidapril 20mg tablets 
Imidapril 5mg tablets 
Indoramin 25mg tablets 
Inositol nicotinate 500mg tablets 
Inositol nicotinate 750mg tablets 
Irbesartan 150mg / Hydrochlorothiazide 12.5mg tablets 
Irbesartan 150mg tablets 
Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets 
Irbesartan 300mg / Hydrochlorothiazide 25mg tablets 
Irbesartan 300mg tablets 
Irbesartan 75mg tablets 
Isosorbide dinitrate 1.25mg spray 
Isosorbide dinitrate 10mg tablets 
Isosorbide dinitrate 20mg modified release capsules 
Isosorbide dinitrate 20mg modified-release capsules 
Isosorbide dinitrate 20mg modified-release tablets 
Isosorbide dinitrate 20mg tablets 
Isosorbide dinitrate 30mg tablets 
Isosorbide dinitrate 40mg modified release capsules 
Isosorbide dinitrate 40mg modified-release capsules 
Isosorbide dinitrate 40mg modified-release tablets 
Isosorbide dinitrate 5mg chewable tablets 
Isosorbide dinitrate 5mg sublingual tablet 
Isosorbide dinitrate 5mg tablets 
Isosorbide mononitrate & aspirin 60mg+75mg modified release tablets 
Isosorbide mononitrate 10mg tablets 
Isosorbide mononitrate 10mg+20mg starter pack 
Isosorbide mononitrate 20mg tablets 
Isosorbide mononitrate 25mg modified-release capsules 
Isosorbide mononitrate 25mg modified-release tablets 
Isosorbide mononitrate 40mg modified release capsules 
Isosorbide mononitrate 40mg modified-release capsules 
Isosorbide mononitrate 40mg modified-release tablets 
Isosorbide mononitrate 40mg tablets 
Isosorbide mononitrate 50mg modified-release capsules 
Isosorbide mononitrate 50mg modified-release tablets 
Isosorbide mononitrate 60mg modified-release capsules 
Isosorbide mononitrate 60mg modified-release tablets 
Isradipine 2.5mg tablets 
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Ivabradine 5mg tablets 
Ivabradine 7.5mg tablets 
Labetalol 100mg tablets 
Labetalol 100mg/20ml solution for injection ampoules 
Labetalol 200mg tablets 
Labetalol 400mg tablets 
Labetalol 50mg tablets 
Lacidipine 2mg tablets 
Lacidipine 4mg tablets 
Lercanidipine 10mg tablets 
Lercanidipine 20mg tablets 
Lidocaine 200mg/10ml (2%) solution for injection ampoules 
Lisinopril 10mg / Hydrochlorothiazide 12.5mg tablets 
Lisinopril 10mg tablets 
Lisinopril 2.5mg tablets 
Lisinopril 20mg / Hydrochlorothiazide 12.5mg tablets 
Lisinopril 20mg tablets 
Lisinopril 5mg tablets 
Lisinopril 5mg/5ml oral solution 
Losartan 100mg / Hydrochlorothiazide 12.5mg tablets 
Losartan 100mg / Hydrochlorothiazide 25mg tablets 
Losartan 100mg tablets 
Losartan 12.5mg tablets 
Losartan 25mg tablets 
Losartan 50mg / Hydrochlorothiazide 12.5mg tablets 
Losartan 50mg tablets 
Methyldopa 125mg tablets 
Methyldopa 250mg tablets 
Methyldopa 500mg tablets 
Metoprolol 100mg / hydrochlorothiazide 12.5mg tablets 
Metoprolol 100mg tablets 
Metoprolol 200mg modified-release / hydrochlorothiazide 25mg tablets 
Metoprolol 200mg modified-release tablets 
Metoprolol 50mg tablets 
Metoprolol 50mg/5ml oral suspension 
Metoprolol 5mg/5ml solution for injection ampoules 
Metoprolol tartrate & chlortalidone 100mg+12.5mg tablets 
Metoprolol tartrate & hydrochlorothiazide 100mg+12.5mg tablets 
Metoprolol tartrate & hydrochlorothiazide 200mg+25mg modified 
release tablets 
Metoprolol tartrate 200mg modified release tablets 
Mexiletine 200mg capsules 
Mexiletine 50mg capsules 
Mibefradil 100mg tablets 
  Appendix 10.7 
 226 
Mibefradil 50mg tablet 
Mibefradil 50mg tablets 
Midodrine 2.5mg tablets 
Midodrine 5mg tablets 
Minoxidil 10mg tablets 
Minoxidil 2.5mg tablets 
Minoxidil 5mg tablets 
Moxisylyte 40mg tablets 
Moxonidine 200microgram tablets 
Moxonidine 300microgram tablets 
Moxonidine 400microgram tablets 
Nadolol 80mg tablets 
Naftidrofuryl 100mg capsules 
Nebivolol 2.5mg tablets 
Nebivolol 5mg tablets 
Nicardipine 20mg capsules 
Nicardipine 30mg capsules 
Nicardipine 30mg modified-release capsules 
Nicardipine 45mg modified-release capsules 
Nicofuranose 250mg gastro-resistant tablets 
Nicorandil 10mg tablets 
Nicorandil 20mg tablets 
Nicotinyl alcohol 25mg tablet 
Nicotinyl alcohol 25mg tablets 
Nifedipine 10mg capsules 
Nifedipine 10mg modified release tablets 
Nifedipine 10mg modified-release capsules 
Nifedipine 10mg modified-release tablets 
Nifedipine 10mg/5ml oral suspension 
Nifedipine 20mg modified release tablets 
Nifedipine 20mg modified-release capsules 
Nifedipine 20mg modified-release tablets 
Nifedipine 30mg modified release tablets 
Nifedipine 30mg modified-release capsules 
Nifedipine 30mg modified-release tablets 
Nifedipine 40mg modified-release tablets 
Nifedipine 5mg capsules 
Nifedipine 60mg modified-release capsules 
Nifedipine 60mg modified-release tablets 
Nimodipine 30mg tablets 
Nisoldipine 10mg modified-release tablets 
Nisoldipine 20mg modified-release tablets 
Nisoldipine 30mg modified-release tablets 
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Olmesartan medoxomil 10mg tablets 
Olmesartan medoxomil 20mg / Hydrochlorothiazide 12.5mg tablets 
Olmesartan medoxomil 20mg / Hydrochlorothiazide 25mg tablets 
Olmesartan medoxomil 20mg tablets 
Olmesartan medoxomil 40mg / Hydrochlorothiazide 12.5mg tablets 
Olmesartan medoxomil 40mg tablets 
Oxerutins 250mg capsules 
Oxprenolol 160mg modified-release tablets 
Oxprenolol 20mg tablets 
Oxprenolol 40mg tablets 
Oxprenolol 80mg tablets 
Oxprenolol hydrochloride 80mg tablets 
Pentoxifylline 400mg modified-release tablets 
Perhexiline maleate 100mg tablet 
Perindopril arginine 10mg tablets 
Perindopril arginine 2.5mg tablets 
Perindopril arginine 5mg / Indapamide 1.25mg tablets 
Perindopril arginine 5mg tablets 
Perindopril erbumine & indapamide 4mg+1.25mg tablets 
Perindopril erbumine 2mg tablets 
Perindopril erbumine 4mg / indapamide 1.25mg tablets 
Perindopril erbumine 4mg tablets 
Perindopril erbumine 4mg/5ml oral suspension 
Perindopril erbumine 8mg tablets 
Phenoxybenzamine 10mg capsules 
Pindolol 10mg / Clopamide 5mg tablets 
Pindolol 15mg tablets 
Pindolol 5mg tablets 
Prazosin 1mg tablets 
Prazosin 1mg tablets and prazosin 500microgram tablets 
Prazosin 2mg tablets 
Prazosin 500microgram tablets 
Prazosin 5mg tablets 
Prazosin hydrochloride 500mcg+1mg starter pack 
Propafenone 150mg tablets 
Propafenone 300mg tablets 
Propranolol & bendroflumethiazide 160mg+5mg modified release 
capsules 
Propranolol & bendroflumethiazide 80mg+2.5mg capsules 
Propranolol 10mg tablets 
Propranolol 160mg modified-release / bendroflumethiazide 5mg 
capsules 
Propranolol 160mg modified-release capsules 
Propranolol 160mg tablets 
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Propranolol 40mg tablets 
Propranolol 40mg/5ml oral solution sugar free 
Propranolol 5mg/5ml oral solution sugar free 
Propranolol 80mg modified-release capsules 
Propranolol 80mg tablets 
Propranolol hydrochloride 10mg tablets 
Propranolol hydrochloride 160mg tablets 
Propranolol hydrochloride 40mg tablets 
Propranolol hydrochloride 80mg tablets 
Quinapril 10mg / Hydrochlorothiazide 12.5mg tablets 
Quinapril 10mg tablets 
Quinapril 20mg tablets 
Quinapril 40mg tablets 
Quinapril 5mg tablets 
Quinidine bisulfate 250mg modified-release tablets 
Quinidine sulfate 200mg tablets 
Quinidine sulfate 300mg tablets 
Ramipril 1.25mg capsules 
Ramipril 1.25mg tablets 
Ramipril 10mg capsules 
Ramipril 10mg tablets 
Ramipril 10mg/5ml oral suspension 
Ramipril 2.5mg capsules 
Ramipril 2.5mg tablets 
Ramipril 2.5mg/5ml oral suspension 
Ramipril 5mg capsules 
Ramipril 5mg tablets 
Ranolazine 375mg modified-release tablets 
Ranolazine 500mg modified-release tablets 
Ranolazine 750mg modified-release tablets 
Sacubitril 24mg / Valsartan 26mg tablets 
Sacubitril 49mg / Valsartan 51mg tablets 
Sacubitril 97mg / Valsartan 103mg tablets 
Sotalol 160mg tablets 
Sotalol 160mg with hydrochlorothiazide 25mg tablet 
Sotalol 200mg tablets 
Sotalol 40mg tablets 
Sotalol 80mg tablets 
Sotalol hydrochloride & hydrochlorothiazide 80mg+12.5mg tablets 
Telmisartan 20mg tablets 
Telmisartan 40mg / Hydrochlorothiazide 12.5mg tablets 
Telmisartan 40mg tablets 
Telmisartan 80mg / Hydrochlorothiazide 12.5mg tablets 
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Telmisartan 80mg / Hydrochlorothiazide 25mg tablets 
Telmisartan 80mg tablets 
Terazosin 10mg tablets 
Terazosin 2mg tablets 
Terazosin 2mg tablets and Terazosin 1mg tablets 
Terazosin 5mg tablets 
Timolol 10mg / Amiloride 2.5mg / Hydrochlorothiazide 25mg tablets 
Timolol 10mg / Bendroflumethiazide 2.5mg tablets 
Timolol 10mg tablets 
Timolol maleate & bendroflumethiazide 20mg+5mg tablets 
Timolol maleate & co-amilozide 10mg+2.5mg+25mg tablets 
Timolol maleate 10mg tablets 
Trandolapril & verapamil hydrochloride 2mg+180mg modified release 
capsules 
Trandolapril 1mg capsules 
Trandolapril 2mg capsules 
Trandolapril 4mg capsules 
Trandolapril 500microgram capsules 
Trandolapril with verapamil 2mg + 180mg modified-release capsule 
Valsartan 160mg / Hydrochlorothiazide 12.5mg tablets 
Valsartan 160mg / Hydrochlorothiazide 25mg tablets 
Valsartan 160mg capsules 
Valsartan 160mg tablets 
Valsartan 320mg tablets 
Valsartan 40mg capsules 
Valsartan 40mg tablets 
Valsartan 80mg / Hydrochlorothiazide 12.5mg tablets 
Valsartan 80mg capsules 
Valsartan 80mg tablets 
Verapamil 120mg modified-release capsules 
Verapamil 120mg modified-release tablets 
Verapamil 120mg tablets 
Verapamil 160mg tablets 
Verapamil 180mg modified-release / trandolapril 2mg capsules 
Verapamil 180mg modified-release capsules 
Verapamil 240mg modified-release capsules 
Verapamil 240mg modified-release tablets 
Verapamil 40mg tablets 
Verapamil 80mg tablets 
Verapamil hydrochloride 120mg modified release capsules 
Verapamil hydrochloride 120mg tablets 
Verapamil hydrochloride 180mg modified release capsules 
Verapamil hydrochloride 240mg modified release capsules 
Xamoterol fumarate 200mg tablets 
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Table 10.7.5 Lipids lowering drugs. 
 Genericname 
Lipids lowering drugs Acipimox 250mg capsules 
Atorvastatin 10mg chewable tablets sugar free 
Atorvastatin 10mg tablets 
Atorvastatin 20mg chewable tablets sugar free 
Atorvastatin 20mg tablets 
Atorvastatin 40mg tablets 
Atorvastatin 60mg tablets 
Atorvastatin 80mg tablets 
Bezafibrate 200mg tablets 
Bezafibrate 400mg modified-release tablets 
Cerivastatin 100microgram tablets 
Cerivastatin 200microgram tablets 
Cerivastatin 300microgram tablets 
Cerivastatin 400microgram tablets 
Cerivastatin sodium 100mcg tablets 
Cerivastatin sodium 200mcg tablets 
Cerivastatin sodium 300mcg tablets 
Cerivastatin sodium 400mcg tablets 
Ciprofibrate 100mg tablets 
Clofibrate 500mg capsules 
Colesevelam 625mg tablets 
Colestipol 5g granules sachets sugar free 
Colestyramine 4g oral powder sachets 
Colestyramine 4g oral powder sachets sugar free 
Eicosapentaenoic acid 170mg / Docosahexaenoic acid 115mg capsules 
Eicosapentaenoic acid 170mg/g / docosahexaenoic acid 115mg/g oral 
liquid 
Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg capsules 
Ezetimibe 10mg tablets 
Fenofibrate 100mg capsule 
Fenofibrate 100mg capsules 
Fenofibrate micronised 160mg tablets 
Fenofibrate micronised 200mg capsules 
Fenofibrate micronised 267mg capsules 
Fenofibrate micronised 67mg capsules 
Fish oil concentrate 1g capsules 
Fish oil concentrate oral liquid 
Fluvastatin 20mg capsules 
Fluvastatin 40mg capsules 
Fluvastatin 80mg modified-release tablets 
Gemfibrozil 300mg capsules 
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Gemfibrozil 600mg tablets 
Ispaghula husk 3.5g sugar free granules 
Nicotinic acid & laropiprant 1g+20mg tablets 
Nicotinic acid 1g / laropiprant 20mg modified-release tablets 
Nicotinic acid 1g modified release tablets 
Nicotinic acid 1g modified-release tablets 
Nicotinic acid 25mg tablet 
Nicotinic acid 375mg + 500mg + 750mg modified-release tablet 
Nicotinic acid 500mg modified-release tablets 
Nicotinic acid 50mg tablets 
Nicotinic acid 750mg modified release tablets 
Nicotinic acid 750mg modified-release tablets 
Nicotinic acid pack 
Pravastatin 10mg tablets 
Pravastatin 20mg tablets 
Pravastatin 40mg tablets 
Rosuvastatin 10mg tablets 
Rosuvastatin 20mg tablets 
Rosuvastatin 40mg tablets 
Rosuvastatin 5mg tablets 
Simvastatin 10mg tablets 
Simvastatin 20mg / Ezetimibe 10mg tablets 
Simvastatin 20mg tablets 
Simvastatin 20mg/5ml oral suspension sugar free 
Simvastatin 40mg / Ezetimibe 10mg tablets 
Simvastatin 40mg tablets 
Simvastatin 40mg/5ml oral suspension sugar free 
Simvastatin 80mg / Ezetimibe 10mg tablets 
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Table 10.7.6 Diuretics. 
 Genericname 
Diuretics Amiloride 2.5mg / Cyclopenthiazide 250microgram tablets 
Amiloride 5mg / Bumetanide 1mg tablets 
Amiloride 5mg / hydrochlorothiazide 50mg/5ml solution 
Amiloride 5mg tablets 
Amiloride hydrochloride 5mg tablets 
Bendroflumethiazide & potassium 2.5mg+7.7mmol modified release tablets 
Bendroflumethiazide & potassium 2.5mg+8.4mmol modified release tablets 
Bendroflumethiazide 2.5mg / potassium chloride 630mg (potassium 8.4mmol) modified-
release tablets 
Bendroflumethiazide 2.5mg tablets 
Bendroflumethiazide 2.5mg/5ml oral suspension 
Bendroflumethiazide 5mg tablets 
Bumetanide & potassium 500mcg+7.7mmol modified release tablets 
Bumetanide 1mg tablets 
Bumetanide 1mg/5ml oral solution sugar free 
Bumetanide 500microgram / potassium chloride 573mg (potassium 7.7mmol) modified-release 
tablets 
Bumetanide 5mg tablets 
Chlorothiazide 500mg tablets 
Chlortalidone 100mg tablets 
Chlortalidone 50mg tablets 
Co-amilofruse 10mg/80mg tablets 
Co-amilofruse 2.5mg/20mg tablets 
Co-amilofruse 5mg/40mg tablets 
Co-amilozide 2.5mg/25mg tablets 
Co-amilozide 5mg+50mg tablets 
Co-amilozide 5mg+50mg/5ml oral solution 
Co-amilozide 5mg/50mg tablets 
Co-flumactone 25mg/25mg tablets 
Co-flumactone 50mg/50mg tablets 
Co-triamterzide 50mg/25mg tablets 
Cyclopenthiazide -k tablets 
Cyclopenthiazide 500mcg tablets 
Cyclopenthiazide 500microgram tablets 
Eplerenone 25mg tablets 
Eplerenone 50mg tablets 
Furosemide & modified release potassium 40mg+10mmol tablets 
Furosemide & potassium 20mg+10mmol modified release tablets 
Furosemide 20mg tablets 
Furosemide 20mg/2ml solution for injection ampoules 
Furosemide 20mg/5ml oral solution 
Furosemide 250mg/25ml solution for injection ampoules 
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Furosemide 40mg / Potassium chloride 600mg (potassium 8mmol) modified-release tablets 
Furosemide 40mg tablets 
Furosemide 40mg/5ml oral solution sugar free 
Furosemide 500mg tablets 
Furosemide 50mg/5ml injection 
Furosemide 50mg/5ml oral solution 
Furosemide 50mg/5ml solution for injection ampoules 
Hydrochlorothiazide 25mg tablets 
Indapamide 1.5mg modified-release tablets 
Indapamide 2.5mg tablets 
Metolazone 500mcg tablets 
Metolazone 5mg tablets 
Spironolactone 100mg capsule 
Spironolactone 100mg tablets 
Spironolactone 25mg tablets 
Spironolactone 25mg/5ml oral suspension 
Spironolactone 50mg / Furosemide 20mg capsules 
Spironolactone 50mg tablets 
Spironolactone 50mg/5ml oral suspension 
Torasemide 10mg tablets 
Torasemide 2.5mg tablets 
Torasemide 5mg tablets 
Triamterene 50mg / Furosemide 40mg tablets 
Triamterene 50mg / benzthiazide 25mg capsules 
Triamterene 50mg capsules 
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Table 10.7.7 Aspirin. 
 Genericname 
Aspirin Aspirin 100mg effervescent tablets 
Aspirin 100mg modified release tablets 
Aspirin 300mg effervescent tablets 
Aspirin 75mg dispersible tablets 
Aspirin 75mg gastro-resistant tablets 
Aspirin 75mg tablets 
Clopidogrel 300mg tablets 
Clopidogrel 75mg tablets 
Dipyridamole 100mg tablets 
Dipyridamole 100mg/5ml oral suspension 
Dipyridamole 200mg modified-release / Aspirin 25mg capsules 
Dipyridamole 200mg modified-release capsules 
Dipyridamole 25mg tablets 
Dipyridamole 50mg/5ml oral suspension sugar free 
Prasugrel 10mg tablets 
Prasugrel 5mg tablets 
Ticagrelor 90mg tablets 
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Appendix 10.8 Obesity-related comorbidity events. 
 
Table 10.8.1 Frequency of obesity-related comorbidity events, with READ codes, among a 









event date Baseline date 
a665801vZ gall J651000 Yes 29-Jun-12 01-Jun-12 
a665801vZ cvd G66..00 Yes 20-Jan-16 01-Jun-12 
a665901i5 cvd G66..00 No 27-May-11 29-Oct-10 
a665901i5 cvd G66..00 No 18-Jun-11 29-Oct-10 
a677504qw gall J64..15 Yes 16-Jan-17 13-Dec-15 
a680201OQ depdem Eu32z11 Yes 08-Feb-12 27-Jun-09 
a689700D1 asthma Fy03.11 Yes 01-Apr-10 27-Jan-10 
a777809pN gord J10y412 No 31-Jul-15 03-Dec-12 
a783200Pj hypert G2...00 No 12-Aug-04 17-Oct-03 
a793903oV depdem E200300 No 19-Jan-15 21-Mar-11 
a793903oV depdem E200300 No 19-Mar-15 21-Mar-11 
a980001rV cvd G33..00 No 25-Jan-17 22-Oct-14 
a980001rV cvd G581.13 No 16-Jan-17 22-Oct-14 
a980001rV cvd 662T.00 No 17-Jan-17 22-Oct-14 
a980001rV cvd G58..00 No 11-Apr-17 22-Oct-14 
a984900dD arthritis N05..11 No 27-Jan-17 31-Dec-12 
a987001dh ckd 1Z12.00 No 10-Aug-15 21-Jan-13 
a987001dh cholath C320.00 No 19-Jan-15 21-Jan-13 
a987001dh gord J10y500 No 09-Mar-16 21-Jan-13 
a987001dh ckd K053.00 No 16-Dec-15 21-Jan-13 
a991000pM depdem Eu32z11 No 31-Aug-12 20-Mar-12 
a991000pM depdem Eu32z11 No 03-Oct-12 20-Mar-12 
a991000pM depdem Eu32z11 No 30-Aug-12 20-Mar-12 
b668701TR depdem E200.00 No 10-Jan-11 14-Dec-10 
b668701TR depdem E135.00 No 24-Jan-11 14-Dec-10 
b688200YT ckd 1Z11.00 No 09-Dec-08 15-Jul-05 
b688200YT ckd 1Z12.00 No 19-Mar-08 15-Jul-05 
b688204Tj gout C34..00 Yes 22-Oct-08 02-Jul-08 
b688204Tj gout C34..00 Yes 05-Oct-11 02-Jul-08 
b688300Zc gout C34..00 No 02-Apr-15 01-Dec-10 
b688300Zc depdem Eu32z11 No 30-Dec-13 01-Dec-10 
b688702UM ckd 1Z11.00 No 29-Sep-08 03-Nov-05 
b688702UM ckd 1Z11.00 No 02-May-08 03-Nov-05 
b793803rB hypert G20..11 Yes 21-Jul-09 26-Jan-09 
  Appendix 10.8 
 236 
b793803rB hypert G20..11 Yes 01-Nov-12 26-Jan-09 
b982301P3 ckd 1Z10.00 No 18-May-11 06-Jul-09 
b982301P3 ckd 1Z10.00 No 12-Feb-10 06-Jul-09 
b982301P3 ckd 1Z10.00 No 13-Jan-14 06-Jul-09 
b982301P3 ckd 1Z10.00 No 05-Mar-12 06-Jul-09 
b982301P3 ckd 1Z10.00 No 25-Mar-13 06-Jul-09 
b9857038i cvd G581.13 Yes 15-Oct-16 15-Feb-15 
b988400gy cvd G3...00 No 01-Jul-00 03-May-00 
b988401LE gall 7810500 No 19-Jul-11 07-Nov-08 
b988401LE gall J64..15 No 08-Apr-11 07-Nov-08 
b9925017D cvd G6...00 Yes 06-Feb-08 04-Feb-08 
b996400IB depdem E200300 Yes 17-Jan-11 02-Nov-07 
b996400IB cholath C320.00 Yes 12-Aug-10 02-Nov-07 
b996400IB cholath C320.00 Yes 08-Dec-08 02-Nov-07 
b996400IB arthritis N053512 Yes 25-Oct-12 02-Nov-07 
b996400IB depdem E113.11 Yes 15-Feb-12 02-Nov-07 
b998900ia gout C34..00 Yes 04-Jan-05 04-Jan-02 
b999801Dx gout C34..00 No 22-Feb-11 26-Jan-09 
b999801Dx ckd 1Z15.00 No 27-Nov-13 26-Jan-09 
b999801Dx gout C34..00 No 24-May-11 26-Jan-09 
c678400PE ckd 1Z12.00 No 27-Oct-10 21-Jul-09 
c6830001U depdem E200.00 Yes 26-Jul-07 14-Aug-06 
c6830001U depdem E200.00 Yes 27-Nov-08 14-Aug-06 
c6830001U depdem E200.00 Yes 29-Jul-11 14-Aug-06 
c6830001U depdem E200.00 Yes 24-Aug-10 14-Aug-06 
c6830001U depdem E135.00 Yes 19-Dec-08 14-Aug-06 
c778105dw gord J15..00 No 13-Jun-11 05-Dec-07 
c778105dw cholath 8BAG.00 No 08-Oct-08 05-Dec-07 
c780500Sc cholath C320.00 No 31-Oct-11 25-Feb-11 
c780502DM ckd 1Z1..00 Yes 21-Aug-13 05-Aug-11 
c780502DM ckd K050.00 Yes 13-Jul-12 05-Aug-11 
c989406l5 arthritis N05..11 Yes 06-Jul-07 16-Nov-04 
c9896013T depdem E200.00 Yes 01-Dec-15 28-Apr-15 
c989603LZ arthritis N05..11 Yes 11-Jan-17 07-Apr-12 
c989700EG arthritis N05..11 No 09-Jul-13 24-Dec-12 
c999602NY asthma R005311 Yes 01-May-12 30-Apr-09 
c999608hx cvd G573000 No 18-Sep-14 02-Nov-12 
c999608hx ckd 1Z12.00 No 08-Jul-15 02-Nov-12 
c999608hx cvd G573000 No 18-Sep-14 02-Nov-12 
c999806f6 cvd G3...00 No 15-May-07 13-Jun-06 
c999806f6 arthritis N05z.00 No 19-Oct-07 13-Jun-06 
c999806f6 arthritis N05z.00 No 06-Aug-07 13-Jun-06 
d671903PU cvd G58..00 Yes 06-Mar-06 09-Dec-04 
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d671903PU cvd G58..00 Yes 29-Jun-06 09-Dec-04 
d671903PU cvd G58..00 Yes 05-Mar-06 09-Dec-04 
d671903PU gout C34..00 Yes 08-Oct-09 09-Dec-04 
d671903PU cvd G58..00 Yes 18-Jul-06 09-Dec-04 
d671903PU gout C34..00 Yes 03-Sep-09 09-Dec-04 
d671903PU cvd G58..00 Yes 09-May-06 09-Dec-04 
d671903PU cvd G58..00 Yes 30-Mar-06 09-Dec-04 
d671903PU cvd G58..00 Yes 07-Apr-06 09-Dec-04 
d671903PU gout C34..00 Yes 22-Oct-09 09-Dec-04 
d672702AN cvd G573000 Yes 12-Feb-14 26-May-11 
d672702AN hypert G20..11 Yes 04-Jun-13 26-May-11 
d675301nN arthritis N11D.00 No 06-Oct-15 25-Sep-12 
d676402bu gout C34..00 Yes 09-Jul-07 20-Jul-04 
d676402bu ckd 1Z13.00 Yes 14-Sep-06 20-Jul-04 
d676402bu cvd G86..11 Yes 10-Nov-06 20-Jul-04 
d676402bu gout C34..00 Yes 02-Dec-04 20-Jul-04 
d676402bu gout C34..00 Yes 07-Jun-07 20-Jul-04 
d676402bu ckd 1Z16.00 Yes 04-Sep-07 20-Jul-04 
d683803FG ckd K054.00 No 11-Nov-13 19-Oct-11 
d687801xE depdem E200300 Yes 03-Nov-09 28-Jul-09 
d779300xa cvd G65..12 Yes 06-Jan-04 26-Jan-01 
d779300xa cvd G64..00 Yes 06-Jan-04 26-Jan-01 
d779300xa depdem Eu32z11 Yes 09-Oct-03 26-Jan-01 
d779300xa cvd G65..12 Yes 06-Jan-04 26-Jan-01 
d779300xa hypert G2...00 Yes 17-Feb-04 26-Jan-01 
d794100Wf ckd 1Z11.00 Yes 28-Feb-07 01-Jul-05 
d980305Cm gord J17z.00 Yes 01-Jul-12 07-Dec-11 
d980305rl gord J101100 No 24-Jan-12 08-Jun-09 
d980305rl gord J10y412 No 23-Aug-10 08-Jun-09 
d980305rl ckd 1Z10.00 No 01-Jul-09 08-Jun-09 
d980305rl gord J17z.00 No 01-Jul-11 08-Jun-09 
d98030A@w arthritis N051B00 No 18-Jun-13 08-Jun-13 
d9844012v cvd G64..11 Yes 10-May-05 16-Jun-04 
d987702Vy gall J671.00 No 04-May-16 13-Jun-11 
d992804vj cvd G573000 No 25-Mar-11 08-Oct-10 
d992804vj cancer B141.00 No 08-Dec-14 08-Oct-10 
d992804vj cvd G580.11 No 03-Feb-11 08-Oct-10 
d992804vj cvd G580.11 No 24-Dec-10 08-Oct-10 
d992804vj cvd G573000 No 11-Jun-12 08-Oct-10 
d992804vj cvd G573000 No 29-Sep-11 08-Oct-10 
d992804vj gord J10y412 No 23-Nov-10 08-Oct-10 
d992804vj cvd G580.11 No 23-Nov-10 08-Oct-10 
d992804vj cvd G573000 No 02-Nov-10 08-Oct-10 
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d992804vj cvd G580.11 No 21-Dec-10 08-Oct-10 
d992804vj cvd G580.11 No 23-Nov-10 08-Oct-10 
d992804vj cvd G573000 No 11-Jun-12 08-Oct-10 
d992804vj gord J10y412 No 12-Nov-10 08-Oct-10 
d992804vj cvd G573000 No 11-Jun-12 08-Oct-10 
d99570031 cvd G87..00 Yes 09-Jul-13 13-Jul-12 
d99570031 cvd G87..00 Yes 23-May-13 13-Jul-12 
d99570031 arthritis N05..11 Yes 18-Jul-13 13-Jul-12 
d99570031 cvd G87..00 Yes 21-May-13 13-Jul-12 
d99570031 arthritis N05..11 Yes 04-Feb-14 13-Jul-12 
d997000gO depdem E113.11 No 23-Apr-15 21-Feb-12 
d997000gO depdem E113.11 No 10-Apr-15 21-Feb-12 
e681704xK ckd 1Z12.00 No 13-Nov-12 29-Aug-12 
e681704xK ckd 1Z12.00 No 25-Sep-12 29-Aug-12 
e977602Vj hypert G2...00 Yes 03-Jun-16 19-Aug-14 
f670400VL arthritis N11D.00 Yes 28-Nov-13 08-Aug-13 
f670401AN arthritis N05zH00 No 17-Jul-13 06-Jul-12 
f673702cw cvd G3...00 No 04-Oct-07 02-Aug-07 
f673702cw depdem E200300 No 29-Jul-11 02-Aug-07 
f673702cw cvd G3...00 No 03-Oct-07 02-Aug-07 
f674900js cholath 8CA4700 No 18-Dec-06 19-Aug-04 
f674900js cholath 8CA4700 No 24-Aug-04 19-Aug-04 
f680300dA cholath C320.00 Yes 13-Dec-07 19-Sep-06 
f680300dA cholath C320.00 Yes 24-Aug-07 19-Sep-06 
f680300dA ckd 1Z12.00 Yes 04-Sep-08 19-Sep-06 
f6818047O hypert G2...00 No 14-May-09 07-Sep-05 
f681804PX gall J64..15 No 31-Mar-14 06-Jun-12 
f977201x0 ckd 1Z11.00 No 20-Nov-07 16-Aug-05 
f986600SB depdem E200300 Yes 12-Dec-15 14-Nov-12 
f986600du gord J10y412 No 10-Sep-12 16-Jul-12 
f986605qV cvd G86..11 Yes 07-Dec-12 09-Nov-09 
f989201xi ckd 1Z12.00 Yes 23-Jan-07 07-Oct-05 
f991301FL asthma H5B..00 No 17-Oct-14 25-Mar-13 
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Appendix 10.9 Exact count of prescribed drugs with pharmacological genericnames.  
 
Table 10.9.1 Frequency of drug use for a cohort of 160 patients throughout 5 years of follow-




Insulin aspart 100units/ml solution for injection 3ml cartridges 169 
Insulin aspart 100units/ml solution for injection 3ml pre-filled disposable devices 518 
Insulin aspart biphasic 30/70 100units/ml suspension for injection 3ml cartridges 145 
Insulin aspart biphasic 30/70 100units/ml suspension for injection 3ml pre-filled disposable 
devices 356 
Insulin biphasic isophane human prb 30:70; 100 units/ml injection 3 
Insulin detemir 100units/ml solution for injection 3ml cartridges 68 
Insulin detemir 100units/ml solution for injection 3ml pre-filled disposable devices 435 
Insulin glargine 100units/ml solution for injection 10ml vials 23 
Insulin glargine 100units/ml solution for injection 3ml cartridges 135 
Insulin glargine 100units/ml solution for injection 3ml pre-filled disposable devices 877 
Insulin glargine 300units/ml solution for injection 1.5ml pre-filled disposable devices 19 
Insulin glulisine 100units/ml solution for injection 10ml vials 1 
Insulin glulisine 100units/ml solution for injection 3ml pre-filled disposable devices 23 
Insulin isophane biphasic human 25/75 100units/ml suspension for injection 3ml cartridges 40 
Insulin isophane biphasic human 25/75 100units/ml suspension for injection 3ml pre-filled 
disposable devices 23 
Insulin isophane biphasic human 30/70 100units/ml suspension for injection 3ml cartridges 257 
Insulin isophane biphasic human 30/70 100units/ml suspension for injection 3ml pre-filled 
disposable devices 403 
Insulin isophane human 100units/ml suspension for injection 3ml cartridges 259 
Insulin isophane human 100units/ml suspension for injection 3ml pre-filled disposable devices 174 
Insulin lispro 100units/ml solution for injection 1.5ml pre-filled disposable devices 3 
Insulin lispro 100units/ml solution for injection 3ml cartridges 90 
Insulin lispro 100units/ml solution for injection 3ml pre-filled disposable devices 77 
Insulin lispro biphasic 25/75 100units/ml suspension for injection 3ml cartridges 24 
Insulin lispro biphasic 25/75 100units/ml suspension for injection 3ml pre-filled disposable 
devices 65 
Insulin lispro biphasic 50/50 100units/ml suspension for injection 3ml cartridges 77 
Insulin lispro biphasic 50/50 100units/ml suspension for injection 3ml pre-filled disposable 
devices 23 










Acarbose 100mg tablets 11 
Canagliflozin 100mg tablets 13 
Dapagliflozin 10mg tablets 127 
Dapagliflozin 5mg tablets 9 
Glibenclamide 5mg tablets 14 
Gliclazide 30mg modified-release tablets 36 
Gliclazide 40mg tablets 16 
Gliclazide 80mg tablets 958 
Glimepiride 1mg tablets 1 
Glimepiride 2mg tablets 48 
Glimepiride 3mg tablets 13 
Glimepiride 4mg tablets 19 
Glipizide 5mg tablets 13 
Metformin & rosiglitazone 1g+4mg tablets 19 
Metformin 1g modified-release tablets 208 
Metformin 500mg modified-release tablets 597 
Metformin 500mg oral powder sachets sugar free 16 
Metformin 500mg tablets 2098 
Metformin 500mg/5ml oral solution 34 
Metformin 750mg modified-release tablets 4 
Metformin 850mg tablets 395 
Pioglitazone 15mg tablets 114 
Pioglitazone 30mg tablets 48 
Pioglitazone 45mg tablets 54 
Repaglinide 1mg tablets 8 
Repaglinide 500microgram tablets 2 
Rosiglitazone 4mg tablets 70 
Rosiglitazone 8mg tablets 22 
Saxagliptin 5mg tablets 3 
Sitagliptin 100mg tablets 330 
Sitagliptin 25mg tablets 13 
Sitagliptin 50mg tablets 7 
Vildagliptin 50mg tablets 6 
GLP-1 Analogues  
Genericname Frequency 
Exenatide 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable devices 78 
Exenatide 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable devices 21 
Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices 235 
Lixisenatide 10micrograms/0.2ml solution for injection 3ml pre-filled disposable devices 2 
Lixisenatide 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices 10 
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Antihypertensive drugs  
Genericname Frequency 
Aliskiren 150mg tablets 84 
Amlodipine 10mg tablets 398 
Amlodipine 5mg tablets 441 
Atenolol 100mg tablets 135 
Atenolol 25mg tablets 95 
Atenolol 25mg/5ml oral solution sugar free 33 
Atenolol 50mg tablets 317 
Bisoprolol 1.25mg tablets 9 
Bisoprolol 10mg tablets 88 
Bisoprolol 2.5mg tablets 97 
Bisoprolol 3.75mg tablets 53 
Bisoprolol 5mg tablets 182 
Bisoprolol 7.5mg tablets 110 
Candesartan 16mg tablets 267 
Candesartan 2mg tablets 4 
Candesartan 32mg tablets 141 
Candesartan 4mg tablets 43 
Candesartan 8mg tablets 46 
Captopril 50mg tablets 33 
Carvedilol 12.5mg tablets 10 
Carvedilol 25mg tablets 64 
Carvedilol 3.125mg tablets 8 
Carvedilol 6.25mg tablets 25 
Diltiazem 120mg modified-release capsules 4 
Diltiazem 120mg modified-release tablets 28 
Diltiazem 180mg modified-release capsules 3 
Diltiazem 200mg modified-release capsules 56 
Diltiazem 240mg modified-release capsules 53 
Diltiazem 300mg modified-release capsules 31 
Diltiazem 90mg modified-release capsules 2 
Doxazosin 1mg tablets 47 
Doxazosin 2mg tablets 25 
Doxazosin 4mg modified-release tablets 10 
Doxazosin 4mg tablets 198 
Doxazosin 4mg/5ml oral suspension 1 
Doxazosin 8mg modified-release tablets 200 
Enalapril 10mg tablets 64 
Enalapril 20mg tablets 89 
Enalapril 5mg tablets 30 
Eprosartan 600mg tablets 24 
Felodipine 10mg modified-release tablets 30 
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Felodipine 2.5mg modified-release tablets 7 
Felodipine 5mg modified-release tablets 33 
Glyceryl trinitrate 400micrograms/dose aerosol sublingual spray 47 
Glyceryl trinitrate 400micrograms/dose pump sublingual spray 45 
Glyceryl trinitrate 500microgram sublingual tablets 33 
Glyceryl trinitrate pump 400mcg CFC-free spray 2 
Irbesartan 150mg tablets 38 
Irbesartan 300mg tablets 42 
Irbesartan 75mg tablets 15 
Isosorbide mononitrate 10mg tablets 14 
Isosorbide mononitrate 20mg tablets 13 
Isosorbide mononitrate 25mg modified-release capsules 5 
Isosorbide mononitrate 25mg modified-release tablets 55 
Isosorbide mononitrate 50mg modified-release capsules 30 
Isosorbide mononitrate 60mg modified-release tablets 191 
Ivabradine 5mg tablets 29 
Labetalol 100mg tablets 1 
Lacidipine 4mg tablets 2 
Lercanidipine 10mg tablets 3 
Lercanidipine 20mg tablets 2 
Lidocaine 200mg/10ml (2%) solution for injection ampoules 3 
Lisinopril 10mg tablets 54 
Lisinopril 2.5mg tablets 107 
Lisinopril 20mg tablets 238 
Lisinopril 5mg tablets 174 
Lisinopril 5mg/5ml oral solution 1 
Losartan 100mg tablets 197 
Losartan 25mg tablets 28 
Losartan 50mg / Hydrochlorothiazide 12.5mg tablets 1 
Losartan 50mg tablets 58 
Methyldopa 250mg tablets 20 
Methyldopa 500mg tablets 2 
Metoprolol 50mg tablets 54 
Nicorandil 10mg tablets 70 
Nicorandil 20mg tablets 40 
Nifedipine 20mg modified-release tablets 18 
Nifedipine 30mg modified-release capsules 216 
Nifedipine 30mg modified-release tablets 33 
Nifedipine 40mg modified-release tablets 33 
Nifedipine 5mg capsules 3 
Nifedipine 60mg modified-release capsules 4 
Olmesartan medoxomil 10mg tablets 55 
Olmesartan medoxomil 20mg tablets 8 
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Perindopril arginine 10mg tablets 4 
Perindopril erbumine 2mg tablets 28 
Perindopril erbumine 4mg tablets 127 
Perindopril erbumine 8mg tablets 17 
Propranolol 40mg tablets 37 
Propranolol 80mg modified-release capsules 1 
Ramipril 1.25mg capsules 111 
Ramipril 10mg capsules 588 
Ramipril 10mg tablets 35 
Ramipril 2.5mg capsules 328 
Ramipril 2.5mg tablets 35 
Ramipril 5mg capsules 406 
Sacubitril 24mg / Valsartan 26mg tablets 1 
Telmisartan 40mg tablets 17 
Timolol 10mg tablets 40 
Verapamil 120mg modified-release tablets 7 
Verapamil 40mg tablets 2 
Lipids lowering drugs  
Genericname Frequency 
Atorvastatin 10mg tablets 484 
Atorvastatin 20mg tablets 226 
Atorvastatin 40mg tablets 790 
Atorvastatin 80mg tablets 327 
Bezafibrate 200mg tablets 17 
Bezafibrate 400mg modified-release tablets 33 
Colestyramine 4g oral powder sachets 1 
Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg capsules 109 
Ezetimibe 10mg tablets 179 
Fenofibrate micronised 160mg tablets 5 
Fenofibrate micronised 200mg capsules 3 
Fenofibrate micronised 267mg capsules 24 
Fenofibrate micronised 67mg capsules 1 
Fluvastatin 80mg modified-release tablets 36 
Nicotinic acid 1g / laropiprant 20mg modified-release tablets 1 
Pravastatin 10mg tablets 3 
Pravastatin 20mg tablets 11 
Pravastatin 40mg tablets 19 
Rosuvastatin 10mg tablets 61 
Rosuvastatin 20mg tablets 26 
Rosuvastatin 40mg tablets 17 
Rosuvastatin 5mg tablets 10 
Simvastatin 10mg tablets 123 
Simvastatin 20mg / Ezetimibe 10mg tablets 17 
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Simvastatin 20mg tablets 291 
Simvastatin 40mg tablets 970 
Simvastatin 40mg/5ml oral suspension sugar free 1 
Simvastatin 80mg tablets 5 
Diuretics  
Genericname Frequency 
Amiloride 5mg / Bumetanide 1mg tablets 31 
Bendroflumethiazide 2.5mg tablets 379 
Bumetanide 1mg tablets 71 
Chlortalidone 50mg tablets 74 
Co-amilofruse 5mg/40mg tablets 22 
Eplerenone 25mg tablets 3 
Eplerenone 50mg tablets 2 
Furosemide 20mg tablets 102 
Furosemide 40mg tablets 857 
Furosemide 40mg/5ml oral solution sugar free 3 
Indapamide 1.5mg modified-release tablets 94 
Indapamide 2.5mg tablets 7 
Spironolactone 25mg tablets 142 
Spironolactone 50mg tablets 18 
Aspirin  
Genericname Frequency 
Aspirin 75mg dispersible tablets 977 
Aspirin 75mg gastro-resistant tablets 163 
Aspirin 75mg tablets 63 
Clopidogrel 75mg tablets 390 
Dipyridamole 100mg tablets 3 
Dipyridamole 200mg modified-release capsules 24 
 
  
 
 
 
